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1 Abstract 
 
The human multidrug resistance P-glycoprotein (P-gp), the product of the MDR1 gene, 
is an ATP-binding cassette (ABC) protein that uses ATP to transport a variety of cyto-
toxic compounds without a common structure or intracellular target, out of the cell. The 
protein is clinically important since it contributes to the phenomenon of multidrug resis-
tance during chemotherapy of human cancers. It has two homologous halves that are 
joined by a linker. Each half consists of a hydrophobic transmembrane domain contain-
ing six transmembrane (TM) segments and a hydrophilic nucleotide-binding domain 
(NBD) containing the nucleotide binding site. 
The aim of this project was the identification and characterization of TMD1/TMD2 con-
tact interface residues, which are important for transport of solutes. Functional assays 
were performed with P-gp mutants, in which the TMD1/TMD2 contact interface resi-
dues were mutated to residues other than cysteine by site directed mutagenesis based on 
overlap extension polymerase chain reaction (OE-PCR). The mutational concept was 
guided by photoaffinity labeling, availability of protein homology models, in-silico im-
portance prediction of residues by real valued evolutionary trace and data-driven dock-
ing results based on previous site-directed mutagenesis data. Thus, hypothesis driven 
generation of P-gp mutants with amino acid residues that will be tolerated in the protein 
to obtain a high number of correctly targeted and functional transporters was performed. 
The glutamine residues Q132 (TM2) in the N-terminal half and Q773 (TM8) in the C-
terminal half of P-gp were found in predicted TM segments. Homology models of P-gp 
suggested that these Q-residues are located between highly photolabelled residues at the 
TM2/11 interface and the contralateral TM5/8 interface. In some species one of these Q 
residues is mutated to R or E, indicating that a charge is tolerated in this position of the 
protein. Thus, Q132 was mutated to Q132A, Q132E and Q132R, and Q773 was mutated 
to Q773A, Q773E and Q773R. In addition Q132A/Q773A, Q132E/Q773E and 
Q132R/Q773R double mutants were generated. Mutants were characterized using efflux 
studies, MRK16 staining and cytotoxicity assays. The Q773R mutant was deficient for 
rhodamine 123 transport, while the Q773E and Q773A mutants were active. Similarly 
the A, E and R mutants in position 132 showed unimpaired rhodamine 123 transports. 
The Q132R/Q773R double mutant was also transport deficient.  
  
  2 
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2 Introduction 
 
2.1 ABC transporters 
Transport proteins form 15% to 30% of membrane proteins in a cell (Sauna and Am-
budkar 2007). Decreased accumulation of natural product toxins in the cells improves 
the likelihood of an organism’s survival. Most of these cytotoxic compounds are lipo-
philic and thus able to enter cells by passive diffusion across the plasma membrane. 
This way of self-defence is aided by active efflux pumps, which intercept toxins at the 
level of the membrane and extrude them back to the cell exterior. These pumps are ei-
ther adenosine triphosphate (ATP)-dependent (primary active) or driven by proton or 
sodium motive force (secondary active). The first group of proteins belongs to the sub-
family of ATP-binding cassette (ABC) transporters (Hyde, Emsley et al. 1990). The 
ATP-binding cassette is found in a variety of prokaryotic and eukaryotic transporters 
(Pohl, Devaux et al. 2005) and thus the ABC protein family represents one of the largest 
and most diverse families of transport proteins.  
Based on the direction of the transport reaction, ABC transporters are separated into two 
subtypes. ABC importers require a binding protein that delivers captured substrates to 
the external face of the transporter. These transporters are only present in prokaryotes. 
(Hollenstein, Dawson et al. 2007) In contrast, ABC exporters capture their substrates 
directly from the cytoplasm or from the inner leaflet of the lipid bilayer (Locher 2004). 
While human cells express only ABC exporters, which facilitate the export of com-
pounds, in bacterial cells many ABC importers can be found, catalyzing the import of 
nutrients into the cell (Loo and Clarke 2008). 
Based on sequence similarities, the human ABC protein family is categorized into seven 
subfamilies, denoted ABC A-G, and consists of 49 members (Dean, Hamon et al. 2001; 
Loo and Clarke 2008), 17 of them are implicated in diseases (Sauna, Kim et al. 2007). 
The ABC transporters bind ATP and use the energy to drive the translocation of various 
substrates such as ions, lipids, peptides, metabolites, chemotherapeutic drugs and anti-
biotics across the plasma membrane as well as intracellular membranes of the endo-
plasmic reticulum (ER), peroxisome and mitochondria, and as such can be associated 
with many disorders in humans (examples are shown in Table 2.1 ). 
 
 
  4 
Protein Transport sub-
strate 
Disorder Species 
ABCA1 Cholesterol Tangier disease Human 
ABCA4 Retinal Stargardt disease Human 
P-gp (ABCB1) Hydrophobic drugs Multidrug resistance Human 
TAP1/2 
(ABCB2/3) 
Peptides Wegener’s granulomato-
sis 
Human 
MRP1 (ABCC1) Leukotrienes Multidrug resistance Human 
MRP2 (ABCC2) GSH conjugates Dubin-Johnson syndrome Human 
CFTR (ABCC7) Chloride channel Cystic fibrosis Human 
SUR1 (ABCC8) K+ channel regula-
tion 
PHHI Human 
BtuCD Vitamin B12  E. coli 
HisJQMP2 Histidine  S. typhimurium 
LmrA Hydrophobic drugs  L. lactis 
MalEFGK2 Maltose  E. coli 
MsbA Lipid A  E. coli,  
V. cholera 
Table 2.1: ABC transporters, transported substrates and associated disorders. 
 
Understanding how ABC transporters work to mediate directional transport of sub-
strates across lipid membranes has been a challenge since the first sequence of a com-
plete ABC transporter gene was published in 1982 (Higgins, Haag et al. 1982). 
 
2.1.1 Structural organisation of ABC transporters 
All ABC transporters are composed of four protein domains or subunits: two hydro-
philic nucleotide-binding domains (NBDs), also known as ATP-binding cassettes, and 
two hydrophobic transmembrane domains (TMDs) (Higgins, Hiles et al. 1986). These 
four core domains are both necessary and sufficient for transport. The NBDs, located in 
the cytoplasm, are the site of ATP binding and hydrolysis, providing the energy needed 
for solute translocation. Despite the high diversity of transport substrates, the sequences 
of the NDBs are remarkably well conserved among the ABC transporter family. These 
conserved motifs include the Walker A (or P-loop) and Walker B sequence, common to 
most proteins that bind nucleotide, and the ABC signature motif (also called LSGGQ 
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motif, linker peptide, or C motif) that contacts the nucleotide in the ATP-bound state. In 
addition, the NBDs of ABC transporters contain the A-loop, D-loop, H-loop, and Q-
loop. In contrast to the NBDs, the TMDs which form the transport pathway mediating 
accessibility to either side of the membrane have higher sequence diversity and vary in 
the total number of transmembrane (TM) helices, length, and architecture (reviewed in 
(Hollenstein, Dawson et al. 2007)). 
The TMDs and the NBDs are separate polypeptide chains in ABC importers. In bacte-
rial exporters a TMD is fused to an NBD, representing a so-called “half-transporter”, 
which as a homodimer or heterodimer forms the functional four-domain canonical 
structure of the ABC transporter (Saurin, Hofnung et al. 1999). In many eukaryotic 
ABC exporters all four domains are expressed as a single polypeptide chain. 
  
2.2 P-glycoprotein 
Mammalian P-glycoprotein is the most well characterized ABC transporter. P-
glycoprotein (P-gp) was discovered by Juliano and Ling (Juliano and Ling 1976) and is 
encoded by the human multidrug resistance (MDR1, ABCB1) gene (Ueda, Cornwell et 
al. 1986; Borst, Evers et al. 2000). Human MDR1 spans over 100 kb on human chromo-
some 7q21 (Yang, Wu et al. 2008). The MDR1 genome contains 29 exons that produce 
a 3843 bp sequence of transcripts encoding the 1280 amino acids P-gp protein with a 
molecular weight of 170 kDa (Yang, Wu et al. 2008).  
P-gp is an ideal model system for studying processes involved in folding and trafficking 
of ABC transporters because these processes can be manipulated by using specific 
chemical/pharmacological chaperones. Processing mutants can be rescued by expres-
sion in the presence of a chemical/pharmacological chaperone such as cyclosporin A 
(Loo, Bartlett et al. 2004). These chaperones also are substrates or modulators of P-gp 
(Loo and Clarke 1997). In many cases, such as ∆F508 in CFRT, the processing muta-
tions are located outside the critical functional domain of the protein so that the mutant 
protein remains functional, but does not traffick to its final destination at the plasma 
membrane (Denning, Anderson et al. 1992). 
P-gp was the first identified eukaryotic ABC transporter and is clinically important be-
cause of its role in conferring multidrug resistance (MDR) to cancer cells (Sauna and 
Ambudkar 2007). The overexpression of P-gp in human cancer cells can make the cells 
simultaneously resistant to a variety of chemically unrelated cytotoxic drugs due to its 
ability to transport these compounds out of the lipid bilayer of the cell.  
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2.3 A medical role in physiology and medicine 
The ability of a cell to protect itself against environmental toxins is an essential biologi-
cal function because many organisms produce toxins to repel ecological competitors, 
and plants rely on toxic secondary metabolites to make themselves unappetizing (Hig-
gins 2007). To survive, most organisms have evolved multidrug transporters to prevent 
cytotoxic molecules entering cells and to clear membranes of unwanted agents. 
 
2.3.1 Cancer chemotherapy 
Chemotherapy is a major form of treatment for many cancers. There are two forms for 
development of resistance to chemotherapy: (I) the single-agent resistance as a result of 
mutations to the target molecule of the chemotherapeutic drug, for example single 
amino acid changes in topoisomerase II result in epipodophyllotoxin resistance (Cam-
pain, Gottesman et al. 1994), and (II) a broad resistance to compounds of diverse struc-
ture and unrelated mechanism of action termed multidrug resistance (MDR) (Dano 
1973). Multidrug resistance is a serious medical problem and presents a major obstacle 
for effective chemotherapeutic treatment of malignant diseases. The remission of a tu-
mour during chemotherapy is successful in tumours that do not express endogenous P-
gp (Loo and Clarke 1999). Tumours that express endogenous P-gp usually compromise 
effectiveness of the chemotherapeutic regimen. First studies showed that P-gp expres-
sion was increased in tumours from colon, adrenal, pancreatic, mammary and renal tis-
sue, even prior to chemotherapy (Cordon-Cardo, O'Brien et al. 1989; van der Valk, van 
Kalken et al. 1990). 
There are many clinical problems associated with over- or underexpression of ATP-
binding cassette transporters on the cell surface (Loo, Bartlett et al. 2005). Overexpress-
sion of ABC multidrug transporters such as the multidrug resistance P-glycoprotein (P-
gp, also known as MDR1 or ABCB1), multidrug resistance-associated protein (MRP1, 
also known as ABCC1), or the breast cancer resistance protein (BCRP, MXR) interferes 
with drug delivery to target organs and/or contribute to the development of multidrug 
resistance of cancer cells by catalysing the extrusion of cytotoxic compounds during 
chemotherapy (Gottesman, Fojo et al. 2002). (Loo, Bartlett et al. 2005) 
Underexpression of mutant ABC transporters due to defective folding and trafficking to 
the cell surface as in the cystic fibrosis conductance regulator (CFTR) and the sulfony-
lurea receptor (SUR1) cause cystic fibrosis (Riordan, Rommens et al. 1989; Cheng, 
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Gregory et al. 1990) and persistent hyperinsulinemic hypoglycemia (Dunne, Kane et al. 
1997; Cartier, Conti et al. 2001). (Loo, Bartlett et al. 2005) 
Multispecific drug efflux pumps confer simultaneous resistance to several drugs (Hol-
land and Blight 1999) and frequently render human disease intractable. MDR presents a 
major challenge to the treatment of disease and the development of novel therapeutics 
(Chang and Roth 2001). 
 
In addition to its expression in cancer cells, P-gp is mainly localized in the apical mem-
brane of epithelial cells in the body, to transport P-gp substrates that are translocated 
from the basolateral to the apical side of the epithelium. Furthermore, P-gp can be found 
in the blood-brain barrier, blood-testis barrier, blood-nerve barrier and in the placenta 
(fetal-maternal barrier) (Smit, Huisman et al. 1999). 
P-gp reduces the intracellular concentrations of a wide range of drugs and xenobiotics 
(Bodor, Kelly et al. 2005). Drugs known to bind to P-gp include verapamil, vinblastine, 
daunorubicin, rhodamine and propafenone type compounds (Gottesman and Pastan 
1993; Schmid, Ecker et al. 1999). It seems to play a key role in the protection of cells 
and in the development of resistance to anticancer agents. Inhibition of P-gp by low 
molecular weight compounds, which themselves are non-toxic, was reported over the 
past decade. A number of clinical studies has been initiated to reverse drug resistance by 
inhibiting drug efflux (reviewed in (Fojo and Bates 2003; Polgar and Bates 2005)). But 
all inhibitors of P-gp entering clinical studies so far have failed. Thus it is important to 
understand the molecular principles of drug recognition and transport, and the predic-
tion of substrate properties of compounds has gained a lot of interest in the pharmaceu-
tical industry (Ecker, Stockner et al. 2008).  
 
2.4 Structure and molecular architecture of P-glycoprotein 
A number of techniques can be used to derive a protein structure. These techniques in-
cluding cryo-electron microscopy (cryo-EM), X-ray crystallography, nuclear magnetic 
resonance (NMR) spectroscopy, and bioinformatics-based approaches can help in eluci-
dation of the functional mechanism of a protein. 
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2.4.1 Topology of P-glycoprotein 
P-gp has the molecular architecture of an ABC protein, a core structure of four domains. 
It is a 170 kDa glycosylated plasma membrane protein and has 1280 amino acids which 
are organized as two homologous halves joined by a linker region of approximately 60 
amino acid residues (Chen, Chin et al. 1986). Each half begins with an amino-terminal 
hydrophobic transmembrane domain (TMD) containing six transmembrane (TM) seg-
ments followed by a carboxy-terminal hydrophilic nucleotide-binding domain (NBD). 
P-gp is made up of a single polypeptide containing all four domains in the order TMD-
NBD-TMD-NBD from N- to C-terminus. The N- and C-terminus are considered to have 
arisen by gene duplication and are 43% identical (Chen, Chin et al. 1986; Raymond and 
Gros 1989). The two TMD-NBD halves have diverged during evolution. The TMD and 
NBD are coupled by a series of intracellular loops (ICL) which extend into the NBDs 
(O'Mara and Tieleman 2007). The two TMDs have been shown to be responsible and 
sufficient for solute recognition (Loo and Clarke 1999). 
 
 
Figure 2.1: Topology of P-gp. P-gp has 12 transmembrane domains and two ATP-binding sites. 
 
2.4.2 Low resolution structures of P-glycoprotein 
At present no high-resolution structure of P-gp is available. The first three-dimensional 
structures for P-gp at low resolution obtained by cryo-electron-microscopy of two-
dimensional crystals were performed by Rosenberg et al. (Rosenberg, Callaghan et al. 
1997; Rosenberg, Mao et al. 2001; Rosenberg, Velarde et al. 2001; Rosenberg, Kamis et 
al. 2003; Rosenberg, Callaghan et al. 2005). The two-dimensional crystals were grown 
in the presence or absence of AMP-PNP, a non-hydrolysable analogue of ATP that is 
known to bind to the NBDs at the same site as ATP. Two-dimensional crystals of P-gp 
trapped at different steps of the transport cycle were correlated with functional changes. 
These data were interpreted to suggest that the transmembrane α–helices undergo dra-
matic conformational changes as a result of ATP binding, hydrolysis and substrate re-
lease. (Rosenberg, Kamis et al. 2003) The 8 Ångstrom (Å) resolution of the structure in 
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the presence of AMP-PNP was sufficiently high to confirm the existence of twelve 
transmembrane α–helices which span the membrane in two blocks of six. Five α–helices 
from each TMD exhibit a pseudo-2-fold symmetry, the sixth α–helices from each do-
main shows a less symmetrical relationship. The 8 Å resolution scan showed the same 
features already previously described in the three-dimensional structure of nucleotide-
free P-gp: the transmembrane α–helices form a central pore, which is exposed at the 
extracellular face and closed at the intracellular face of the membrane. In contrast to the 
nucleotide-free P-gp structure, the transmembrane α–helices of the AMP-PNP-bound P-
gp also enclose a central pore which is less closed at the intracellular face of the mem-
brane and, additionally, is open to the lipid phase along one side with a gap appearing 
between two domains. This access from the lipid bilayer to the central pore might allow 
transport of lipophilic substrates from the membrane. 
 
2.4.3 Protein homology models of P-glycoprotein  
In the absence of high resolution structural data for P-gp, an alternative is to generate a 
protein homology model that provides a three-dimensional map of a protein. The avail-
ability of structures of a target protein at the atomic level is a critical factor for struc-
ture-based drug design. Protein homology models are based on the assumption of struc-
tural homology between a structurally resolved protein, the template and a protein of 
unknown conformation, the target. Sequence homology and an identical number of pre-
dicted transmembrane spanning helices are important for the selection of templates for 
modelling of membrane proteins (Ecker, Stockner et al. 2008). The quality of a homol-
ogy model is determined by the accuracy of the sequence alignment between the protein 
of interest and the template protein, and the quality of the crystal structure used as the 
modelling template.  
 
2.4.3.1 Available template crystal structures for P-glycoprotein  
2.4.3.1.1 MsbA as template crystal structure  
Several groups, including our own, have generated models based on the MsbA struc-
tures of E. coli and V. cholerae (Chang and Roth 2001; Chang 2003; Seigneuret and 
Garnier-Suillerot 2003; Stenham, Campbell et al. 2003; Pleban, Kopp et al. 2005; Reyes 
and Chang 2005), which were the only available structures at this time. MsbA, the lipid 
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A flippase found in Gram-negative bacteria, was the first structure of a full length ABC-
transporter at 4.5 Å published in 2001 (Chang and Roth 2001). MsbA was crystallized 
as a homodimer of two monomers composed of an N-terminal TMD fused to a C-
terminal NBD. It shows an identical number of TM-helices and the protein sequence is 
36% and 32% identical to the N-terminal and C-terminal halves of human MDR1, re-
spectively (Altschul, Gish et al. 1990). The crystal structure was obtained in the absence 
of substrate and nucleotide, showed an inverted V-shape and was later referred to as the 
open apo structure. Subsequently, MsbA from V. cholerae was resolved to 3.8 Å 
(Chang 2003). In this structure the NBDs were much closer. Again this structure was 
obtained in the absence of solutes and nucleotide and termed closed apo structure. 
Availability of these structures seemed to open a path for protein homology modelling 
of P-gp (Ecker, Stockner et al. 2008). 
However, a homology model is an approximation of the structure and the exact posi-
tioning of the various domains may differ between template and target. 
 
2.4.3.1.2 Sav1866 as template crystal structure 
In September 2006 the crystal structure of a bacterial ABC transporter, Sav1866 from 
Staphylococcus aureus, was published (Dawson and Locher 2006). This first Sav1866 
structure has been resolved to 3.0 Å. The Sav1866 structure, as MsbA, is a 
homodimeric ABC transporter that is homologous to P-gp. Sav1866 was crystallized in 
the presence of two adenosine diphosphate (ADP) molecules bound at the interface of 
the NBDs, the P-loops and the ABC signature motifs of opposing subunits. The NBDs 
of the Sav1866 homodimer are similar in structure to those of other ABC transporters 
(Dawson and Locher 2006). These domains show conserved ATP-binding and -
hydolysis motifs at the shared interface in a head-to-tail arrangement (Schneider and 
Hunke 1998; Hopfner, Karcher et al. 2000; Smith, Karpowich et al. 2002). In 2007 the 
authors published the crystal structure of Sav1866 in complex with AMP-PNP (Dawson 
and Locher 2007). A comparison and superposition of both structures, the AMP-PNP-
bound Sav1866 and the ADP-bound Sav1866, indicated that these structures are essen-
tially identical and represent the ATP-bound state of the transporter. The apparently 
different structures of MsbA were indicated to be reconcilable with the Sav1866 when 
mirrored and under the assumption that the published topology of the MsbA structures 
was wrong. This consequently led to retraction of all three incorrect MsbA structures in 
the December 2006 issue of Science (Chang, Roth et al. 2006).  
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The overall architecture differs from the side-by-side arrangement of TMDs as observed 
for the ABC importers BtuCD (Locher, Lee et al. 2002), HI1470/1 (Pinkett, Lee et al. 
2007), ModB2C2 (Hollenstein, Frei et al. 2007), and MalFGK2 (Oldham, Khare et al. 
2007). In ABC exporters the TMDs interact with the helical domains of the NBDs 
through coupling helices that are located in the loops between TM helices (Rees, John-
son et al. 2009). One intracellular loop of each TMD makes contact with the contralat-
eral NBD. The coupling helices are domain swapped (Hollenstein, Dawson et al. 2007). 
The two subunits exhibit a considerable twist (Dawson and Locher 2006). 
The transmembrane helices of Sav1866 diverge into two discrete ‘wings’ which point 
away from one another towards the cell exterior of the membrane, providing what might 
be thought of as an outward-facing conformation. Helices from both TMDs contribute 
to form each of these two ‘wings’(Dawson and Locher 2006). The helix arrangement 
observed in Sav1866 is consistent, except for helices 6 and 12, with cross-linking stud-
ies which identified neighbouring TM helices in human P-gp (Dawson and Locher 
2006). Helices 6 and 12 are positioned closer to each other than in the Sav1866 crystal 
structure (Stockner, de Vries et al. 2009). The arrangement of the 12 canonical trans-
membrane helices observed for Sav1866 is in agreement with the ABC exporter topol-
ogy (Dawson and Locher 2006). Also, they are consistent with electron density maps of 
human P-gp and cross-linking restraints (Stenham, Campbell et al. 2003). The ATP-
bound state of the NBDs, with the two nucleotide-binding domains in close contact, is 
likely to be coupled to the outward-facing conformation of the TMDs. In this conforma-
tion the helices line a central cavity, which is open to the cell exterior.  
 
The three previously published structures from Escherichia coli (E. coli), Vibrio chol-
erae and Salmonella typhimurium were revised by the group of Chang. Now all models 
show the same topology as Sav1866 (Ward, Reyes et al. 2007). 
 
2.4.4 Architecture of the transmembrane subunits 
The crystal structures of five full ABC transporters have become available. Four of 
them are importers: The vitamin B12 transporter BtuCD from E. coli, the metal-chelate-
type transporter HI1470/1 from Haemophilus influenzae, the molybdate transporter 
ModBC from Archaeoglobus fulgidus in complex with its binding protein (ModA), and 
the maltose transporter MalFGK2 from E. coli in complex with the maltose-binding pro-
tein (MBP). ABC importers require a periplasmic or cell surface-associated substrate-
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binding protein that captures the substrates with high affinity and delivers them to the 
external face of the transporter (Quiocho and Ledvina 1996). Only the binding protein, 
not the transporter, binds the substrate. In contrast, ABC exporters recruit their sub-
strates directly from the cytoplasm or, in the case of very hydrophobic substrates, from 
the inner leaflet of the plasma membrane. After retraction of the incorrect MsbA struc-
tures, there are currently only two similar structures of ABC exporters, that of the mul-
tidrug transporter Sav1866 from S. aureus and that of the MsbA from V. cholerae.  
The E. coli BtuCD protein mediates vitamin B12 uptake. The BtuCD and the HI1470/1 
TMDs contain a total of 20 transmembrane α-helices (10 from each TMD) with the N 
and C termini located in the cytoplasm. This is in contrast to the 12 helices of P-gp. 
BtuCD shows a closed internal (cytoplasmic) gate which is formed by the intracellular 
loops between TM4 and TM5 of each BtuC subunit (Hollenstein, Dawson et al. 2007). 
In contrast, HI1470/1 consisting of two membrane-spanning HI1471 subunits and two 
nucleotide-binding HI1470 subunits reveals a closed external gate formed by the ex-
tracellular loops between TM5 and helix5a from each HI1471 subunit.  
The structure of ModBC shows a closed gate near the external side of the membrane. 
Each ModB subunit crosses the membrane 6 times for a total of 12 transmembrane 
segments in the transporter (Hollenstein, Dawson et al. 2007). The structure of the 
MalFGK2 shows five subunits: the two transmembrane subunits, MalF and MalG, com-
posing eight and six TM helices, the two nucleotide-binding MalK subunits, and MBP. 
The crystal structures of these transporters suggest at least two major states: an inward-
facing conformation with the substrate translocation pathway open to the cytoplasm, 
and an outward-facing with the translocation pathway facing the opposite side of the 
membrane (Oldham, Khare et al. 2007). While ModBC and HI1470/1 reveal inward-
facing conformations, BtuCD, MalFGK2 and Sav1866 adopt outward-facing states 
(Oldham, Khare et al. 2007). 
 
2.4.5 Transmission interface 
The NBD-TMD contact interface transmits critical conformational changes induced by 
binding and hydrolysis of ATP. These conformational changes are transmitted via non-
covalent interactions at the share interfaces. The region of the NBD that interacts with 
the TMD primarily involves the L loops (EAA sequence) of the TMDs (Mourez, Hof-
nung et al. 1997; Locher, Lee et al. 2002), and the Q loops (Smith, Karpowich et al. 
2002) and structurally diverse regions (Schmitt, Benabdelhak et al. 2003) of the NBDs, 
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that are in close proximity to each other and mediates the interactions between TMD 
and NBD. 
 
2.5 Mechanisms of transport 
There is no high-resolution crystal structure of a complete eukaryotic ABC exporter 
(complete structures of MalK and BtuCD have been published meanwhile). To gain a 
better understanding about domain-domain interactions in ABC transporters such as P-
gp, it will be necessary to obtain crystal structures of the protein in different conforma-
tions (Loo and Clarke 2008). A number of isolated nucleotide binding domains (NBDs) 
of ABC-transporters has been crystallized and studied in detail (Karpowich, Martsinke-
vich et al. 2001; Schmitt and Tampe 2002; Procko, Ferrin-O'Connell et al. 2006; Sauna 
and Ambudkar 2007). But to understand binding of solutes to the TMDs and the trans-
port process of multispecific drug efflux pumps remains a major scientific challenge. 
Drug binding to P-gp involves an induced-fit mechanism (Loo, Bartlett et al. 2003), 
such that binding of substrate or inhibitor may change the structure of P-gp and thus 
complicate the interpretation of crystallography studies. 
In early studies of bacterial ABC transporters many different groups have published the 
link between substrate transport and ATP-binding and hydrolysis at the NBDs (Hobson, 
Weatherwax et al. 1984; Higgins, Hiles et al. 1985; Bishop, Agbayani et al. 1989; 
Mimmack, Gallagher et al. 1989; Panagiotidis, Reyes et al. 1993). 
 
2.5.1 How is the transport process powered? 
The mechanism how transport is mediated is very complex. 
Binding of ATP flips the ABC transporters into an outward-facing conformation, 
whereas dissociation of the hydrolysis products ADP and phosphate returns them to an 
inward-facing conformation (reviewed in (Dawson, Hollenstein et al. 2007)). Confor-
mational changes in the NBDs, induced by binding and hydrolysis of ATP along the 
dimer interface are coupled to conformational changes in the TMDs that then mediate 
transport of substrate. 
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2.5.2 Motor domains NBDs 
The motor domains of ABC transporters, the NBDs, are between 200 and 300 amino 
acids in length and contain a number of conserved motifs (Schneider and Hunke 1998; 
Dawson, Hollenstein et al. 2007). The Walker A motif has a consensus sequence of 
GxxGxGKST, where x represents any amino acid; the Walker B motif consists of four 
hydrophobic amino acids followed by two negatively charged residues, aspartate and 
glutamate (Walker, Saraste et al. 1982). The Walker A motif binds the phosphate 
groups of the nucleotide. The aspartate residue of the Walker B motif coordinates the 
Mg2+ ion through H2O (Karpowich, Martsinkevich et al. 2001; Yuan, Blecker et al. 
2001; Verdon, Albers et al. 2003) and the glutamate residue of the Walker B motif 
binds to the attacking water and the Mg2+ ion (Moody, Millen et al. 2002; Smith, Kar-
powich et al. 2002). The ABC signature motif also contacts the nucleotide, but only in 
the ATP-bound state, and the Q-loop is in the contact interface with the TMD. Both, the 
general fold and the arrangement of the NBDs are conserved. The NBDs present these 
motifs at the shared interface. The arrangement of the NBDs is called head-to-tail or 
Rad50-like after the structure of the Rad50 protein in which it was first visualized 
(Hopfner, Karcher et al. 2000). They face each other across a dimer with the following 
orientation: two composite ATP binding sites are formed between the P-loop (Walker A 
motif) of one NBD and the LSGGQ motif (C-sequence) of the other and vice versa 
(Jones and George 1999). A number of isolated NBDs or subunits have been crystal-
lized (Diederichs, Diez et al. 2000; Hopfner, Karcher et al. 2000; Gaudet and Wiley 
2001; Karpowich, Martsinkevich et al. 2001; Yuan, Blecker et al. 2001; Smith, Kar-
powich et al. 2002; Chen, Lu et al. 2003; Lu, Westbrooks et al. 2005) since the first 
structure, the HisP protein from Salmonella typhimurium (Hung, Wang et al. 1998) was 
published. Many soluble ABCs have solute-independent ATPase activity when isolated 
from their cognate TM domains (Liu, Liu et al. 1999; Karpowich, Martsinkevich et al. 
2001), proposing that ATP interacts primarily with the NBDs. The structures of the 
ATP-bound state of isolated NBDs which include both importers and exporters have 
been reported. 
 
2.5.3 How are solutes transported 
P-gp transports substrates which passively diffuse across the lipid bilayer and enter the 
cytoplasm. 
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Various distinct mechanisms have been proposed in the literature for coupling of drug 
transport to ATP hydrolysis. 
Early studies of the mammalian multidrug resistance P-gp by Alan Senior’s group de-
fined the biochemistry of the ATPase cycle and proposed the alternating catalytic site 
model with drug transport linked to relaxation of a high-energy NBD conformation 
generated by ATP hydrolysis (Senior, al-Shawi et al. 1995). In addition, these studies 
showed that the two catalytic sites are both required for transport function (Figure 2.2).  
 
Figure 2.2: Alternating catalytic sites cycle of ATP hydrolysis by P-gp (adapted from (Senior, al-
Shawi et al. 1995)). Rectangels represent the two TMDs. Circels, squares and hexagon represent 
different conformations of the N- and C-catalytic sites of NBD1 and NBD2. ATP binding at the N-
site allows ATP hydrolysis at the C-site. 
 
Subsequently, several related models for transport appeared (Senior and Gadsby 1997; 
Nikaido and Ames 1999; van Veen, Margolles et al. 2000; Sauna and Ambudkar 2001) 
for other transporters. These models assumed that the two NBDs which hydrolyze ATP, 
thus supplying the energy for translocation, operate alternately and may therefore be 
coupled to distinct steps in the transport cycle (Higgins and Linton 2004).  
The recent availability of structural data in combination with biochemical and genetic 
studies of several ABC transporters have led to the ATP-switch model of function (Hig-
gins and Linton 2004; Linton and Higgins 2007). 
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2.5.4 The catalytic cycle of P-gp - The ATP-switch model  
The ATP-switch model involves communication via conformational changes in both 
directions, between the NBDs and TMDs (Higgins and Linton 2004). This model sug-
gests a switch between two principal conformations of the NBDs:  
• formation of a closed dimer formed by binding two ATP molecules at the dimer 
interface, and 
• dissociation of the closed dimer to an open dimer facilitated by ATP hydrolysis 
and release of Pi and ADP. 
Switching between the open and closed conformations of the dimer induces conforma-
tional changes in the TMDs necessary for transport of substrate across the membrane 
(Higgins and Linton 2004). 
The model consists of four steps (see also (Higgins and Linton 2004)) (Figure 2.3): 
 
Step one: Substrate binding to P-gp 
The basal state of P-gp has low affinity for ATP, and the NBDs are in the open dimer 
configuration. The binding site for the transport substrate on the TMDs is accessible 
from the cytoplasmic face of the membrane. Transport substrate binding to its high-
affinity binding site(s) on the TMDs of P-gp initiates the transport cycle. There are sev-
eral studies which appear to show that this is the first step in the transport cycle. 
Petronilli et al. (Petronilli and Ames 1991) and Davidson et al. (Davidson, Shuman et 
al. 1992) generated mutant proteins of bacterial ABC NBDs HisP and MalK in which 
the ATPase activity of the transporter is uncoupled from periplasmic protein binding, 
leading to futile cycles of ATP hydrolysis.  
Binding of the transport substrate induces a conformational change which is transmitted 
to the NBDs to initiate the ATP catalysis cycle. Several studies have shown substrate-
induced conformational changes in the NBDs of P-gp (Liu and Sharom 1996; Son-
veaux, Vigano et al. 1999), TAP (Neumann, Abele et al. 2002), MRP1 (Manciu, Chang 
et al. 2003), and the bacterial histidine (Kreimer, Chai et al. 2000) and maltose per-
meases (Mannering, Sharma et al. 2001). 
 
Step two: ATP binding to P-gp 
The second step in the transport cycle, the ATP binding, provides the energy input re-
quired for translocation of the drug from the inner leaflet of the membrane to the outside 
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of the cell. ATP binding induces closed NBD dimer formation and a major conforma-
tional change in the TMDs to initiate translocation. 
Martin and colleagues used radioligand-binding techniques to characterize vinblastine 
interaction sites on P-gp and determine how drug binding site parameters are altered 
during a catalytic cycle of P-gp (Martin, Berridge et al. 2000; Martin, Berridge et al. 
2000; Martin, Higgins et al. 2001). The authors showed that the binding capacity for 
vinblastine on P-gp decreased when the protein was incubated with the non-
hydrolyzable ATP analogues AMP-PNP (Martin, Higgins et al. 2001) and ATP-γ-S 
(Martin, Berridge et al. 2000). These data suggest that ATP binding, in the absence of 
ATP hydrolysis, causes the initial shift to a low-affinity conformation of the drug bind-
ing site. Studies by van Veen et al. showed the presence of two vinblastine binding sites 
in the bacterial LmrA transporter, a homolog of P-gp: A low-affinity binding site ex-
posed at the extracellular (outside) surface of the membrane and a high-affinity binding 
site exposed at the intracellular (inside) surface of the membrane (van Veen, Margolles 
et al. 2000). Only the low-affinity binding site is accessible for vinblastine in the 
ADP/vanadate-trapped LmrA protein which corresponds to a posthydrolysis situation. 
These data suggest that ATP binding or hydrolysis provides the conformational change 
by which the transport substrate is translocated to the outside of the cell. 
 
Step three: ATP hydolysis 
ATP hydrolysis, the trigger is unknown, initiates the transition of the NBD closed dimer 
to the open dimer and returns the transporter to its basal state (Higgins and Linton 
2004). Many groups used the technique of vanadate trapping with 8-azido-ATP or 8-
azido-ADP to obtain a posthydrolytic transition state when studying the catalytic sites 
of P-gp (Urbatsch, Sankaran et al. 1995; Urbatsch, Sankaran et al. 1995; Sharma and 
Davidson 2000; Payen, Gao et al. 2003; Urbatsch, Tyndall et al. 2003). The ATPase 
activity is inhibited by vanadate. 
 
Step four: Restore P-gp to the basal state 
Pi and then ADP are released and the protein is ready to initiate another transport cycle. 
  18 
 
 
Figure 2.3: The ATP-switch model for the transport cycle of vinblastine by P-gp (adapted from 
(Linton and Higgins 2007)).  
 
2.5.5 Binding of solutes to TMDs 
2.5.5.1 Photolabelling of P-gp with substrate analogues 
In our group photolabelling of P-gp has been used in combination with high resolution 
mass spectrometry to identify helices involved in binding of propafenone analogues 
(Pleban, Kopp et al. 2005). Six photoaffinity ligands of different mass related to the 
compound propafenone were used to photolabel P-gp by irradiation at a wavelength of 
340-360nm. These compounds have previously been shown to be P-gp substrates and 
inhibitors (Chiba, Ecker et al. 1996; Schmid, Ecker et al. 1999). After irradiation, P-gp 
was purified by SDS-polyacrylamide gel electrophoresis and proteolytically degraded 
by chymotrypsin digestion. Ligand-labeled peptides were identified by matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. The mass 
spectrum shows masses corresponding to component peptide fragments with covalently 
bound ligand, which can be identified and aligned. Peptide fragments which are cova-
lently modified by the photoligand shift from their original position in the mass spec-
trum to an m/z position, which is increased by the ligand mass (Ecker, Pleban et al. 
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2004). The photoaffinity labelling allowed the identification of four TM helices, TMs 3, 
5, 8 and 11, indicating that these four TM segments are involved in the substrate-
binding event (Pleban, Kopp et al. 2005). These helices are located at the TMD/TMD 
interfaces. The highest labelling scores were observed for residues M197 in TM3 and 
F951 in TM11, and A311 in TM5 and T769 in TM8 for the TM 5/8 interface (Figure 
2.4). In addition, methionine residues which have been reported to show a preferred 
reaction with benzophenone-type ligands (Rihakova, Deraet et al. 2002) are shown as 
red crosses. A number of methionine residues were not labeled and thus inaccessible for 
the photoligands (Pleban, Kopp et al. 2005). The ability of benzophenones to react with 
aliphatic residues was reported by Dorman et al. (Dorman and Prestwich 2000). 
 
 
Figure 2.4 Frequency distribution analysis of photolabeling (adapted from (Pleban, Kopp et al. 
2005)). The number of labeled fragments in which each particular amino acid residue in the pri-
mary sequence of P-gp is found is plotted as a function of this amino acid position. Predicted TM 
segments are shown in magenta, and the remainder of the sequence is in black. For easier orienta-
tion, a schematic representation is shown below the graph. TMDs 1 and 2 represent the N-terminal 
and C-terminal transmembrane domains, and the motor domains NBD1 and NBD2 are shown in 
blue. The linker region is indicated in gray, and the C-terminal hexa-His tag is depicted in black. 
The positions of methionine residues are highlighted by red symbols (x). The highest labeling is 
observed for putative TMs 3, 5, 8, and 11. In addition, the loop region connecting TMs 9 and 10 
(extracellular loop 5) has a high labeling score. 
 
In our group a protein homology model of P-gp was generated to allow projection of 
labelling data on a 3 dimensional model of the protein using the crystal structure of V. 
cholerae MsbA as template (Pleban, Kopp et al. 2005). A side and top view of the ho-
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mology model of P-gp is shown in Figure 2.5. At this time the crystal structure of MsbA 
was the only available template structure. 
 
 
 
Figure 2.5 Side and top view of a P-gp homology model based on the V. cholerae MsbA structure 
(adapted from (Pleban, Kopp et al. 2005)). The N-terminal half of P-gp is depicted in dark blue, the 
C-terminal half is in cyan. Residues with the highest labelling are shown in yellow and red. Met197 
in TM3 and Phe951 in TM11 are depicted in yellow. These residues are located on different halves 
of P-gp and thus, helices 3 and 11 contribute to one of the two TMD/TMD interfaces. Ala311 in 
TM5 and Thr769 in TM8 are depicted in red and are located at the other TMD/TMD interface. 
 
These studies suggested the existence of two pseudosymmetric binding pockets at the 
two TMD/TMD interfaces. 
 
2.6 Objectives of the thesis 
An important goal in understanding the mechanism of drug transport has been to iden-
tify the locations of the drug-binding sites of P-gp. Presently, the location of the drug 
binding sites of multispecific drug efflux transporters is undefined because of the lack 
of high resolution structures of ABC-transporters with bound substrate. Thus, alterna-
tive approaches are needed to provide insight into the structure and function of P-gp.  
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The aim of this project was the identification and characterization of TMD1/TMD2 con-
tact interface residues, which are important for transport of solutes. Functional assays 
were performed with P-gp mutants, in which the TMD1/TMD2 contact interface resi-
dues were mutated to residues other than cysteine by site directed mutagenesis based on 
overlap extension polymerase chain reaction (OE-PCR). The mutational concept was 
guided by photoaffinity labelling, availability of protein homology models, in-silico 
importance prediction of residues by real valued evolutionary trace (JMB 2003) and 
data-driven docking results (JACS 2004, HADDOCK) based on previous site-directed 
mutagenesis data. Thus, hypothesis driven generation of P-gp mutants with amino acid 
residues that will be tolerated in the protein to obtain a high number of correctly tar-
geted and functional transporters was performed. 
Another aspect of this project was correction of protein folding in mutants by pharma-
cological chaperones. Mutations often result in folding abnormalities, which lead to the 
newly synthesized protein being retained at the endoplasmic reticulum (ER) by the ER 
quality control machinery. 
 
Objective 1: Identification of amino acid residues in the protein, which are important for 
transport. TMD1/TMD2 contact interface residues were mutated to residues other than 
cysteine. 
A large number of functionally important P-gp residues within the TMDs have previ-
ously been identified by systematic site directed mutagenesis experiments in both hu-
man and mouse P-gp. The group of David Clarke exchanged every single residue in 
predicted transmembrane segments of human P-gp to cysteine by using a site directed 
mutagenesis approach. The protein contains only seven endogenous cysteine residues, 
all of them were mutated to alanine (Loo and Clarke 1995) resulting in an active cys-
teine-less P-gp. Residues that line TMD1/TMD2 contact interfaces have been identified 
to impair function when mutated to cysteines and reacted with cysteine reactive sub-
strate molecules. A large number of those residues are known to participate in drug 
transport as demonstrated by mutagenesis and solute cross-linking experiments (Loo 
and Clarke 2005). 
 
Objective 2: Influence of pharmacological chaperones on protein folding. 
Many mutants do not correctly traffic to the plasma membrane. Proteins which are un-
able to adopt a stable conformation because of a specific mutation or aberrant glycosy-
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lation are trapped in the ER (Welch and Brown 1996). These proteins are targeted to a 
degradative pathway. Different chaperones interact with unfolded or misfolded proteins 
to allow the protein to pass the secretory pathway (Brown, Hong-Brown et al. 1996). 
Two glutamine residues (Q132 and Q773) of P-gp are located at the domain interfaces. 
It was considered possible that these glutamine residues if mutated to other amino acids 
cause the protein to be retained in the ER. The mutant protein would then be degraded 
rapidly. P-gp has been reported to be a good model system for the study of folding de-
fects and action of pharmacological chaperones. It is possible to monitor cell surface 
expression of the transporter using a P-gp-specific antibody and flow cytometry. 
  
2.6.1 Rational selection of residues 
Why glutamine residues? Is it rational to mutate the glutamine residues at the position 
132 and 773?  
The glutamine residues are:   
 a. highly conserved  
 b. located at the interfaces  
 c. predicted by in-silico docking to contribute highest energy to interaction with 
 propafenone analogues 
d. located in the vicinity of amino acids showing high labelling with photoaffin-
ity ligands  
 
Alignments of the N- and C-terminal half of P-gp  
Sequence alignments of the amino- and carboxy-terminal half of P-gp indicate two con-
served glutamine (Q) residues in positions 132 and 773 (shown in Figure 2.6). Q773 is 
the only residue in helix 8 other than G763 that is conserved between helix 2 and helix 
8.  
 
Figure 2.6: Partial sequence alignments of TMs 2 and 8 of the N- and C-terminal half of P-gp. The 
transmembrane segments are highlighted in turquoise. Glutamine residues at positions 132 and 773 
are shown in red. 
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Position of the glutamine resisdues at each of the TMD/TMD interfaces 
Position of the glutamine residues Q132 and Q773 at each of the TMD/TMD interfaces 
are shown in Figure 2.7. 
 
Figure 2.7: Top view (A) and side view (B) of the P-gp model (generated in our group with VMD 
1.85). TMDs are only shown (NBDs omitted). The N-terminal half of P-gp is depicted in yellow, the 
C-terminal half is in grey. Residues M197 (TM3), A311 (TM5), T769 (TM8), and F951 (TM11) have 
been shown to be highly accessible for photoaffinity ligands. Gludamine residues Q132 (TM2) and 
Q773 (TM8) are shown in red. The TM5/TM8 interface is highlighted by a yellow circle. 
 
Data-driven docking of propafenones to each of the interfaces 
To gain additional insights into the binding mechanism of drugs to P-gp, computational 
docking was used to generate structural models. High Ambiguity Driven DOCKing 
(HADDOCK) was initially developed as a protein-protein docking tool (Dominguez, 
Boelens et al. 2003). HADDOCK has been used in a large number of studies, including 
protein-protein docking (van Dijk, de Vries et al. 2005; van Dijk, Fushman et al. 2005; 
Volkov, Ferrari et al. 2005; de Vries, van Dijk et al. 2006), protein-peptide docking 
(Tzakos, Fuchs et al. 2004; Denisov, Chen et al. 2006), protein-DNA docking (van Dijk, 
van Dijk et al. 2006), protein-RNA docking (Volpon, D'Orso et al. 2005) and protein-
ligand docking (Schieborr, Vogtherr et al. 2005). The data-driven docking program 
HADDOCK, developed and performed by the group of Alexandre Bonvin, was used to 
study binding of propafenone analogues to P-gp. HADDOCK distinguishes between 
active and passive residues. Information derived from photoaffinity labelling and site 
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directed mutagenesis is complemented by data-driven docking. Protein-ligand contact 
profiles identified two glutamine residues, Q132 in TM2 and Q773 in TM8 adopting 
identical positions in sequence alignments of the amino- and carboxy-terminal half of P-
gp, at each of the interfaces as privileged interaction partners. 
 
 
Figure 2.8: TM 3/11 interface (generated by Sjoerd de Vries in Dr. Alexandre M.J.J. Bonvin’s 
group at Utrecht University): One pose of the most highly ranked cluster is shown. H-bonding con-
tacts with Q132 in TM2 are predicted. The most highly accessible residues for propafenone photo-
ligands (residues M197 in TM3 and F951 in TM11) are in close proximity of the ligand, though a 
bias for these residues is not introduced during the docking procedure. 
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Figure 2.9: TM 5/8 interface (generated by Sjoerd de Vries in Dr. Alexandre M.J.J. Bonvin’s group 
at Utrecht University): Two individual poses of the most highly ranked cluster are shown. The 
movements occurring during the flexible refinement stage of docking are illustrated by different 
backbone and rotamer positions. The two ligands are shown in different coloring. In both poses the 
ligand makes two H-bonding contacts with residue Q773 in TM8 and an aromatic stacking interac-
tion with residue Y307 in TM5. The photolabelled residues A311 in TM5 and T769 in TM8 are 
again in close proximity of the ligand. 
 
Determination of sequence variation 
Evolutionary variation in both, Q132 and Q773, positions is low as indicated by multi-
ple sequence alignments of P-gp sequences of different species using real valued evolu-
tionary trace (rvET) (Mihalek, Res et al. 2004) (http://mammoth.bcm.tmc.edu). Genera-
tion of mutants was guided by the mutational space explored by nature. 
 
 
The central objective of this work was to study the functional biology of P-glycoprotein 
by combining site directed mutagenesis and direct transport assays. The influence of the 
mutations on function was measured by drug accumulation assays in whole cells. 
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3 Materials and methods 
 
3.1 Chemicals and reagents 
10mM dNTP Mix (Fermentas, Cat. No. R0191) 
2mM dNTP Mix (Fermentas, Cat. No. R0241) 
Ampicillin (Sigma, Cat. No. A9518) 
C219 (Eubio, Austria, Cat. No. ALX 801002) 
Goat anti-mouse Ig FITC (BectonDickinson, Cat. No. 349031) 
Gateway® LR ClonaseTM Enzyme Mix (Invitrogen, 20 reactions Cat. No. 11791-019) 
GenEluteTM Plasmid Miniprep Kit (Sigma, Cat. No. PLN350) 
GFX PCR DNA and Gel Band Purification Kit (Amersham Biosciences, Cat. No. 27-
9602-01) 
Gentamicin (Invitrogen, Cat. No. 15750-060) 
HiSpeed® Plasmid Midi Kit (QIAGEN, Cat. No. 12643) 
Isopropyl-ß-thiogalactopyranoside (IPTG) (Invitrogen, Cat. No. 15529-019) 
Hygromycin B (Invitrogen, Cat. No. 10687-010) 
IgG2a (BectonDickinson, Cat. No. 340394) 
iScriptTMcDNA Synthesis Kit (BioRad, 25 reaction kit Cat. No. 170-8890) 
Kanamycin (Gibco, Cat. No. 11815-024) 
LipofectamineTM 2000 (Invitrogen, Cat. No. 11668-027) 
MRK 16, monoclonal antibody to P-glycoprotein, (Alexis Biochemicals, Cat. No. 801-
008-C150) 
PageRulerTM Prestained Protein Ladder (Fermentas, Cat. No. SM0679) 
Platinum Taq polymerase (5units/µl) (Invitrogen, Cat. No. 10966-018) 
Pfu DNA Polymerase, native and 10x PCR Buffer with MgSO4 (Fermentas, Cat. No. 
EP0571) 
Rapid DNA Ligation Kit (Fermentas, Cat. No. K1422) containing T4 DNA Ligase 
(5u/µl), 5x Rapid Ligation Buffer and water (nuclease-free) 
Restriction endonucleases (Fermentas): BamHI (Cat. No. ER0051) 
      SalI (Cat. No. ER0641) 
      XbaI (Cat. No. ER0685) 
      XhoI (Cat. No. ER0691) 
      EcoRI (Cat. No. ER0271) 
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Rhodamine 123 (Sigma, Cat. No. R8004) 
Tetracycline (Sigma, Cat. No. T3258) 
TRIzol® Reagent (Invitrogen, Cat. No. 15596-026) 
X-Gal (Sigma, Cat. No. B9146) 
 
3.2 Solutions 
Solutions were made using de-ionised or ultra-pure water. 
Sterilisation was carried out by autoclaving at 125°C for 20 minutes, or by filtration 
using a 0.2 µm filter (Millipore, SLGS03355). 
 
3.3 Chemical structures of compounds 
The following chemicals were used in this work: 
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Figure 3.1: Structure of Cyclosporin A. Formula: C62H111N11O12; Molecular Weight: 1202.61  
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Figure 3.2: Structure of GPV01. Formula: C21H27NO3; Molecular Weight: 341.44 
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Figure 3.3: Structure of GPV31. Formula: C28H31FN2O3; Molecular Weight: 462.56 
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Figure 3.4: Structure of GPV51. Formula: C20H25NO3; Molecular Weight: 327.42 
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Figure 3.5: Structure of rhodamine 123. Formula: C21H17ClN2O3; Molecular Weight: 380.82  
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Figure 3.6: Structure of verapamil. Formula: C27H38N2O4; Molecular Weight: 454.6. 
 
GPV01, GPV31 and GPV51 are propafenone analogues which were synthesized ac-
cording to published procedures (Chiba, Burghofer et al. 1995; Chiba, Ecker et al. 
1996). Stock solutions were prepared in pure DMSO and the final DMSO concentration 
did not exceed 0.2% (v/v). 
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3.4 Microbiology 
3.4.1 Bacterial strains 
One shot® TOP10, one shot® DB3.1, one shot® ccdB Survival T1 Phage-Resistant cells 
and MAX efficiency® DH10BacTM chemically competent E. coli cells were supplied by 
Invitrogen.  
 
Library Efficiency® DB3.1TM Chemically Competent E. coli Cells (Cat. No. 11782-018) 
Genotype 
F- gyrA463 endA1 ∆(sr1-recA) mrcB mrr hsdS20(rB
-, mB
-) supE44 ara14 galK2 lacY1 
proA2 rpsL20(Smr) xyl5 ∆leu mtl1 
 
One Shot® TOP10 Chemically Competent E. coli Cells (Cat. No. C4040-03) 
Genotype 
F- mrcA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 araD139 ∆(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG  
 
One shot® ccdB Survival T1 Phage-Resistant Chemically Competent E. coli Cells (Cat. 
No. C7510-03) 
Genotype 
F- mrcA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 ara ∆139 ∆(ara, 
leu)7697 galU galK rpsL (StrR) endA1 nupG tonA::Ptrc-ccdA 
 
MAX Efficiency® DH10BacTM Chemically Competent E. coli Cells (Cat. No. 10361-
012) 
Genotype 
F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 endA1 araD139 
∆(ara, 
leu)7697 galU galK λ- rpsL nupG/bMON14272/pMON7124 
 
The DB3.1 E. coli strain contains a gyrase mutation (gyrA643) that renders it resistant 
to CcdB effects and can support the propagation of plasmids containing the control of 
cell death (ccd)B gene (Bernard and Couturier 1992; Miki, Park et al. 1992; Bernard, 
Kezdy et al. 1993). The ccdB Survival T1 Phage-Resistant E. coli cells are also resistant 
to the CddB effects. 
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3.4.2 Bacterial culture medium, culture and storage 
Lysogeny broth (LB)-Bouillon: Peptone from casein 10 g/l, yeast extract 5.0 g/l, 
sodium chloride 10 g/l  (MERCK, Darm-
stadt, Germany, Cat. No. 1.10285.0500); stored at 
room temperature 
LB agar: Peptone from casein 10 g/l, yeast extract 5.0 g/l, 
sodium chloride 10.0 g/l, Agar-agar 12.0 g/l 
(MERCK, Darmstadt, Germany, Cat. No. 
1.10283.0500); stored at room temperature 
S.O.C. medium: 2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM 
glucose (Invitrogen, Cat. No. 15544-034); stored at 
room temperature 
 
Selection media: 
Solid or liquid growth media were supplemented with kanamycin to a final concentra-
tion of 50µg/ml kanamycin or with ampicillin to a final concentration of 100µg/ml or 
with kanamycin (50 µg/ml), gentamicin (7 µg/ml), tetracycline (10 µg/ml), X-Gal (100 
µg/ml) and IPTG (40 µg/ml).  
 
LB agar plates containing the appropriate antibiotic to select for the vector were stored 
at 4°C for approximately 2 weeks, liquid selection media were always prepared fresh. 
Bacteria were grown in liquid media with shaking (300rpm), or on plates in an incuba-
tor, at 37°C. For long-term storage bacteria were frozen at -80°C in a mixture of 850 µl 
LB medium and 150 µl glycerol. 
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3.5 Moleculare Biology 
3.5.1 Plasmids 
All plasmids used in this study were purchased from Invitogen.  
Product Amount Catalog no. 
pEF5/FRT/V5-DEST GatewayTMVector 6 µg V6020-20 
pENTRTM4 10 µg 11818-010 
pDESTTM8 6 µg 11804-010 
pOG44 20 µg V6005-20 
pENTRTM/SD/D-TOPO® Cloning Kit 20 reactions K2420-20 
 
The entry vector, pENTR4 and both destination vectors, pEF5/FRT/V5-DEST and 
pDEST8, are components of the Gateway® Technology system (Invitrogen). The Gate-
way® Technology cloning method is based on the site-specific recombination properties 
of the bacteriophage lambda (Landy 1989) (Invitrogen 2003). The site-specific recom-
bination properties of this bacteriophage provide a rapid and efficient way of moving 
the coding sequence into multiple vector systems in a directional and specific way for 
functional analysis and protein expression (Hartley, Temple et al. 2000). The lambda 
site-specific recombination system facilitates integration of the lambda genome into the 
E. coli chromosome and switches between the lytic and lysogenic pathways (Invitrogen 
2003). The components of the lambda recombination system are modified to improve 
the specificity and efficiency of the system (Bushman, Thompson et al. 1985; Invitro-
gen 2003). 
 
The pENTR4 vector contains a multiple cloning site, rrnB transcription termination 
sequences preventing basal expression of the PCR product in E. coli, the kanamycin 
resistance gene for selection in E. coli, the pUC origin for high-copy replication and 
maintenance of the plasmid in E. coli, and a Kozak consensus sequence for efficient 
translation initiation in eukaryotic systems (Invitrogen 2004). In addition, the pENTR4 
vector has attachment (att) L sites (100 bps) and is used to clone restriction fragments, 
which do not contain att sites to generate entry clones. A ccdB gene is located between 
the two attL sites for negative selection (Invitrogen 2004). Before cloning, the pENTR4 
vector must be digested on each site of the ccdB gene for removing the ccdB gene. The 
att sites, attL1 and attL2, allow site-specific recombination of the entry clone with a 
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destination vector (pEF5). The destination vector contains attR sites (125 bps), attR1 
and attR2, and recombines with the entry clone in a LR reaction to generate an expres-
sion clone containing attB sites (25 bps). Therefore, attL1 sites react only with attR1 
sites and attL2 sites react only with attR2 sites (Invitrogen 2003). The recombination 
reaction is mediated by the LR ClonaseTM Enzyme Mix (Invitrogen, 20 reactions, Cat. 
No. 11791-019). The LR Clonase Enzyme Mix is a mixture of enzymes that bind to 
specific sequences (att sites), bring together the target sites, cleave them, and covalently 
attach the DNA using a lytic pathway (Invitrogen 2003). The lytic pathway is catalyzed 
by bacteriophage lambda Integrase (Int) and Excisionase (Xis) proteins, and the E. coli 
Integration Host Factor (HIF) protein (Invitrogen 2003).  
 
LR recombination reaction: 
Component Sample 
Entry clone (100-300 ng/reaction) 0.5-2 µl 
Destination vector (300 ng/reaction) 2 µl 
5x LR Clonase Reaction Buffer 2 µl 
TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA To 8 µl 
 
2 µl of the LR Clonase Enzyme Mix were added to each sample which was then vor-
texed briefly. The LR recombination reaction was incubated for 1 hour at 25°C. After 
incubation 1 µl Proteinase K was added and the samples reincubated for 10 minutes at 
37°C. Then 2 µl of each reaction were transformed into 50 µl of One Shot TOP10 
Chemically Competent Cells in an Eppendorf tube and incubated 30 minutes on ice. 
The cells were heat-shocked by incubating at 42°C for 30 seconds and placed on ice for 
approximately 2 minutes. After cooling, 250 µl S.O.C. medium was added and the tubes 
were incubated at 37°C for 1 hour at 300 rpm in a shaking thermoblock (Eppendorf 
Thermomixer comfort). Finally, the cells were spread on LB plates containing 100 
µg/ml Ampicillin and incubated overnight at 37°C. The generated clones were screened 
by size exclusion and restriction enzyme digestion. 
 
The first cloning experiments were done using the pENTR/SD/D-TOPO vector to clone 
PCR products containing no att sites to generate entry clones. The forward primer has to 
be designed in a manner that allows the ATG initiation codon of the PCR product to 
directly follow the CACC sequence being the prerequisite for directional cloning (Invi-
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trogen 2006). These 4 nucleotides pair with the overhang sequence GTGG in each 
pENTR TOPO vector (Invitrogen 2006). Mixing the PCR product and pENTR TOPO 
vector starts the TOPO Cloning Reaction resulting in an entry clone. Unfortunately, the 
insert always proofed to be either too short or in the reverse orientation.  
 
The pEF5 destination vector contains the following components (see also (Invitrogen 
2002)): 
• human EF-1alpha promoter for high-level expression of mammalian cells 
• T7 promoter 
• two recombination sites, attR1 and attR2 
• chloramphenicol resistance gene located between the two attR sites for coun-
terselection 
• ccdB gene between the two attR sites 
• bovine growth hormone (BGH) polyadenylation sequence for proper termination 
and processing of the recombinant transcript 
• FLP Recombination Target (FRT) for Flp recombinase-mediated integration of 
the vector into Flp-InTM host cell line 
• hygromycin resistance gene that lacks a promoter and an ATG initiation codon, 
therefore transfection of the pEF5 vector alone into mammalian host cells will 
not confer hygromycin resistance to the cells 
• pUC origin  
• the ampicillin (bla) resistance gene for selection in E. coli 
• SV40 early polyadenylation signal for efficient transcription termination and 
polyadenylation of mRNA 
 
The pEF5 vector allows high-level, constitutive expression of a coding sequence in a 
variety of mammalian hosts using the Flp-InTM system. 
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Figure 3.7: The map of the pENTR4 vector. Enzymes with unique restriction sites are shown, en-
zymes with two or more restriction sites are not shown. KanR: Kanamycin resistance gene, T1: 
rrnB T1 transcription termination sequence, T2: rrnB T2 transcription termination sequence 
 
 
 
Figure 3.8: The map of the pENTR4MDR1 vector. Enzymes with unique restriction sites are 
shown, enzymes with two or more restriction sites are not shown. KanR: Kanamycin resistance 
gene, T1: rrnB T1 transcription termination sequence, T2: rrnB T2 transcription termination se-
quence 
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Figure 3.9: The map of the pEF5 vector. Enzymes with unique restriction sites are shown, enzymes 
with two or more restriction sites are not shown. AmpR: Ampicillin resistance gene, BGH pA: Bo-
vine growth hormone polyadenylation sequence, CmR: Chloramphenicol resistance gene, FRT: 
FLP Recombination Target site, HygromycinR: Hygromycin resistance gene, PEF-1 alpha: EF-
1alpha promoter, SV40 pA: SV40 early polyadenylation signal 
 
Figure 3.10: The map of the pEF5MDR1 vector. Enzymes with unique restriction sites are shown, 
enzymes with two or more restriction sites are not shown. AmpR: Ampicillin resistance gene, BGH 
pA: Bovine growth hormone polyadenylation sequence, FRT: FLP Recombination Target site, 
HygromycinR: Hygromycin resistance gene, PEF-1 alpha: EF-1alpha promoter, SV40 pA: SV40 
early polyadenylation signal 
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Figure 3.11: The map of the pOG44 vector. Enzymes with unique restriction sites are shown, en-
zymes with two or more restriction sites are not shown. Amp: Ampicillin resistance gene, PCMV: 
human cytomegalovirus immediate-early enhancer/promoter, SV40 pA: SV40 late polyadenylation 
signal 
 
The pDESTTM8 vector has the following features (see also (Invitrogen 2004): 
• Polyhedrin gene promoter from Autographa californica multi nuclear polyhe-
drosis virus (AcMNPV) for high-level expression of the gene of interest (Possee 
and Howard 1987). 
• Mini-Tn7 elements for site-specific transposition into the bacmid DNA propa-
gated in E. coli (Luckow, Lee et al. 1993). 
•  Two recombinates sites, attR1 and attR2 
• Chloramphenicol resistance gene located between the two attR sites for coun-
terselection 
• ccdB gene between the two attR sites 
• The ampicillin (bla) resistance gene for selection in E. coli 
• The gentamicin resistance gene for selection of transformants containing recom-
binant bacmid DNA 
• SV40 early polyadenylation signal for efficient transcription termination and 
polyadenylation of mRNA 
• pUC origin  
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With the pDEST8 vector the gene of interest can be moved into a bac-to-bac baculovi-
rus expression system. The Bac-to-Bac baculovirus expression system is a rapid and 
efficient method to generate recombinant baculoviruses based on the site-specific trans-
position properties of the Tn7 transposon (Luckow, Lee et al. 1993) (Invitrogen 2004). 
The DH10BacTM E. coli host strain contains a baculovirus shuttle vector (bacmid) and a 
helper plasmid and allows generation of a recombinant baculovirus for high-level ex-
pression of the gene of interest in insect cells (Invitrogen 2004). The baculovirus shuttle 
vector propagates in the DH10Bac E. coli as a large plasmid which confers resistance to 
kanamycin and can complement a lacZ deletion present on the chromosome to form 
colonies which are blue (Lac+) in the presence of X-gal and the inducer IPTG (Invitro-
gen 2004). The helper plasmid encodes the transposase and confers resistance to tetra-
cycline.  
 
Figure 3.12: Generation of recombinant baculovirus and gene (MDR1) expression using the bac-to-
bac baculovirus expression system (adapted from (Invitrogen 2009)). 
 
1 ng of each pDEST8 construct was transformed into 50 µl of MAX Eficiency 
DH10Bac Chemically Competent Cells in an Eppendorf tube and incubated for 30 min-
utes on ice. The cells were heat-shocked by incubating at 42°C for 30 seconds and 
placed on ice for approximately 2 minutes. After cooling, 900 µl S.O.C. medium were 
added and the tubes were incubated at 37°C for 4 hours at 300 rpm in a shaking ther-
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moblock (Eppendorf thermomixer comfort). Finally, the cells were spread on LB plates 
containing 50 µg/ml kanamycin, 7 µg/ml gentamicin, 10 µg/ml tetracycline, 100 µg/ml 
X-gal, and 40 µg/ml IPTG. The plates were incubated for 48 hours at 37°C. White colo-
nies were picked for analysis because insertions of the mini-Tn7 into the mini-attTn7 
attachment site on the bacmid disrupt the expression of the LacZα peptide (blue/white 
selection). The bacmid was then isolated and purified. 
 
Analyzing recombinant bacmid DNA by PCR: 
PCR analysis was performed to verify the presence of the MDR1 gene in the recombi-
nant bacmid. The bacmid contains M13 forward and M13 reverse priming sites flanking 
the mini-attTn7 site (Invitrogen 2009). 
 
Reaction mix per sample: 
Recombinant bacmid DNA (100 ng) 0.5-1 µl 
10X PCR Buffer 2.5 µl 
10 mM dNTP Mix 0.5 µl 
50 mM MgCl2 0.75µl 
Primer_for (10 µM stock) 1 µl 
Primer_rev (10 µM stock) 1 µl 
ddH2O 18-18.5 µl 
Platinum Taq polymerase (5 units/µl) 0.25 µl 
Total Volume  25 µl 
 
 
Primer Nucleotide sequence (5’ → 3’) 
M13_for 5’-GTTTTCCCAGTCACGAC-3’ 
M13_rev 5’-CAGGAAACAGCTATGAC -3’ 
MDR1Hind_for 5’-GCCCAAGACAGAAAGCTTAGTACC-3’ 
MDR1Hind_rev 5’-GGTACTAAGCTTTCTGTCTTGGGC-3’ 
MDR1Q132R_for 5’-GCTGCTTACATTCGTGTTTCATTTTG-3’ 
MDR1Q132R_rev 5’-CAAAATGAAACACGAATGTAAGCAGC-3’ 
MDR1Q773R_for 5’-CATTTTTCCTTCGAGGTTTCACATTTG-3’ 
MDR1Q773R_rev 5’-CATTTTTCCTTCGAGGTTTCACATTTG-3’ 
Table 3.1: Oligonucleotides used for analyzing recombinant bacmid DNA. 
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The thermal cycling conditions were as following: 
Step Temperature, °C Time, min Number of Cycles 
Initial Denaturation 93 3 1 
Denaturation 94 0.75  
Annealing 55 0.75 35 
Extension 72 5  
Final Extension 72 7 1 
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If transposition was successful, bands with the following sizes should be visible on the 
agarose gel: 
Primerpair bps 
(approximately) 
Template 
M13_for ;  
M13_rev 
 
6278 G185V; G185V-Q132R; G185V-Q773R;  
G185V-Q132R/Q773R 
M13_for;  
MDR1Hind_rev 
 
3800 G185V; G185V-Q773R;  
G185V-Q132R/Q773R 
MDR1Hind_for;  
M13_rev 
 
2640 G185V; G185V-Q132R;  
G185V-Q132R/Q773R 
MDR1Q132R_for;  
MDR1Hind_rev 
 
1671 G185V; G185V-Q132R 
 
MDR1Q132R_for; 
M13_rev 
 
4285 G185V-Q132R 
MDR1Q132R_for; 
MDR1Q773R_rev 
 
1951 G185V-Q132R/Q773R 
M13_for;  
MDR1Q132R_rev 
 
2155 G185V-Q132R; G185V-Q132R/Q773R 
MDR1Q773R_for ; 
M13_rev 
 
2353 G185V-Q773R; G185V-Q132R/Q773R 
M13_for;  
MDR1Q773R_rev 
 
4077 G185V-Q773R 
MDR1Hind_for; 
MDR1Q773R_rev 
304 G185V-Q773R 
Table 3.2: PCR was performed to verify the presence of the mutated MDR1 gene in the recombi-
nant bacmid. The table shows the primerpairs, expected PCR products and templates which were 
used to amplify the mutated MDR1. 
 
After this procedure, the recombinant bacmids, containing P-gp mutants, were ready to 
transfect insect cells to produce recombinant baculovirus. 
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3.5.2 Preparation of plasmid DNA 
3.5.2.1 Small-scale plasmid DNA preparation 
The GenEluteTM Plasmid Miniprep Kit was used to generate small-scale plasmid DNA 
preparations as described by the manufacturer (Sigma-Aldrich 2006). The protocol is 
based on a modified alkine-SDS lysis procedure, which was first described by Birnboim 
and Doly (Birnboim and Doly 1979). All steps were carried out at room temperature. 
1.5 ml bacterial cells from a 5 ml overnight recombinant E. coli culture were harvested 
by centrifugation for 1 minute at 14,000 rpm in an Eppendorf 5415C centrifuge (Ep-
pendorf, Germany). The supernatant was discarded and the cell pellet was completely 
resuspended in 200 µl Resuspension Solution (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 
100 µg/ml RNase A). Resuspended cells were lysed by adding 200 µl Lysis Solution (2 
mM NaOH, 1% SDS), mixed by gentle inversion and incubated for 5 minutes. The alka-
line lysis procedure denatures plasmid DNA. After 5 minutes, 350 µl Neutraliza-
tion/Binding Solution (3.0 M Potassium acetate pH 5.5) was added and the tube gently 
inverted causing the precipitation of cell debris, proteins, lipids, SDS, and chromosomal 
DNA as a cloudy, viscous precipitate. The lysate was then centrifuged for 10 minutes at 
14,000 rpm. For maximized binding of DNA to the membrane, GenElute Miniprep 
Binding Columns were prepared by adding 500 µl Column Preparation Solution (750 
mM NaCl, 50 mM MOPS, 15% ethanol, 0.15% TritonX-100, pH 7.0) and centrifuged 
for 1 minute by 14,000 rpm. The flow-through liquid was discarded and the cleared lys-
ate was transferred to the prepared column and centrifuged for 1 minute at 14,000 rpm. 
As before, the flow-through liquid was discarded and the columns were washed with 
750 µl wash solution (1.0 M NaCl, 50 mM MOPS, 15% ethanol, pH 8.5) to remove 
contaminants followed by centrifugation for 1 minute at 14,000 rpm. The eluted wash 
solution was discarded and the columns were centrifuged as before to remove excess 
ethanol. After centrifugation, the column was transferred to a fresh collection tube and 
plasmid DNA was eluted by adding 50 µl ddH2O to the column followed by centrifuga-
tion for 1 minute at 14,000 rpm. Plasmid DNA was now ready for immediate use in 
restriction enzyme digestion or storage at -20 °C. 
 
3.5.2.2 Large-scale plasmid DNA preparation 
Large-scale plasmid DNA preparations were generated using the HiSpeed® Plasmid 
Midi Kit as described by the manufacturer (QIAGEN 2005). It is a similar protocol as 
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the GenEluteTM Plasmid Miniprep Kit. Bacterial cells from 50 ml of an overnight cul-
ture were harvested by centrifugation at 3,500 rpm for 30 minutes at 4 °C in an Eppen-
dorf 5403 centrifuge (Eppendorf, Germany). The cell pellet was resuspended in 6 ml 
Resuspension Buffer (50 mM Tris-HCl pH 8.0; 10 mM EDTA; 100 µg/ml RNase A) 
and 6 µl LyseBlue, a color indicator which provides visual identification of optimum 
buffer mixing. Then 6 ml Lysis Buffer (200 mM NaOH, 1% SDS) were added, and the 
content of the tube mixed by inversion followed by 5 minutes incubation at room tem-
perature. The cell suspension was homogeneously blue after addition of Lysis Buffer. 
After incubation 6 ml Neutralization Buffer (3.0 M Potassium acetate pH 5.5) were 
added to the lysate and mixed by inversion. A white precipitate containing cell debris, 
proteins and genomic DNA became visible. The lysate was transferred into the barrel of 
the QIAfilter Cartridge which was capped and incubated for 10 minutes at room tem-
perature. During the incubation, a HiSpeed Midi Tip was equilibrated by adding 4 ml 
Equilibration Buffer (750 mM NaCl, 50 mM MOPS, 15% isopropanol, 0.15% TritonX-
100, pH 7.0). The column was allowed to empty by gravity flow. After incubation, the 
cap from the QIAfilter outlet nozzle was removed, and the plunger was gently inserted 
into the QIAfilter Cartridge and the lysate was filtered into the previously equilibrated 
HiSpeed Midi Tip. The cleared lysate was allowed to enter the resin by gravity flow. 
The HiSpeed Midi Tip was washed with 20 ml Wash Buffer (1.0 M NaCl, 50 mM 
MOPS, 15% isopropanol, pH 7.0) and the DNA was eluted with 5 ml Elution Buffer 
(1.25 M NaCl, 50 mM MOPS, 15% isopropanol, pH 8.5). The DNA was precipitated by 
adding 3.5 ml isopropanol to the eluted DNA, followed by mixing and incubatoin for 5 
minutes at room temperature. During the incubation, the plunger from a 20 ml syringe 
was removed and the QIAprecipitator Midi Module was attached onto the outlet nozzle. 
The elute/isopropanol mixture was then transferred into the 20 ml syringe, the plunger 
was inserted and the mixture was filtered through the QIAprecipitator using constant 
pressure. The QIAprecipitator was removed from the syringe, the plunger was pulled 
out, the QIAprecipitator, reattached to the syringe and 2 ml 70% ethanol was added to 
the syringe. The DNA was washed by inserting the plunger and pressing the ethanol 
through the QIAprecipitator using constant pressure. The last step was repeated twice 
without ethanol to dry the membrane by pressing air through the QIAprecipitator. The 
outlet nozzle of the QIAprecipitator was dried with absorbent paper to prevent ethanol 
carryover. The same procedure was used to elute DNA by pressing 500 µl ddH2O 
through the QIAprecipitator. (all: (QIAGEN 2005)) 
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The size, quality and recovery of DNA were determined by quantitative analysis on an 
1.6% agarose gel (1.6% agarose, 0.25 µg/ml ethidium bromide, in TAE buffer). 1 µl of 
DNA was mixed with 9 µl ddH20 and 1 µl loading buffer (0.25% bromophenol blue, 
0.25% xylene cyanol, 30% glycerol, in ddH20), loaded into sample wells and electro-
phoresed at 50 V. The recovery of DNA was compared with 10 µl MassRuler DNA 
LadderMix (Fermentas, Cat. No. SM0403). The DNA was visualised using UV screen 
and images were recorded. 
Plasmid DNA was now ready for immediate use in restriction enzyme digestion, clon-
ing, PCR, transfection and sequencing or storage at -20 °C. 
 
3.6 Generation of P-gp construct 
A full-length human MDRl cDNA coding for human P-gp with 6 tandem histidine resi-
dues at its carboxy-terminus (P-gpHis6), a gift from Suresh V. Ambudkar (Maryland, 
USA), was cloned as a BamHI to XhoI fragment into a pENTR4 vector to give 
pENTR4MDR1H6. The plasmid was linearized at the BamHI site and then blunt-ended 
with the Klenow fragment of DNA polymerase I disrupting the open reading frame with 
a second initiation codon. Nevertheless, there was a second Kozak sequence that is nec-
essary for efficient initiation of translation in eukaryotic cells at the NcoI restriction site. 
A Kozak sequence contains the ATG initiation codon, a A or G at position -3 and a G at 
position +4 (CCATGG). The NcoI restriction site is the first restriction site in the multi-
ple cloning site of the pENTR4 vector. Unfortunately, MDR1 cDNA contains this en-
zyme site too, and another restriction site was used for cloning generating a second ini-
tiation codon. As a precaution, a fragment of the pENTR4 vector containing an A to T 
mutation disrupting the initiation codon was created and introduced into the pENTR4 
vector (CCTTGG) by site-directed mutagenesis based on overlap extension polymerase 
chain reaction (OE-PCR). Then the pENTR4 vector was cut with SalI and XbaI and the 
MDR1 cDNA was subcloned as a SalI to XbaI fragment into the vector. Finally, the 
pENTR4MDR1H6 vector was used as template for generation of P-gp mutants by OE-
PCR. To generate a pENTR4 vector without the ccdB gene as a control, the entry vector 
was digested on each site of the ccdB gene with the double cutter EcoRI and recircular-
ized.  
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3.7 Generation of P-gp mutants 
Using site-directed mutagenesis based on OE-PCR mutated residues or nucleotides 
were introduced into the MDR1H6 gene. All construct sequences were ascertained by 
DNA sequencing (performed by IBL, Austria).  
 
3.7.1 Overlap extension PCR 
Overlap extension PCR was developed by Higuchi et al. (Higuchi, Krummel et al. 
1988) and by Ho and colleagues (Ho, Hunt et al. 1989) almost simultaneously. Outside 
primers, mutagenic complementary oligodeoxyribo-nucleotide (oligo) middle primers 
and the polymerase chain reaction (PCR) were used to generate two DNA fragments 
with overlapping ends and intended mutations, both of which were introduced by two 
mutagenic middle primers. These fragments were combined in a subsequent ‘fusion’ 
reaction in which the overlapping ends annealed, allowing the 3' overlap of each strand 
to serve as a primer for the 3' extension of the complementary strand (Ho, Hunt et al. 
1989). The resulting fusion product was amplified further by PCR using two outside 
primers. Specific alterations in the nucleotide (nt) sequence were introduced by incorpo-
rating nucleotide changes into the overlapping oligo primers (Opitz, Jenkins et al. 
1998). The human MDR1H6 DNA was used as the template DNA for the overlap ex-
tension PCR technique for generation of the P-gp mutants. The primers were designed 
with the software package Clone Manager v.8.0 (SciEd Software NC, USA). All four 
primers (outside_for, outside_rev, mutagenic_for and mutagenic_rev) were used for the 
first round of PCR. The second round of PCR using primers outside_for and out-
side_rev resulted in a fusion product that was purified. The cDNA was then restriction 
digested and subcloned into the the pENTR4 vector. The resulting DNA fragment was 
sequenced. 
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Amino acid 
change 
Primer out-
side_for 
Primer mutage-
nic_for 
Primer mutage-
nic_rev 
Primer out-
side_rev 
Q132A 
 
NcoImut_for MDR1Q132A_for MDR1Q132A_rev Hind_rev 
Q132E 
 
NcoImut_for MDR1Q132E_for MDR1Q132E_rev Hind_rev 
Q132R 
 
NcoImut_for MDR1Q132R_for MDR1Q132R_rev Hind_rev 
Q773A 
 
Hind_for MDR1Q773A_for MDR1Q773A_rev MDR1blunt_rev 
Q773E 
 
Hind_for MDR1Q773E_for MDR1Q773E_rev MDR1blunt_rev 
Q773R 
 
Hind_for MDR1Q773R_for MDR1Q773R_rev MDR1blunt_rev 
G185V 
 
NcoImut_for MDR1G185V_for MDR1G185V_rev Hind_rev 
Table 3.3: Primer for site-directed mutagenesis of P-gp using overlap extension PCR 
 
 
 
Primer Nucleotide sequence (5’ → 3’) 
 
MDR1Q132A_for 5’-CTGCTTACATTGCGGTTTCATTTTGG-3’ 
MDR1Q132A_rev 5’-CCAAAATGAAACCGCAATGTAAGCAG-3’ 
MDR1Q132E_for 5’-GGTTGCTGCTTACATTGAAGTTTCATTTTG-3’ 
MDR1Q132E_rev 5’-CAAAATGAAACTTCAATGTAAGCAGCAACC-3’ 
MDR1Q132R_for 5’-GCTGCTTACATTCGTGTTTCATTTTG-3’  
MDR1Q132R_rev 5’-CAAAATGAAACACGAATGTAAGCAGC-3’ 
MDR1Q773A_for 5’-CATTTTTCCTTGCGGGTTTCACATTTGGC-3’ 
MDR1Q773A_rev 5’-GCCAAATGTGAAACCCGCAAGGAAAAATG-3’ 
MDR1Q773E_for 5’-CATTTTTCCTTGAAGGTTTCACATTTG-3’ 
MDR1Q773E_rev 5’-CAAATGTGAAACCTTCAAGGAAAAATG-3’ 
MDR1Q773R_for 5’-CATTTTTCCTTCGAGGTTTCACATTTG-3’ 
MDR1Q773R_rev 5’-CATTTTTCCTTCGAGGTTTCACATTTG-3’ 
MDR1G185V_for 5’-GATTAATGAAGTTATTGGTGACAAAATTGG-3’ 
MDR1G185V_rev 5’-CCAATTTTGTCACCAATAACTTCATTAATC-3’ 
NcoImut_for 5’-CAGGCTCCACCTTGGGAACC-3’ 
Hind_for 5’-GCCCAAGACAGAAAGCTTAGTACC-3’ 
Hind_rev 5’-GGTACTAAGCTTTCTGTCTTGGGC-3’ 
MDR1blunt_rev 5’-ACAAATTGATAAGCAATGCTTTC-3’ 
NcoImut_rev 5’-GGTTCCCAAGGTGGAGCCTG-3’ 
Table 3.4: Oligonucleotides used for site-directed mutagenesis to generate P-gp mutants. Nucleo-
tides in bold and underline indicate the mutagenic nucleotides which differ from the wild-type se-
quence. Underlined nucleotides indicate the mutagenic nucleotides which disrupted the NcoI re-
striction site in the pENTR4 vector.  
 
Two rounds of PCR were necessary to generate mutations in the desired position of the 
MDR1 gene. MDR1 cDNA was divided into two halves, an N-terminal and a C-terminal 
half, resulting in an approximately 2000 bps long PCR product for each half. Q132 and 
  48 
G185 were located in the N-terminal, and Q773 in the C-terminal half. The following 
protocol was used:  
 
First round of PCR:  
Plasmid pENTR4MDR1H6 (~5 ng) was used as the template for generation of 
pENTR4MDR1H6G185V. Two outside primers and two mutagenic middle primers 
(each containing mutated nucleotides) were used to generate PCR products 1 and 2 in 
separate reactions. The primers were designed in such a way that an overlap region in 
the two PCR fragments would be created. DNA polymerase Pfu (Fermentas, Cat. No. 
EP0572) was used to reduce the chance of getting undesired mutations during the PCR.  
Reaction mix per sample: 
ddH2O 16.75 µl 
10x Buffer 2.5 µl 
2 mM dNTP each 2.5 µl 
Template: pentry vector 1µl 
DNA polymerase Pfu 0.25 µl 
Primer_for (10 µM stock) 1 µl 
Primer_rev (10 µM stock) 1 µl 
Total volume 25 µl 
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The thermal cycling conditions were as following: 
 
Step Temperature, °C Time, min Number of Cycles 
Initial Denaturation 95 2 1 
Denaturation 95 0.5  
Annealing 45 0.5 5 
Extension 72 4  
Denaturation 95 0.5  
Annealing 50 0.5 25 
Extension 72 4  
Final Extension 72 5 1 
 
The first round PCR products were isolated by agarose gel electrophoresis. Gel frag-
ments were visualised using a UV screen, excised with a scalpel and purified using 
GFXTM PCR DNA and gel band purification kit (Amersham Biosciences, 27-9602-01).  
 
Second round of PCR:  
Purified PCR products 1 and 2 served as templates and were mixed in an equal volume. 
The two outside primers were used to amplify the full-length MDR1 product. Pfu DNA 
polymerase was used for 30 cycles of amplification. 
 
Reaction mix per sample: 
ddH2O 16.75 µl 
10x Buffer 2.5 µl 
2 mM dNTP each 2.5 µl 
Template: Mixture of PCR product 1 and 2 (equal volume) 1µl 
DNA polymerase Pfu 0.25 µl 
Primer_for 1 µl 
Primer_rev 1 µl 
Total volume 25 µl 
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The above PCR conditions were modified slightly:  
Step Temperature, °C Time, min Number of Cycles 
Initial Denaturation 95 2 1 
Denaturation 95 0.5  
Annealing 50 0.5 30 
Extension 72 4  
Final Extension 72 5 1 
 
 
The final products were cut with SalI (Fermentas, Cat. No. ER0641) and HindIII (Fer-
mentas, Cat. No. ER0501) or HindIII and XbaI (Fermentas, Cat. No. ER0682) restric-
tion enzymes, and the approximately 2.0-kbp fragments containing the half-length 
MDR1 gene were subcloned into SalI-HindIII-pENTR4MDR1H6 or HindIII-XhoI-
pENTR4MDR1H6 to create mutant versions of pENTR4MDR1H6. The ligation was 
carried out with the Rapid DNA Ligation Kit from Fermentas (Cat. No. K1422) contain-
ing the T4 DNA Ligase (5u/µl), 5x Rapid Ligation Buffer and water (nuclease-free).  
Reaction mix per sample: 
Insert X µl 
Vector X µl 
ddH2O Up to 19 
5x Rapid Ligation Buffer 4 µl 
T4 DNA Ligase (5u) 1 µl 
Total volume 20 µl 
 
5 µl of the ligation mixture were used for transformation 50 µl One Shot TOP10 
Chemically Competent Cells as before. The cells were spread onto LB agar plates with 
50 µg/ml kanamycin and incubated overnight at 37°C. 
 
3.7.2 Purification of DNA from solution or gel bands 
For purifying PCR products, restriction fragments and plasmid DNA, the GFX PCR 
DNA and Gel Band Purification Kit was used as described by the manufacturer (Amer-
shamBiosciences 2005). All steps were carried out at room temperature. 
Purification from solution: 
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The GFX column was placed in a collection tube and 500 µl capture buffer, containing 
acetate and chaotrope, were added to the GFX column. The DNA solution (up to 100 
µl) was transferred to the GFX column, mixed thoroughly by pipetting the sample up 
and down (4-6 times) causing denaturation of proteins and then centrifuged for 30 sec-
onds in an Eppendorf 5415C centrifuge (Eppendorf, Germany) at 14,000 rpm. Then the 
sample was passed through the GFX column to capture the DNA onto the glass fiber 
matrix. The flow-through was discarded and the GFX column was placed back inside 
the collection tube. Then the matrix-bound DNA was washed with 500 µl wash buffer 
(10 mM Tris-HCl pH 8.0, 1 mM EDTA, in 80% ethanol) to remove salts and other con-
taminants and centrifuged for 30 seconds at 14,000 rpm. After centrifugation, the GFX 
column was transferred to a fresh 1.5 ml eppendorf tube and the DNA eluted by adding 
50 µl ddH2O. After 1 minute incubation, the purified DNA was recovered by centrifuga-
tion for 1 minute at 14,000 rpm. (all: (AmershamBiosciences 2005)) 
 
Purification from gel bands:  
The gel slice of agarose containing the DNA band to be purified was carefully excised 
using a scalpel and a UV light box and was then cut into smaller pieces. The pieces 
were transferred to a preweighted empty 1.5 ml eppendorf tube. The eppendorf tube 
containing the agarose slice was weighed again to determine the approximate volume of 
the gel slice. For each 10 mg of gel slice 10 µl Capture Buffer were added. The tube 
was closed, mixed by vortexing and incubated at 60 °C for 15 minutes or until the gel 
was completely melted. During incubation, the GFX column was placed in a collection 
tube. After the agarose was completely dissolved, the eppendorf tube was briefly centri-
fuged to collect the sample at the bottom of the tube and the sample was transferred to 
the GFX column. After 1 minute incubation, the GFX column was centrifuged for 30 
seconds. Further steps were the same as before in the “purification from solution”. (all: 
(AmershamBiosciences 2005)) 
 
3.8 Agarose gel electrophoresis 
DNA fragments were separated by agarose gel electrophoresis (1.6% agarose, 0.25 
µg/ml ethidium bromide, in TAE). Samples were mixed with 10% of the loading buffer 
volume, loaded into sample wells, and electrophoresed at constant 50 V. The electro-
phoresis chamber was filled with 1xTAE containing 0.25 µg/ml ethidium bromide. One 
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lane on each gel was loaded with 10 µl Mass Ruler DNA Ladder Mix (Fermentas, Cat. 
No. SM0403). The DNA was visualised using a UV screen and images were recorded.  
 
10x TAE:  400 mM Tris base 
       10 mM EDTA 
       1.14% Acetic acid 
   Stored at 4°C 
Loading buffer: 0.25% bromophenol blue 
   0.25% xylene cyanol 
   30% glycerol 
   Stored at room temperature 
Ethidium bromide solution: 0.5 mg/ml in ddH2O, stored at room temperature 
    
3.9 Mammalian tissue culture 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Cat. No. 12800-116), 0.25% Trypsin-
EDTA (Cat. No. 25200), Lipofectamine 2000 (Cat. No. 11668027), Donor Bovine Se-
rum (DBS) (16030-074), Zeocin (Cat. No. R250-01) and Hygromycin B (Cat. No. 
10687-010) were purchased from Invitrogen. 
 
Human HEK 293 (FlpIn-293) cells and mouse NIH 3T3 fibroblasts (Flp-In-3T3), sup-
plied by Invitrogen, were grown as monolayers in a T75 tissue culture flask (VWR, Cat. 
No. 734-2167) and maintained by regular passage in DMEM supplemented with 4.5 g/l 
glucose, 2 mM L-glutamine, 1 mM sodium pyruvat and 10% DBS (vol/vol) under 5% 
CO2 at 37°C with a water vapour-saturated atmosphere.  
 
All manipulations were performed in a sterile environment with sterile plastics and 
glassware. 
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3.10 Generation of stable mammalian expression cell lines 
Cell lines and reagents were supplied from Invitrogen. 
Cell Line Amount Catalog No. 
Flp-In-293 3 x 106 cells, frozen R750-07 
Flp-In-3T3 3 x 106 cells, frozen R761-07 
 
 
 
Stable mammalian expression cell lines were generated using the Flp-InTM system de-
scribed by the manufacturer (Invitrogen 2002). With the Flp-In system it is possible to 
integrate and express a gene of interest in mammalian Flp-In cells at a specific genomic 
location (Invitrogen 2002). The Flp-In cell lines from Invitogen stably express the lacZ-
ZeocinTM fusion gene whose expression is controlled by the SV40 early promoter and 
contain a Flp Recombination Target (FRT) site which has been inserted just down-
stream of the ATG initiation codon of the lacZ-ZeocinTM fusion gene. The FRT site 
serves as the binding and cleavage site for the Flp recombinase (Invitrogen 2002). Flp-
In cell lines are Zeocin-resistant. An expression vector containing the gene of interest is 
then integrated into the genome via Flp recombinase-mediated DNA recombination at 
the FRT site (O'Gorman, Fox et al. 1991) (Invitrogen 2002). Expression of the gene is 
controlled by the human CMV promoter. Another component of the Flp-In System is 
the pOG44 plasmid which constitutively expresses the Flp recombinase (Broach and 
Hicks 1980; Broach, Guarascio et al. 1982; Buchholz, Ringrose et al. 1996) under the 
control of the human CMV promoter. (Invitrogen 2002) 
The pOG44 plasmid and the pEF5MDR1 vector were cotransfected into the Flp-In-3T3 
host cell line. Upon cotransfection, the Flp recombinase expressed from pOG44 medi-
ated a homologous recombination event between the FRT sites (integrated into the ge-
nome and on pEF5MDR1) such that the pEF5MDR1 construct was inserted into the 
genome at the integrated FRT site (Invitrogen 2002). Insertion of pEF5MDR1 into the 
genome at the FRT site brings the SV40 promoter and the ATG initiation codon (from 
pFRT/lacZeo) into proximity and frame with the hygromycin resistance gene (from 
pEF5MDR1 lacking the promoter and the ATG initiation codon), and inactivates the 
Reagent Catalog No. 
ZeocinTM R250-01 
Hygromycin B 10687-010 
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lacZ-Zeocin fusion gene (Invitrogen 2002). Thus, stable Flp-In expression cell lines 
could be selected for hygromycin resistance, Zeocin sensitivity, lack of β-galactosidase 
activity, and expression of the P-gp protein (Invitrogen 2002). 
 
3.10.1 Stable cell transfection using Lipofectamine 2000 
Human HEK 293 cells and mouse NIH 3T3 fibroblasts (Flp-In-3T3) were cultured in 
DMEM supplemented with 4.5 g/l glucose, 2mM L-glutamine, 1mM sodium pyruvat 
and 10% DBS at 37°C in 5% CO2. The cells were grown in presence of 100 µg/ml Zeo-
cin. One day prior to transfection, the cells were seeded onto six-well plates (Greiner 
bio one, Cat. No. 657160) in aliquots of 1 x 106 per well in the corresponding medium 
containing 10% DBS (1 ml medium/well) without Zeocin. After 24 hours, the growth 
medium of the cells was replaced with serum-/antibiotic-free medium (Opti-MEM) and 
the cells were treated with 2 µg/ml Lipofectamine 2000 complex in the corresponding 
Opti-MEM serum-/antibiotic-free medium (Invitrogen, Cat. No. 31985-047) according 
to the manufacturer’s instructions (Invitrogen 2006) for 2 hours at 37°C. The cells were 
stably transfected in 6-well plates with pEF5 vector (Invitrogen) or pEF5 vector con-
taining the human MDR1 gene. After 2 hours 2% donor bovine serum was added into 
the Opti-MEM. After 24 hours the cells were trypsinized and passaged at a 1:10 dilution 
into a T25 flask with fresh growth medium (DMEM containing 10% donor bovine se-
rum). The following day the cells were selected with 200 µg/ml hygromycin B (Invitro-
gen, Cat. No. 10687-010). Nontransfected cells were killed by hygromycin B. The me-
dium containing hygromycin B was exchanged every 3 to 4 days. 
 
3.10.1.1 Expression of mutants 
Human HEK 293 cells and mouse NIH 3T3 fibroblasts were transfected with the mu-
tated MDR1 cDNAs as described before. P-gp processing mutants expressed functional 
P-gp when they were kept in the presence of drug substrates or modulators of P-gp that 
correct the folding defect. To test for the effect of compounds on expression of P-gp 
processing mutants, cells were grown for 24h in Dulbecco’s modification of Ea-
gle’smedium (DMEM) with 10% (v/v) donor bovine serum at 37 °C in a 5% CO2 incu-
bator in the presence of 10 µM cyclosporin A (CsA). CsA is a substrate of P-gp and acts 
like a powerful chemical chaperone promoting maturation of P-gp (Loo and Clarke 
1997). Other compounds used as pharmacological chaperones were 50 µM  verapamil 
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and 50 µM GP51. Compounds were prepared as 500 X stocks in DMSO. Control cells 
were incubated in the presence of 0.2% (v/v) DMSO. Cells were harvested and prepared 
for the MRK16 staining. 
 
3.11 Western blot analysis 
3.11.1 Preparation of protein samples for SDS-Polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Cells were seeded onto 6-well plates in aliquots of 1 x 106 cells per well in the corre-
sponding DMEM medium containing 10% DBS (2 ml medium/well) and in the pres-
ence of 10 µM CsA. Control cells were incubated in the presence of 0.2% (v/v) DMSO. 
After 24 hours, the cells were washed three times with ice-cold PBS and lysed directly 
in the wells by adding 60 µl of lysis buffer containing 1% of a protease inhibitor cock-
tail (Sigma, Cat. No. P8340) and incubated for 10 minutes. All steps were carried out on 
ice. After incubation, the cells were removed with a rubber policeman, transferred in an 
Eppendorf tube, broken with an ultrasonic stick for 2 seconds and incubated for 1 hour 
on ice. The samples were stored overnight at -20°C.  
 
PBS:      137 mM NaCl 
     2.7 mM KCl 
     1.5 mM KH2PO4 
     8.1 mM Na2HPO4.12H2O 
     Adjust to pH 7.4 
 
Lysis buffer (prepared fresh): 62.5 mM Tris base, pH 6,8 
8 M urea 
20 mM EDTA 
20 mM EGTA 
10% Glycerol 
1% SDS 
 
After 24 hours, the samples were thawed and centrifuged for 10 minutes at 14,000 rpm 
at 4°C. The supernatants were transferred into fresh Eppendorf tubes and vortexed. 
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3.11.2 Protein determination using Bradford protein assay 
The Bradford protein assay (Bio-Rad, Cat. No. 500-0006) is a dye-binding assay. The 
absorbance maximum for an acidic solution of Coomassie Brilliant Blue G-250 dye 
shifts from 465 nm to 595 nm when binding to proteins occurs (BioRad 1994). Protein 
concentration was determined using the Bradford protein microassay by absorbance at 
595 nm. A protein standard curve was made using bovine serum albumin (BSA) 
(Sigma, Cat. No. A4503) with concentrations of 0, 1, 2, 4, 6, 8, 10, 15 and 20 µg/ml. 
 
BSA-Standard: 
Standard BSA (100 µg/ml) ddH2O Bio-Rad-Reagent 
0 µg/ml 0 µl 400 µl 100 µl 
1 µg/ml 5 µl 395 µl 100 µl 
2 µg/ml 10 µl 390 µl 100 µl 
4 µg/ml  20 µl 380 µl 100 µl 
6 µg/ml 30 µl 370 µl 100 µl 
8 µg/ml 40 µl 360 µl 100 µl 
10 µg/ml 50 µl 350 µl 100 µl 
15 µg/ml 75 µl 325 µl 100 µl 
20 µg/ml 100 µl 300 µl 100 µl 
 
Samples: 
Sample ddH2O Bio-Rad-Reagent 
2,5 µl 397,5 µl 100 µl 
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3.11.3 SDS-PAGE 
Proteins were separated by electropheresis through vertical 0.75 mm thick polyacryla-
mide gels (0.1% SDS, 8% acrylamide). The samples were diluted and made up to 10 µl 
with PBS to equal protein amounts. Then equal amounts of protein were mixed with the 
4x sample buffer in a 3:1 ratio and incubated for 30 minutes at 40°C in a water bath to 
denature the proteins. After cooling down, the samples were loaded onto the gel. 
 
4x sample buffer:   50% Glycerol 
     24% 0.5 M Tris-HCl (pH 6.8) 
     21% ddH2O 
     8% (w/v) SDS 
     A dash of bromophenol blue 
5% 2-Mercaptoethanol  
Prepared just before use  
 
10x running buffer:   250 mM Tris base 
     1.92 M Glycine 
     1% SDS 
     Stored at room temperature 
 
Polyacrylamide gel: per gel (0.75 mm thickness)  
 
Stacking gel (4% acrylamide): 
Reagent Volume 
ddH2O 1.54 ml 
30% Acrylamid:Bis-acrylamide mix (29.2:0.8) 340 µl 
3 M Tris-HCl, pH 8.45; 0.3% SDS 620 µl 
10% APS 20 µl 
TEMED 2 µl 
Total volume 2.522 ml 
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Separating gel (8% acrylamide) 
Reagent Volume 
ddH2O 2.4 ml 
30% Acrylamide:Bis-acrylamide mix (29.2:0.8) 1.6 ml 
3 M Tris-HCl, pH 8.45/0.3% SDS 2 ml 
10% APS 30 µl 
TEMED 3 µl 
Total volume 6.33 ml 
 
10% Ammonium Persulfate (APS) (Sigma, Cat. No. 248614): aliquots were stored at     
-20°C 
10% SDS: stored at room temperature 
 
3 M Tris-HCl, pH 8.45; 0.3% SDS:  3 M Tris-HCl 
      0.3% SDS 
      Adjust to pH 8.45 
      Stored at room temperature  
 
The solutions were prepared in 50 ml Falcon tubes. The polymerisation of the separat-
ing gel was initiated by the addition of N,N,N´,N´-teteramethylethane-1,2-diamine 
(TEMED) (Sigma, Cat. No. T9281) and filled in a Bio-Rad Mini Protean II gel cassette. 
Each gel was immediately overlaid with a thin layer of 30% isopropanol. After polym-
erisation, the overlay was removed and the gel surface was rinsed with ddH2O. TEMED 
was added to the stacking gel to initiate polymerisation and was overlaid onto the sepa-
rating gel. A 15-well comb was inserted. After polymerisation, the gel cassettes were 
put into the electrophoresis chamber according to the manufacturer’s instructions. The 
chamber was filled with 1x running buffer and after removing the comb, the wells were 
rinsed with 1x running buffer prior to loading samples. One lane was loaded onto each 
gel with 2 µl Page Ruler Prestained Protein Ladder (Fermentas, Cat. No. SM0671) to 
enable the subsequent determination of protein molecular weights. Slots without any 
protein sample were filled with sample buffer. Electrophoresis was performed at con-
stant 180V for 80 minutes at 4°C.  
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3.11.4 Detection of proteins by Western blotting 
Proteins, separated by SDS-PAGE, were then electroblotted onto nitrocellulose mem-
branes (Bio-Rad, Cat. No. 162-0115) using a Bio-Rad Mini Blotting apparatus, accord-
ing to the manufacturer’s instructions. Membrane, sponges and 3MM filter paper were 
prepared by soaking in western transfer buffer for 1 minute. The transfer components 
were put together as followed: 
White side of the cassette (facing positive electrode) 
Sponge 
Filter paper 
Nitrocellulose membrane 
Gel 
Filter paper 
Sponge  
Black side of the cassette (facing negative electrode) 
 
Air bubbles between gel and nitrocellulose membrane were removed by rolling a glass 
eprouvette over the filter paper. The sandwich was assembled together with an ice block 
for cooling the buffer into the blotting apparatus. Electroblotting was carried out in 
transfer buffer at 0.4 A (0.06 A/ gel) for 45 minutes at 4°C. 
 
Transfer buffer: 25 mM Tris base 
   192 mM Glycin 
   20% Methanol 
   1% SDS 
   Stored at 4°C and used again several times 
 
3.11.4.1 Detection of proteins by Ponceau S 
Total protein visualisation was carried out using the Ponceau S (Sigma, Cat. No. 78376) 
staining, immediately after SDS-PAGE to ensure complete transfer of proteins. The 
nitrocellulose membrane was placed in the Ponceau S solution for 5 minutes at room 
temperature. After visualisation of the proteins, the membrane was washed in ddH2O at 
room temperature for 5 minutes to destain the gel.  
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Ponceau S:   1% Ponceau 
    30% Trichloracetic acid 
    30% Sulfosalicylic acid 
 
3.11.4.2 Immunodetection 
10x TBS:   200 mM Tris base 
    1.45 M NaCl 
    Adjust to pH7.4 
 
Washing buffer (TBS-T): 1x TBS buffer 
    0.1% Tween 20 
 
Bloking solution:  5% (w/v) nonfat dry milk in TBS-T 
    Prepared just before use 
 
Primary antibody: 
Primary antibodies were attenuated in blocking solution at the recommended dilution. A 
dash of NaN3 was added to each antibody solution to avoid contamination. The primary 
antibodies were used again for several times and stored at 4°C. 
The P-gp specific monoclonal antibody C219 was obtained from Eubio, Austria (Cat. 
No. ALX801-002) and diluted 1:250 in 1% BSA in TBS-T. 
Anti-ß-Actin (Sigma, Cat. No. A2228) was diluted 1:5000 in 3% BSA in TBS-T. 
 
Secondary antibody: 
The secondary antibody goat anti-mouse IgG-HRP conjugate (Bio-Rad, Cat. No. 170-
6516) was diluted 1:10000 in blocking solution. 
 
After Ponceau S destaining, the membrane was cut according to the protein sizes. One 
membrane could be used to detect up proteins with different sizes: the upper part for P-
gp (170 kDa) and the lower part for ß-Actin loading control (42 kDa) detection. The 
membranes were washed with TBS-T for 10 minutes and treated with 5% nonfat dry 
milk in TBS-T overnight at 4°C on a belly dancer for blocking. On the next day the 
membranes were washed three times for 5 minutes with washing buffer and incubated 
with primary antibody for 1 hour at room temperature on the belly dancer. After 1 hour, 
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the antibodies were removed and stored in the fridge until next use. Subsequently, the 
blots were washed three times with TBS-T for 10 minutes on the belly dancer and incu-
bated for 1 hour at room temperature with a secondary antibody with shaking on the 
belly dancer. After incubation, the secondary antibody was discarded and the mem-
branes were washed three times as before. Finally, antibody labelled proteins were visu-
alized with ChemiGlowTM West (Alpha Innotech Corporation, CA, USA). The 
ChemiGlow West working solution was prepared prior to use by mixing the Lumi-
nol/Enhancer Solution and the Stable Peroxidase Solution in equal volumes. The mem-
branes were incubated for 5 minutes at room temperature and wrapped in plastic wrap. 
For detection a CCD camera in the ChemiImagerTM 4400 (Biozym) was used. Quantifi-
cation was performed using the AlphaEaseFC software. 
 
3.11.5 Determination of MDR1 gene expression levels by real -time quantitative 
RT-PCR 
Real-time reverse transcription (RT) - PCR was used to assess the influence of cyc-
losporine A (CsA) on an mRNA level. Cells incubated with DMSO served as control. 
 
3.11.5.1 Isolation of total RNA from cells 
Total cellular RNA was isolated with TRIzol reagent (Invitrogen, Cat. No. 15596-026) 
as recommended by the manufacturer (Invitrogen 2007). One day prior to homogeniza-
tion, the cells were seeded onto 6 cm diameter tissue culture dishes (Greiner Bio-One, 
Germany, Cat. No. 628160) in aliquots of 1x 106 per culture dish in the corresponding 
medium containing 10% DBS (5 ml medium/dish) and in the presence of 10 µM CsA. 
Control cells were incubated in the presence of 0.2% (v/v) DMSO. After 24 hours, the 
cells were washed and lysed directly in the culture dish by adding 800 µl of TRIzol re-
agent. The cell lysate was passed several times through a pipette, incubated for 1 minute 
at room temperature to permit the complete dissociation of nucleoprotein complexes 
and transferred to an eppendorf vial. The samples were stored at -80°C until RNA isola-
tion.  
The homogenized samples were briefly vortexed and centrifuged for 10 minutes at 
12,000 rpm at 4 °C. For phase separation, 150 µl of chloroform were added per 800 µl 
of TRIzol reagent, shaked by hand for 15 seconds and incubated at room temperature 
for 5 minutes. The samples were centrifuged at 12,000 x g for 10 minutes at 4°C. The 
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mixture separated into a lower red, phenol-chloroform phase, an interphase, and a color-
less upper aqueous phase containing the RNA. The aqueous phase (~400 µl) was trans-
ferred to a fresh tube, mixed with 400 µl isopropyl alcohol and incubated at room tem-
perature for 10 minutes. After centrifugation at 12,000 x g for 10 minutes at 4°C, the 
supernatant was removed and the RNA pellet washed with 750 µl of 70% ethanol. The 
samples were mixed by vortexing and centrifuged at 7,500 x g for 5 minutes at 4°C. 
After the washing step, the RNA pellet was dried (air-dry) for approximately 10 min-
utes and dissolved in 50 µl diethylpyrocarbonate (DEPC)/DNase by passing the solution 
a few times through a pipette tip. To remove remaining DNA contamination 1-2 u of 
TurboTM DNase from Ambion was added to each sample and incubated for 15 minutes 
at 37 °C. The the samples were incubated for 10 minutes at 85 °C to inactivate the en-
zyme.  
RNA concentration was determined by absorbance at 260 nm. 
E260nm x (dilution)
-1 x e-1 = concentration µg/ml 
e-1 = 40 for single stranded RNA 
To ensure equal loading and integrity of the RNA, 2 µg RNA were diluted in 5 µl RNA 
sample buffer containing ethidium bromide and run on MOPS/EDTA agarose gels. The 
amount of loaded RNA was controlled by visualisation on an UV screen. 
 
  63
3.11.5.2 RNA separation on MOPS/EDTA agarose gels 
10x MOPS/EDTA: 
MOPS 200 mM 
Na-acetate 50 mM 
EDTA 10 mM 
Adjust to pH 7.0  
 
RNA sample buffer: 
Formamide 15 ml 
10x MOPS 3 ml 
37% Formaldehyde 4.8 ml 
RNase free H2O 2 ml 
Glycerol 2 ml 
10% (w/v) Bromophenol blue 1.6 ml 
Optional: 5 µl ethidium bromide (1 mg/ml)  
Storage at -20 °C  
 
MOPS/EDTA gel (1.2%): 
Total volume 50 ml 
Agarose 0.6 g 
H20 42.5 ml 
10x MOPS 5 ml 
37% Formaldehyde 2.5 ml 
 
The RNA samples supplemented with sample buffer were heated up to 65 °C for 3 min-
utes causing the resolution of secondary structures in the RNA. Then the RNA samples 
were cooled on ice and loaded on a 1.2% MOPS/EDTA gel. 
 
3.11.5.3 Reverse transcription 
For cDNA synthesis, 1 µg of total RNA was reverse transcribed with an iScript cDNA 
synthesis kit (Bio-Rad, Cat. No. 170-8890) containing a mixture of oligo d(T) primers 
and random hexamer nucleotides.  
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Reaction mix per sample: 
5x iScript reaction mix 4 µl 
iScript reverse transcriptase 1 µl 
Nuclease free H2O X µl 
RNA template 1 µg of total RNA X µl 
Total volume 20 µl 
 
Reaction condition: 
 
 
3.11.5.4 SYBER green real-time PCR analysis 
SYBER green real-time PCRs were performed with 0.5 µl of the RT reaction mixture 
by the iCycler iQ system (Bio-Rad) and Taq DNA Polymerase (recombinant) from 
Fermentas (Cat. No. EP0402) to quantify PCR assays. Reactions were performed in 
doublets. The RT reaction product was amplified in a 25 µl reaction with the MDR1 
specific forward and reverse primer. The samples were heated to 95°C for 3 minutes 
and then amplified for 40 cycles consisting of 95°C for 20 seconds, 60°C for 25 seconds 
and 72°C for 25 seconds. The mouse hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) housekeeping gene was amplified as a control and used to normalise mRNA 
levels between different samples. 
 
Temperature, °C Time, min 
25 5 
42 30 
85 5 
4 ∞ 
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Reaction mix per sample: 
10x Taq buffer 2.5 µl 
10 mM dNTP each 0.5 µl 
25 mM MgCl2 2.5 µl 
TaqDNA polymerase (5U/µl) 0.2 µl 
Primer F (10 pmol/µl) 0.25 µl 
Primer R (10 pmol/µl) 0.25 µl 
FITC Flourescein Calibration Dye (1 µM) 0.9375 µl 
10x Syber Green (Bio-Rad) 1 µl 
DEPC 11.8625 µl 
Template 5.0 µl 
Total volume 25.0 µl 
 
Real-time PCR reaction: 
 
MC: melting curve 
AT: annealing temperature 
 
RT-HPRT primer: 
Primer Nucleotide sequence (5’ → 3’) 
RT-HPRT_for GCTGGTGAAAAGGACCTCT 
RT-HPRT_rev CACAGGACTAGAACACCTGC 
AT: 59°C 
 
Temperature, °C Time Number of Cycles 
95 3 min  
95 
AT 
72 
20 sec 
25 sec 
25 sec 
 
40x 
95 
MC 
 
60  
20 ∞  
  66 
RT-MDR1 primer: 
Primer Nucleotide sequence (5’ → 3’) 
RT-MDR1_for CGAAGAGTGGGCACAAACCAG 
RT-MDR1_rev GTGGTGGCAAACAATACAGGTTCC 
AT: 60°C 
 
3.12 P-gp surface expression  
3.12.1 P-gp surface expression for efflux studies 
For the efflux assay, wild-type and mutant P-gp surface expression levels were com-
pared and determined by a flow cytometer (FACSCalibur, BectonDickinson). Cells 
were trypsinized and counted, 200,000 cells were washed once with PBS and incubated 
with 50 µl MRK16 anti-P-glycoprotein primary antibody in PBS (10 µg/ml) at room 
temperature for 30 minutes. The rest of the cells was used for the rhodamine 123 efflux 
assay. After the incubation period, the cells were washed twice with PBS and treated 
with 50 µl Goat Anti-mouse IgG FITC (GAM Ig FITC) (BectonDickinson) in PBS. 
Cells were protected from light and incubated 30 minutes on ice. After the incubation 
period, cells were washed again twice with PBS and then resuspended in 200 µl PBS. 
The binding of the FITC-labeled P-gp antibody was analyzed with a flow cytometer 
(FACSCalibur, Becton Dickinson). Fluorescence was measured by counting 5,000 
events with an excitation wavelenght of 488 nm. 
 
3.12.2 P-gp surface expression increase using pharmacological chaperones 
Mutations of amino acids are responsible for reduced levels or absence of functional 
proteins at a required location. These mutant proteins, synthesized in the endoplasmic 
reticulum, are defective in folding and trafficking (processing mutants). 
The expression of P-gp and P-gp mutants in HEK 293 and NIH 3T3 cells was proven by 
surface protein expression analysis using the selective monoclonal antibody MRK16 
and the FITC-labelled second antibody used in flow cytometry analysis. We tried dif-
ferent compounds as pharmacological chaperones, for example CsA, verapamil and 
GPV51. GPV51 is a propafenone which was designed in our group. The cells were pre-
treated for 24 hours with 10 µM CsA, 50 µM verapamil and 50 µM GPV51. After 24 
hours the cells were trypsinized and counted for MRK16 staining. The prodecure is the 
same as before. 
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3.13 Transport studies 
3.13.1 Rhodamine 123 zero trans efflux studies 
The rhodamine 123 efflux assay is a direct and accurate functional method to measure 
inhibition of P-gp mediated transmembrane transport (Chiba, Ecker et al. 1996; Chiba, 
Holzer et al. 1998). Rhodamine 123 is a fluorescent substrate for the P-glycoprotein 
efflux pump (Kang, Fisher et al. 2004). 
NIH 3T3 cells (7.5 x 105 at 37°C or 1.5 x 106 at 28°C) of each respective stable cell line 
were seeded into 9.4 cm diameter tissue culture dishes (Greiner Bio-One, Germany, Cat. 
No. 633171) using the corresponding medium containing 10% DBS and in the absence 
of hygromycin B. The cells were incubated at 37°C or 28°C depending on the P-gp mu-
tant. After 48 hours, the medium was removed by pipetting from the culture dish into 
the lid of the culture dish and the cells were trypsinized with 800 µl of trypsin (Gibco) 
for 2-3 min at room temperature. The reaction was stopped by addition of the medium 
from the lid back into the culture dish. Cells were transferred to a 50 ml Falcon tube, 
counted, and approximately 2 x 106 cells were pelleted for 6 minutes at 1,100 rpm at 4 
°C in an Eppendorf 5403 Centrifuge (Eppendorf, Germany). 
After centrifugation, the supernatant was removed through suction, and the cells were 
resuspended in 10 ml DMEM medium containing 10% DBS, 50 mM HEPES (Merck, 
Cat. No. 110110.0250) pH7.8 and rhodamine 123 (Rh123) (Sigma, Austria) at a final 
concentration of 0.2 µg/ml (0.53 µmol/L). The cell suspension was incubated for 30 
minutes using a gently shaking water bath at 37 °C, resulting in a steady state of rhoda-
mine 123 accumulation. After incubation, the tube was chilled on ice water and 9 ml of 
its content aliquoted and transferred to 9 FACS tubes (Becton Dickinson, Cat. No. 
352052). These tubes were centrifuged for 6 minutes at 1,100 rpm at 4 °C in an Eppen-
dorf 5415C Centrifuge (Eppendorf, Hamburg, Germany) and washed once with 1 ml ice 
cold DMEM medium to remove extracellular fluorochrome. The tubes were centrifuged 
and the supernatant removed as described before. The cell pellets were resuspended in 
900 µl DMEM medium containing either no modulator or modulator at various concen-
trations ranging from 164 nM to 100 µM (1:2.5 serial dilutions) depending on solubility 
and the expected potency for the modifier. The DMEM medium was prewarmed at       
37 °C in a water bath. The time dependent decrease in cellular mean fluorescence was 
determined in the presence of eight serial diluted concentrations (1:2.5) for the GPV01 
modulator. After 90, 180, 270 and 360 seconds, aliquots (200 µl) of the incubation mix-
ture were transferred to tubes containing an equal volume of ice-cold stop solution 
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(DMEM medium containing GPV31 at a final concentration of 10 µM). Samples were 
kept in an ice water bath until the measurement was performed within 1 hour with a 
Becton Dickinson FACSCalibur flow cytometer (Becton Dickinson, Vienna, Austria). 
Viable cells were gated on the basis of forward and side scatter (Chiba, Ecker et al. 
1996). To determine the mean fluorescence values the excitation and emission wave-
lengths were 488 nm and 534 nm, respectively and five thousand gated events were 
accumulated (Chiba, Ecker et al. 1996). 
 
3.13.2 Daunomycin steady state studies 
HEK 293 cells were cultured in DMEM medium containing 10% DBS and in the ab-
sence of hygromycin B. Cells were trypsinized for 2-3 min at room temperature and the 
reaction was stopped by addition of DMEM medium containing 10% DBS. Cells were 
transferred to a 50 ml Falcon tube, counted, and approximately 2 x 106 cells were pel-
leted for 6 minutes at 1,100 rpm at 4 °C in an Eppendorf 5403 Centrifuge (Eppendorf, 
Germany). 
After centrifugation, the supernatant was removed through suction, and the cells were 
resuspended in 10 ml DMEM medium containing 10% DBS, 50 mM HEPES, pH7.8 
and daunomycin (Sigma-Aldrich, Cat. No. D8809) at a final concentration of 3 µM. 10 
µl DMSO and different inhibitor concentrations were added to 990 µl aliquots of the 
mixture depending on the expected potency of the compounds. Tubes containing these 
aliquotes were incubated for 30 minutes using a gently shaking water bath at 37 °C. 
During this time every single tube was spun with a vortex for optimal agitation. After 
incubation the cells were chilled on ice, pelleted, washed once with 1 ml ice-cold 
DMEM medium containing 10% DBS. Cells were again pelleted and resuspended in 
200 µl ice-cold stop solution (DMEM medium containing GPV31 at a final concentra-
tion of 5 µM). Samples were kept in an ice water bath until the measurement was per-
formed. The prodecure is the same as before in section 3.13.1.  
 
3.13.3 Cytotoxicity of rhodamine 123 in FlpIn NIH 3T3 cells 
Cells (5 x 105) of each respective stable cell line were seeded into a 25-cm2 tissue cul-
ture flask without hygromycin B. After 48 hours, the medium was removed by suction 
from the subconfluent tissue culture flask, washed with 5ml PBS and trypsinized with 1 
ml of trypsin (Gibco) for 2-3 min (checked under microscope) at room temperature. The 
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reaction was stopped by addition of 13 ml DMEM/20%DBS and the cells were trans-
ferred to a 100 ml tissue culture glass flask with 56 ml of medium (this means 1:5 split 
from confluency). The cells were counted for 0 time points and seeded into 24 well 
plates (1 ml/well) in dupilcates for each day of a 3-day growth study. After 1 hour 1 ml 
of medium with varying concentrations of rhodamine 123 in ddH2O and lacking DBS 
was added into each well, resulting in a 1:2 serial dilution of rhodmamine 123 ranging 
from 2.34 mM to 150 mM. The first well was left without rhodamine 123 addition. 
Every 24 hours after the initial seed, the cell number from each plate was determined 
with a Casy cell counter (Innovatis AG, Germany). The medium was removed from the 
24-well plate by suction, washed with 1ml of PBS and trypsinized with 100µl of trypsin 
solution. The reaction was then stopped by addition of 120µl of medium and the total 
volume (220µl) was transferred to a count vial containing ~9.8ml of counter fluid and 
counted with a Casy cell counter to measure the number of surviving cells. During the 
study, the growth medium was not changed. 
 
3.13.4 Determination of first order rate constant (FORC) and IC50 values of 
modulators 
Rhodamine 123 zero trans efflux 
Cells were loaded with fluorescent substrate and efflux was determined in absence and 
presence of different inhibitor concentrations. At time point zero the extracellular con-
centration of the fluorochrome was zero and the intracellular concentration was high as 
compared to the extracellular concentration during the whole experiment. The effluxed 
fluorescent substrate did not reenter to any significant extent. Initial efflux in the zero 
trans efflux experiments was calculated from the time dependent exponential decrease 
in mean fluorescence by nonlinear regression analysis using least squares. First order 
rate constants (Vmax/Km) were calculated for each experiment. Dose response curves of 
modifier concentrations were calculated as the independent variable versus first order 
rate constants and were fitted according to follow equation: 
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v    first order rate constant as a function of modulator concentration  
Vmax the initial rate of efflux observed in the cell line in the absence of 
a modulator  
ME   modulator efficacy 
c    the modifier concentration 
n   Hill coefficient 
 
IC50 values of modulators were calculated from the dose response curves of the first 
order rate constant versus the modifier concentration. The IC50 value is the concentra-
tion of the modulator yielding a half-maximal effect. 
 
Daunomycin steady state  
In contrast, the steady state protocol evaluates steady state levels of fluorochrome inside 
the cell at different concentrations of pump inhibitors. The extracellular concentration is 
higher than the intracellular concentration and the fluorescent substrate enters the cells 
by diffusion along the concentration gradient. Two processes occur simultaneously: the 
transporter pumps solutes to the extracellular side and a concentration gradient depend-
ent diffusion of substrate occurs at the same time. Therefore, the steady state accumula-
tion levels of fluorochrome are a function of the pump activity and of diffusion rates of 
the compounds. 
In steady state experiments the mean fluorescence units of the starting inhibitor concen-
tration were calculated with the following equation: 
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MFUC0  Mean fluorescence unit of starting inhibitor concentration 
MFUCinf – C0 Mean fluorescence unit of inhibitor concentration after 30 min-
utes minus starting concentration 
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[S]   Substrate concentration 
n   Hill coefficient 
 
For comparing IC50 values of the steady state assay with those of the zero trans efflux 
experiment it was multiplied with the quotient C0/Cinf (beginning concentration divided 
through end concentration) (Stein 1997). 
 
3.13.5 Flow cytometer 
Flow cytometry was performed using a FACSCalibur flow cytometer (Becton Dickin-
son, Vienna, Austria). FACS flow sheath fluid (Cat. No. 342003) and 5 ml polypropyl-
ene FACS tubes (Cat. No. 352052) were purchased from BDBiosciences. 
Cells were cooled in an ice water bath and measured within 1 hour. Every tube after 
another was measured. 
It is possible to measure straylight and fluorescent signals with a flow cytometer. An 
argon-ion laser detects the single cells by forward scattered light (FSC) which is a 
measure for cell size and side scattered light (SCC) which stands in relation to cell 
structure (granularity of cells). Cells were shown in a correlated two-parameter dot plot: 
FSC against SSC. 
Cell data were evaluated after measurement, the viable population was differentiated 
from dead cells with an automatic attractor (BD-software package of BD flow cytome-
try). To determine the mean fluorescence values five thousand gated events were accu-
mulated. The cell population could be more differentiated from other cells with a subat-
tractor inside of the first gate. 
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4 Results 
 
4.1 Motivation for selection of mutated residues  
4.1.1 Which residues at the TMDs interfaces should be mutated? 
The high resolution structure of the Sav1866 transporter has a twisted topology. Evi-
dence for an analogous architecture of P-glycoprotein was presented by the group of 
Kenneth Linton in 2007 (Zolnerciks, Wooding et al. 2007). Using cross-linking analy-
sis, the authors showed that the intracellular loop (ICL) 4 within TMD2 forms an inter-
face with NBD1 of P-gp. In earlier studies by Loo and Clarke (Loo, Bartlett et al. 2004) 
and Stenham et al (Stenham, Campbell et al. 2003) in Linton’s group cysteines were 
introduced into both the extracellular end of transmembrane segments 2 and 11. These 
data showed that transmembrane helix 2 is close to transmembrane helix 11. Likewise, 
transmembrane helix 5 was shown to be close to transmembrane helix 8 (Stenham, 
Campbell et al. 2003; Loo, Bartlett et al. 2004). The equivalent transmembrane helices 
in the Sav1866 structure, helices 2, 5’ and 2’, 5 of the monomers, corresponding to heli-
ces 5/8 and 2/11 in P-gp, form the contact interfaces between the two TMDs. In addi-
tion, site directed mutagenesis studies by the group of David Clarke indicated that resi-
dues lining these interfaces impair the ability of the transporter to function properly 
when mutated to cysteines (Loo and Clarke 2005). Most of these residues cannot be 
protected by substrates from reacting with MTS-coupled verapamil or rhodamine 123. 
Alignments of the N- and C-terminal half of P-gp indicate two conserved glutamine 
residues which are predicted to be located in predicted transmembrane segments 2 and 8 
(Figure 4.1). Q132 in the N-terminal half and Q773 in the C-terminal half align. These 
two residues are the only non-glycine residues which are conserved between TM helices 
2 and 8 (Figure 4.1). 
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Figure 4.1: Sequence alignments of the N- and C-terminal half of P-gp using Clustal 2.0.8 multiple 
sequence alignment. The transmembrane segments are highlighted in turquoise. Glutamine resi-
dues which were mutated in this study are shown in red. For easier orientation, a partial sequence 
alignment of TMs 2 and 8 is shown above the alignment. 
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A total of 9 glutamine residues are found in predicted TM segments. Our homology 
model of P-gp suggests two of these glutamine residues to be located in between most 
highly photolabelled residues M197 and F951 (Q132) at the TM3/11 interface and 
A311 and T769 (Q773) at the TM5/8 interface. In addition, these residues are capable of 
forming H-bonds with solutes/inhibitors and are predicted in docking experiments to be 
involved in solute interaction. 
 
4.1.2 Which mutants should be generated? 
The next question was which mutants should be generated at the positions 132 and 773 
to yield fully functional transporters?  
To estimate the relative evolutionary pressure on residues in P-gp, our group used a 
method originally published in 2004 by Mihalek et al. (Mihalek, Res et al. 2004) . It is 
helpful to have an estimate of the relative importance of residues as a guide when a pro-
tein is intended to be mutated. When exploring the mutational space of nature a high 
number of correctly targeted and functional transporters is expected to be obtained. De-
termination of sequence variation which is based on multiple sequence alignments 
(MSAs) using the real valued evolutionary trace (rvET) was performed by Ivana Mi-
halek. The conservation patterns show that these two glutamine residues are not con-
served among P-gps of all species. At least one of these glutamines, however is con-
served in P-gps of species ranging from bacteria to humans. Glutamine residues are un-
charged polar residues, which were replaced by nonpolar alanine residues, a positively 
charged arginine or a negatively charged glutamic acid, individually or in combination. 
MSAs indicated that a charge might be tolerated in this position of the protein. In this 
study, the influence of replacement of glutamine by positively or negatively charged or 
by uncharged amino acid residues was investigated in order to characterize their possi-
ble role in the transport process. 
Importantly, a number of residues which had been identified as being critically involved 
in rhodamine 123 and verapamil binding, are located in vicinity of these residues in 
protein homology models of P-gp. 
 
4.2 Generation of expression vectors 
In this study the site directed mutagenesis experiments were guided by the mutational 
space explored and delineated by nature. We have created a series of constructs to be 
  76 
able to express mutants of P-gp. Q123 and Q773 were mutated to glutamic acid, argin-
ine and alanine, individually or in combination. Mutants were generated in the wt and in 
the G185V background in the entry vector using overlap extension PCR. After site di-
rected mutagenesis, the pEF5 vector encoding for P-gp or P-gp mutants were generated 
via LR recombination reaction. 
 
G185V background Wildtype background 
Q132A Q132A 
Q773A Q773A 
Q132A/Q773A Q132A/Q773A 
Q132E  
Q773E Q773E 
Q132E/Q773E  
Q132R  
Q773R Q773R 
Q132R/Q773R  
Table 4.1. Constructs of P-gp mutants. 
 
It was expected that a replacement leads to altered substrate binding and transport, 
which can be analysed by efflux assays of diverse substrates. 
 
4.3 Creation of stable cell lines expressing P-gp mutants 
To determine potential effects of the expression of Q132 and Q773 mutants, we carried 
out stable transfection in FlpIn HEK 293 and mouse FlpIn NIH 3T3 cell lines express-
ing the wt or mutant form of P-gp by using the vector pEF5. 
 
Expression and function of P-gp in FlpIn HEK 293 cells 
Stable transfectants were obtained by selection in 200 µg/ml hygromycin B and surviv-
ing clones were screened by flow cytometry using the MRK16 antibody, which detects 
P-gp on the cell surface recognizing an external epitope. We started with the transfec-
tion of HEK 293 cells with the vectors pEF5MDR1H6G185V and pEF5 as control. The 
P-gp G185V mutant was first isolated from highly colchicine-resistant cell lines (Choi, 
Chen et al. 1988). Cells expressing G185V P-gp had a decreased rate of colchicine up-
take when compared to cells with wild-type P-gp (Omote, Figler et al. 2004). It has 
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been shown that this mutation is responsible for high colchicine resistance. In addition, 
the G185V mutation near transmembrane domain 3 of human P-gp confers an increased 
resistance to etoposide and doxorubicin but a decreased resistance to vinblastine, Taxol 
and actinomycin D (Ruth, Stein et al. 2001). 
To estimate the amount of non-specific binding of mouse monoclonal antibodies to hu-
man cell-surface antigens a mouse IgG2a antibody was used as fluorescence control. 
This antibody reacts specifically with keyhole limpet hemocyanin (KLH), an antigen 
not expressed on human cells or human cell lines (BectonDickinson). The P-gp overex-
pressing human T-lymphoblast cell line CCRF-CEM VCR 1000, provided by V. Gek-
eler (Byk Gulden, Konstanz, Germany), served as a positive control and mock trans-
fected cells served as the negative control. The CCRFvcr 1000 cell line has been charac-
terized previously (Gekeler, Weger et al. 1990; Gekeler, Frese et al. 1992; Chiba, Ecker 
et al. 1996). Using goat anti-mouse Ig FITC (GAM Ig FITC) resulting mean fluores-
cence units (MFU) were measured by flow cytometry (Figure 4.2: MRK16 and IgG2a 
staining. Red bars refer to cells incubated with MRK16 and blue bars to those incubated 
with IgG2a control antibody.).  
 
Figure 4.2: MRK16 and IgG2a staining. T-lymphoblast cell line CCRF-CEM VCR 1000 (vcr1000), 
HEK 293 cells transfected with G185V P-gp (G185V) and mock transfected HEK 293 cells (Mock) 
are shown. Red boxes are cells incubated with MRK16 and blue boxes are cells incubated with 
IgG2a as control. 
 
To test the pump activity of the transfected cell lines, steady state experiments were 
performed. The pump activity of G185V P-gp was compared to mock transfected cells. 
In this protocol inhibitor and fluorochrome are added simultaneously and a steady state 
is reached after 30 minutes. In addition, inhibition of the pump increases intracellular 
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fluorochrome levels and therefore the pump activity. An example of such an experiment 
is given in Figure 4.3: Daunomycin steady state experiments with HEK 293 cells. By 
measuring cellular mean fluorescence units (MFU) in the absence and presence of 8 
different concentrations of the propafenone analogue GPV31, IC50 values were calcu-
lated using a hyperbolic curve fit. Left: HEK 293 cells transfected with G185V P-gp. 
Right: Mock transfected HEK 293 cells. The IC50 value for G185V P-gp was 0.21 µM.  
 
Figure 4.3: Daunomycin steady state experiments with HEK 293 cells. By measuring cellular mean 
fluorescence units (MFU) in the absence and presence of 8 different concentrations of the 
propafenone analogue GPV31, IC50 values were calculated using a hyperbolic curve fit. Left: HEK 
293 cells transfected with G185V P-gp. Right: Mock transfected HEK 293 cells.  
 
The P-gp clone positive for the G185V mutation was expanded for further study. We 
tested different compounds as inhibitors and compared the pump activity between 
G185V and mock transfected cells. The propafenone analogues which were used have 
different lipophilicity. Lipophilicity (calculated logP) is a main determinant for biologic 
activity of the compounds with respect to MDR inhibition (Chiba, Ecker et al. 1996; 
Schmid, Staudacher et al. 2003). LogP values of the compounds were calculated based 
on the incremental method described by Ghose et al. (Ghose and Crippen 1987). Highly 
lipophilic compounds have high potency (1/IC50 values) because in the membrane, the 
site of pharmacological action, lipophilic compounds accumulate. IC50 values for 
G185V P-gp expressing HEK 293 cells were determined by daunomycin steady state 
experiments using different propafenone analogues. Results are summarized in Table 
4.3. To compare IC50 values of the steady state assay with those of the zero trans efflux 
experiment they were multiplied with the quotient C0/Cinf (accumulation at an inhibitor 
concentration of zero divided by accumulation rate at infinite concentration of inhibitor 
  
(Stein 1997). In the example 
propafenone analogue GPV31 was 
in the zero trans efflux protocol
The corrected IC50 value was 
tained in the steady state protocol is that any inhibition of the transporter results in an 
increase of the intracellular concentration of solute and thus an increase
This partially antagonizes the
actual values. For the theory behind the correction term specified above the reader is 
referred to the work of Stein et al. 
Table 4.2: All used compounds listed 
of G185V P-gp expressed in HEK 293 cells and 
 
In a comparison of 24 compounds, the 
tained in these steady state experiments 
well with those obtained in the
CCRFvcr 1000 cells (Figure 
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illustrated in Figure 4.3 the apparent IC50
0.21 µM. To compare it with the IC50 value
 it was multiplied by 0.718 (426.7 MFU/594.1
0.15 µM. The rational for correction of IC
 inhibition leading to observed IC50 which are higher than 
 
with their calculated lipophilicity, IC50 values and log(1/
wt-P-gp in CCRFvcr 1000 cells. 
modulator log potency (log(1/IC50
of G185V P-gp HEK 293 cell line 
 daunomycin zero trans efflux studies 
4.6).  
 value of the 
 obtained 
 MFU). 
50 values ob-
d pump rate. 
 
IC50) 
) values) ob-
correlated 
performed in 
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Figure 4.4: Correlation between log potency values obtained for HEK 293 cell containing G185V P-
gp line in daunomycin steady state experiments and log potency values for the P-gp overexpressing 
human T-lymphoblast cell line CCRF-CEM VCR 1000 as determined by a zero trans efflux proto-
col. Results for a set of propafenone analogues are shown. The propafenone analogs are located 
close to the solid line which represents the ideal 1:1 correlation. Data points represent the mean of 
at least duplicate determinations. 
 
Mock transfected cells served as negative control and the effect of propafenone 
ananlogues observed in these cells was negligible for most compounds. An important 
observation however, was that the mock transfected cells did sometimes show some 
pump activity because of endogenously expressed human wt P-gp. In the representative 
experiment for compound GPV31 shown in Figure 4.3, the highest loading level at the 
highest compound concentration was 600 MFU/cell for G185V P-gp and 550 MFU/cell 
for mock transfected cells. To overcome the human endogenous P-gp expression in 
HEK 293 cells, we switched to the NIH 3T3 mouse cell line which is also compatible 
with the Flp-In system but expressing very much lower endogenous P-gp levels.  
 
Expression and functional characterization of P-gp in FlpIn3T3 cells 
Mutated membrane proteins with impaired folding often fail to reach the plasma mem-
brane (Loo, Bartlett et al. 2005). They are retained in an inactive form in the endoplas-
mic reticulum (ER) by the cell’s quality control mechanism and are rapidly degraded 
(Pind, Riordan et al. 1994; Chen, Bartlett et al. 2000; Loo, Bartlett et al. 2005). In publi-
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cations of Loo and Clarke a majority of mutants showed correct targeting to the plasma 
membrane in the presence of the pharmacological chaperone cyclosporine A (CsA). In 
order to correct the trafficking deficiency of mutant P-gp and study the transporter func-
tionally, the P-gp mutants were grown in the presence of 10 µM CsA as previously sug-
gested by Loo, Bartlett and Clarke. In fact, the P-gp expression level was higher in the 
presence of CsA which is shown in Figure 4.5 for the example of the G185V, G185V-
Q132R/Q773R P-gp. We tested two different incubation times for 10 µM CsA. How-
ever, incubation for 24 hours could rescue the double R mutant and increase the expres-
sion level of G185V P-gp. The mock transfected cells only showed a small stimulation. 
After 48 hours, the effect diminished except for the double R mutant in which it was 
identical. 
 
Figure 4.5: MRK16 and IgG2a staining. Red boxes are cells incubated with MRK16 and blue boxes 
are cells incubated with IgG2a as control.  
 
4.4 Characterization of P-gp expression at the protein level 
We investigated whether CsA could influence the P-gp expression level. For this pur-
pose, we performed Western blot analysis with the specific monoclonal C219 antibody 
which recognizes a highly conserved amino acid sequence found in the nucleotide bind-
ing domain of P-gp. We observed a significant increase of all P-gp mutant proteins in 
NIH 3T3 cells, which were preincubated with 10 µM CsA for 24 hours at 37°C. Control 
cells were incubated with DMSO only. The C219 antibody also recognized the mouse 
P-gp but the difference between mock transfected cells was negligible (Figure 4.6). 
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Figure 4.6: Effect of CsA on maturation of P-gp mutants. NIH3T3 cells expressing mutants were 
preincubated with 10 µM CsA (+) or DM SO only (-) for 24 hours at 37°C. Equivalent amounts of 
whole cell SDS extracts were then subjected to SDS-PAGE and Western blot analysis with the 
monoclonal anti-P-glycoprotein antibody C219. The positions of the mature form (170 kDa) of P-gp 
mutants are indicated. 
 
4.5 Effect of CsA on mRNA level 
SYBR green real-time reverse transcription PCR was used to asses the influence of CsA 
on mRNA level. The mouse hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
gene was used to normalise mRNA levels between different samples. CsA had no effect 
on mRNA level (Figure 4.7). 
 
Figure 4.7: SYBR green real-time RT-PCR analysis of P-gp mutants. Total RNA isolated from P-gp 
mutants NIH 3T3 cells was reverse transcribed, and PCR was performed with primers specific for 
cDNA of the MDR1 gene. Red boxes refer to cells incubated with 10 µM CsA for 24 hours and blue 
boxes refer to cells incubated with the solvent DMSO as control. Left: Gene expression levels were 
normalized to HPRT levels and shown as expression levels of P-gp mutants relative to those of the 
control. Right: Gene expression levels were normalized to HPRT levels and shown as expression 
levels of P-gp mutants relative to those of the control (arbitrarily set to 1). 
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4.6 Pharmacological chaperones 
We tested whether mutations introduced in TM segments 2 and 8 (forming part of the 
drug binding pocket) inhibit maturation of the protein. The presence of P-gp and P-gp 
mutant protein in HEK 293 and NIH 3T3 cells was detected by surface protein expres-
sion analysis using the selective monoclonal antibody MRK16 and the goat anti mouse 
FITC-labelled secondary antibody. The fluorescence intensity of some P-gp mutants 
was comparable to the background fluorescence intensity, thus the level of P-gp expres-
sion was negligible. Pharmacological chaperones such as cyclosporin A and  verapamil 
are predicted to promote maturation of P-gp processing mutants.  
 
4.6.1 Surface expression of P-gp in FlpIn NIH 3T3 fibroblasts 
We tried different compounds as pharmacological chaperones, for example CsA,  vera-
pamil and GPV51. These tests are useful, especially in terms of optimization of concen-
tration of substrates. Thus, the first step was to compare various concentration of the 
propafenone analogue GPV51 for the efficiency in promoting maturation of P-gp. For 
this, cells were incubated in the absence or presence of 10 different concentrations rang-
ing from 1.17 to 300 µM (1:2 serial dilution) of GPV51 for 24 hours to optimize the 
tolerable dosage of GPV51 to act as a pharmacological chaperone. Additionally, cyc-
losporin A at a concentration of 10 µM was used as a control. After a 24 hour incuba-
tion, the distribution pattern of the protein expression level was determined by immuno-
cytochemical staining using the monoclonal antibody MRK16 as described above. Fig-
ure 4.50 - Figure 4.54 represent the mean of two independently performed experiments. 
The arginine mutants were tested due to the comparability of the G185V-Q773R and 
G185V-Q132R/Q773R mutants’ expression levels to those of the mock transfected 
cells. The arginine mutants were compared to G185V P-gp and mock transfected cells. 
All arginine mutants showed a higher expression in the presence of CsA and GPV51 
compared to the control.  
 
The G185V P-gp and Q132R, Q773R and Q132R/Q773R P-gp mutants in the G185V 
background showed a concentration-dependent increase in the expression level of P-gp 
(Figure 4.8 - Figure 4.11). However, the mock transfected cells showed a similar pattern 
(see Figure 4.12). Incubation of all R mutants in the presence of GPV51 gave a similar 
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pattern. The propafenone analogue GPV51 was able to increase the expression level of 
all R mutants to a small extent (shown in Figure 4.9 - Figure 4.11).  
 
 
Figure 4.8: Distribution pattern of the protein expression level of G185V P-gp expressing NIH3T3 
cells. In the absence and presence of 10 different concentrations of the propafenone analogue 
GPV51, the tolerable dosage was tested. Incubation with 10 µM CsA served as control. 
 
 
 
Figure 4.9: Distribution pattern of the protein expression level of G185V-Q132R P-gp expressing 
NIH3T3 cells. In the absence and presence of 10 different concentrations of the propafenone ana-
logue GPV51, the tolerable dosage was tested. Incubation with 10 µM CsA served as control. 
 
 
 
Figure 4.10: Distribution pattern of the protein expression level of G185V-Q773R P-gp expressing 
NIH3T3 cells. In the absence and presence of 10 different concentrations of the propafenone ana-
logue GPV51, the tolerable dosage was tested. Incubation with 10 µM CsA served as control. 
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Figure 4.11: Distribution pattern of the protein expression level of G185V-Q132R/Q773R P-gp 
expressing NIH3T3 cells. In the absence and presence of 10 different concentrations of the 
propafenone analogue GPV51, the tolerable dosage was tested. Incubation with 10 µM CsA served 
as control. 
 
 
Figure 4.12: Distribution pattern of the protein expression level of mock transfected NIH3T3 cells. 
In the absence and presence of 10 different concentrations of the propafenone analogue GPV51, the 
tolerable dosage was tested. Incubation with 10 µM CsA served as control. 
 
The expression levels of the G185V P-gp and G185V P-gps mutants are increased by a 
24 hours pre-treatment with the pharmacological chaperone GPV51. 
We used 50 µM GPV51 for further experiments due to the fact that a more than 20% 
increase in endogenous mouse P-gp expression ensued from administration of higher 
concentrations (shown in Figure 4.12: Control: 100%, 75 µM GPV51: 179%). At 150 
and 300µM the effect was less pronounced than at 75µM.  
For compounds such as cyclosporin A and  verapamil which are predicted to promote 
maturation of P-gp processing mutants we used published concentrations: 10 µM cyc-
losporin A (CsA) and 50 µM  verapamil (Vera).  
The next step was to compare these compounds in their effect on P-gp mutants. The 
effect of CsA,  verapamil and GPV51 on P-gp expression level was determined by im-
munocytochemical staining using the monoclonal antibody MRK16 as described above. 
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DMSO was required at a final concentration of 0.2% to prepare CsA and GPV51 stocks.  
Verapamil was prepared in water. Therefore 0.2% final concentration of DMSO was 
added to control cells and cells that were incubated with  verapamil for 24 hours.  
 
Figure 4.13: MRK16 staining of G185V P-gp, Q132A, Q773A and Q132A/Q773A P-gp mutants in 
the G185V background, and mock transfected NIH 3T3 cells. All cell lines were preincubated for 
24 hours with 10 µM CsA, 50 µM Vera and 50 µM GPV51. Control cells were incubated with 
DMSO. 
 
Figure 4.14: MRK16 staining of G185V P-gp, Q132E, Q773E and Q132E/Q773E P-gp mutants in 
G185V background, and mock transfected NIH 3T3 cells. All cell lines were preincubated for 24 
hours with 10 µM CsA, 50 µM Vera and 50 µM GPV51. Control cells were incubated with DMSO. 
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Figure 4.15: MRK16 staining of G185V P-gp, Q132R, Q773R and Q132R/Q773R P-gp mutants in 
G185V background, and mock transfected NIH 3T3 cells. All cell lines were preincubated for 24 
hours with 10 µM CsA, 50 µM Vera and 50 µM GPV51. Control cells were incubated with DMSO. 
 
The expression level of all mutants was increased by a 24 hours pre-incubation with 
CsA,  verapamil and GPV51. The best effect was obtained with the chaperone CsA, 
followed by  verapamil. The propafenone analogue GPV51 only was able to increase 
the expression level of all mutants to a small extent. 
  
4.6.2 Surface expression of P-gp in FlpIn HEK 293 cells 
The effect of CsA,  verapamil and GPV51 on P-gp expression level also was tested in 
HEK 293 cells expressing G185V P-gp, G185V-Q773R and G185V-Q132R/Q773R 
mutants. 
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Figure 4.16: MRK16 staining of G185V P-gp, Q773R and Q132R/Q773R P-gp mutants in G185V 
background, and mock transfected HEK 293 cells. All cell lines were preincubated for 24 hours 
with 10 µM CsA, 50 µM Vera and 50 µM GPV51. Control cells were incubated with DMSO. 
 
The mock transfected HEK 293 control cells showed a higher background expression 
compared to mock transfected NIH 3T3 control cells based on the human endogenous 
P-gp. 
Apart from that, the expression pattern for the G185V P-gp, G185V-Q773R and double 
R mutant are similar in both human and mouse cell lines preincubated with CsA,  vera-
pamil and GPV51. 
 
4.7 Cytotoxicity of rhodamine 123 
The purpose of this experiment was to investigate the effect of rhodamine 123 on MDR 
and therefore the influence on cell growth in FlpIn NIH 3T3 transfected cell lines. The 
drug resistance of stable cells expressing MDR1 wild-type or MDR1 mutants was 
evaluated by measuring the cell viability after exposing them to a wide range of rhoda-
mine 123 concentrations. The cells were incubated in the absence or presence of various 
concentrations ranging from 2.34 µM to 150 µM (1:2 serial dilutions) of rhodamine 123 
for 24 hours, 48 hours and 72 hours. The cell number was determined with a Casy cell 
counter (Innovatis AG, Germany). At the beginning we compared G185V P-gp and wt 
P-gp. Mock transfected cells again served as negative control. All cytotoxicity experi-
ments were performed in duplicate, using cells obtained from independent experiments. 
Experimental data are presented as the mean ± standard deviation (S.D.). The cells ex-
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pressing G185V P-gp exhibit higher resistance to rhodamine 123, suggesting a gain of 
function phenotype (Figure 4.17 - Figure 4.19). The concentrations required for 50% 
cell death (half maximal effective concentration, IC50) after 72 hours incubation for wt 
P-gp, G185V P-gp and mock transfected cells were 104 µM, 306.3 µM and 32.5 µM. 
Thus, G185V P-gp was of great interest for mutant characterization. We used this 
G185V “gain-of-function” mutation in all of the mutants in order to be able to study 
them functionally by flow cytometry using rhodamine 123 as a substrate. 
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Figure 4.17: Cell growth as a percentage of control for G185V P-gp, wt P-gp and mock transfected 
NIH3T3 cells after 24 hours incubation with rhodamine 123 at 37°C. Each experiment was per-
formed in duplicate. 
 
Figure 4.18: Cell growth expressed as a percentage of control for G185V P-gp, wt P-gp and mock 
transfected NIH3T3 cells after 48 hours incubation with rhodamine 123 at 37°C. Each experiment 
was performed in duplicate. 
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Figure 4.19: Cell growth expressed as percentage of control for G185V P-gp, wt P-gp and mock 
transfected NIH3T3 cells after 72 hours incubation with rhodamine 123 at 37°C. Each experiment 
was performed in duplicate. 
 
All mutants were compared with G185V P-gp and mock transfected cells. Cell surface 
labelling of P-gp was carried out for all cell lines, in parallel with cytotoxicity experi-
ments. These additional studies confirmed the expression of all A mutants (shown in 
Figure 4.20) and E mutants (shown in Figure 4.22). The R mutants showed a different 
expression pattern (shown in Figure 4.24). The Q773R and Q132R/Q773R had an ex-
pression level which was similar to that of mock transfected cells, i.e. did not show traf-
ficking to the plasma membrane. The expression level was higher than in positive con-
trols in Q132E, Q132R and Q773A mutants. Both Q773A and Q132E showed a small 
increase, but expression of the Q132R mutant was significantly increased. 
As before, all cytotoxicity experiments were performed in duplicate using cells obtained 
from independent experiments with the same concentration of rhodamine 123. How-
ever, only the 72 hour time point is shown (Figure 4.21, Figure 4.23 andFigure 4.25). 
Experimental data are presented as the mean ± standard deviation (S.D.).  
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Figure 4.20: MRK16 staining of G185V P-gp, G185V A mutants and mock transfected cells. All 
mutants were expressed. Each experiment was performed in duplicate. 
 
 
 
Figure 4.21: Cell growth expressed as percentage of control for G185V P-gp, G185V A mutants and 
mock transfected NIH3T3 cells after 72 hours rhodamine 123 incubation at 37°C. Each experiment 
was performed in duplicate. 
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Figure 4.22: MRK16 staining of G185V P-gp, G185V E mutants and mock transfected cells. All 
mutants were expressed. Each experiment was performed in duplicate. 
 
 
Figure 4.23: Cell growth expressed as a percentage of control for G185V P-gp, G185V E mutants 
and mock transfected NIH3T3 cells after 72 hours rhodamine 123 incubation at 37°C. Each ex-
periment was performed in duplicate. 
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Figure 4.24: MRK16 staining of G185V P-gp, G185V R mutants and mock transfected cells. Q773R 
and Q132R/Q773R mutants were not expressed. Each experiment was performed in duplicate. 
 
 
Figure 4.25: Cell growth expressed as percentage of control for G185V P-gp, G185V E mutants and 
mock transfected NIH3T3 cells after 72 hours rhodamine 123 incubation at 37°C. Each experiment 
was performed in duplicate. 
 
The IC50 values after a 72 hour incubation with G185V P-gp, Q132A, Q773A and 
Q132A/Q773A in the G185V background, and mock transfected cells were 173 µM, 99 
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µM, 145 µM, 92 µM and 25 µM (shown in Figure 4.21). These results indicated that an 
alanine substitution at position 132 and 773, individually or in combination had little 
influence on the substrate properties of rhodamine 123 and therefore little influence on 
cell survival. 
The IC50 values after 72 hours incubation with G185V P-gp, Q132E, Q773E and 
Q132E/Q773E in the G185V background, and mock transfected cells were 238 µM, 958 
µM, 57 µM, 76 µM and 40 µM (shown in Figure 4.23). Surprisingly, we found that 
Q132E is a “gain of function” mutation because of the fourfold higher IC50 value (four-
fold higher resistance) as compared to the G185V background. 
The IC50 values after 72 hours incubation with G185V P-gp, Q132R, Q773R and 
Q132R/Q773R in the G185V background, and mock transfected cells were 283 µM, 
401 µM, 86 µM, 60 µM and 71 µM (shown in Figure 4.25). Although both the Q132R 
and the Q132E mutant showed a similar behaviour, the Q132R showed essentially iden-
tical resistance as compared to the G185V background. The Q132R/Q773R double mu-
tant essentially showed the same IC50 value as the mock tranfected cells. Similarly, the 
difference between IC50 values of Q773R and mock transfected cells was negligible. 
 
4.8 Rhodamine 123 zero trans efflux experiments 
The pump activity of the transfected cell lines were tested by zero trans efflux experi-
ments. To examine whether rhodamine 123 is recognized as substrate by P-gp mutants, 
we determined the transport of rhodamine 123 in NIH 3T3 cells stably expressing P-gp 
mutants’ compared to G185V P-gp and mock transfected cells. 
 
Because of the fact that the Q773R and Q132R/Q773R in the G185V background did 
not traffic to the plasma membrane, the first experiments were performed by adding 
CsA at a concentration of 10 µM at 37°C for 24 hours. All R mutants and both G185V 
P-gp and mock transfected cells were incubated with CsA serving as control. After 24 
hours the cells were washed three times with 90% DBS and 10% DMEM for 20 minutes 
at 37°C to remove CsA from the cultures. The time dependent efflux of rhodamine 123 
was followed over 6 minutes (time points 60, 120, 180, 240, 300 and 360 seconds). First 
order rate constants (FORCs) were obtained by simultaneous fit of duplicate datapoints 
by an exponential function and normalized for expression rates (Figure 4.27). 
We also examined the expression level for all cell lines by cell surface labelling of P-gp 
with MRK16 in parallel to the efflux experiment. Additionally, unstimulated cells 
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served as control. Thus we carried out seven stimulated and five unstimulated inde-
pendent MRK16 stainings for each cell line (shown in Figure 4.26). CsA incubation 
promoted expression of all mutant P-gps to levels observed for G185V P-gp. An exactly 
identical expression was not required, because FORCs are linearly dependent on protein 
expression rates in a zero trans efflux protocol. Experimental data are presented as the 
means ± S.D. 
  
 
Figure 4.26: MRK16 staining of G185V P-gp, Q132R, Q773R and Q132R/Q773R P-gp mutants in 
G185V background, and mock transfected cells. The values are expressed as percent of G185V set 
to 100%. The values are mean 
+ 
standard deviations. Left: unstimulated cells (N=5). Right: Cells 
were incubated with 10 µM CsA for 24 hours (N=7). 
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Figure 4.27: Rhodamine 123 zero trans efflux without modulator. The diagramme shows the trans-
port rate of rhodamine 123 of G185V P-gp, Q132R, Q773R and Q132R/Q773R P-gp mutants in 
G185V background. The slope obtaining through linear regression of FORC versus MFU values of 
all cell lines are calculated and indicated above the bar. Cells were preincubated with 10 µM CsA 
for 24 hours (N=7). 
 
To compare different flux rates in mutants to each other the transport rates have to be 
normalized for expression rate. The Q132R mutant showed 29% efflux rates of G185V 
control, Q773R and the double mutant showed 32% and 21%, respectively. The rhoda-
mine 123 transport rate for G185V P-gp showed high interexperimental variation, 
which we interpreted as possibly due to incomplete remove of CsA. To overcome the 
effect of potentially incomplete CsA removal, surface expression was increased by 
shifting to a growth temperature of 28°C. The expression level increased in all of the R 
mutants (Figure 4.55). 
Different compounds, GPV01, GPV02, GPV12, GPV31, GPV46, and GPV57, were 
tested for their modulating activity in the rhodamine 123 efflux assays for wt, G185V P-
gp and mock transfected cells (shown in Table 4.3). A time dependent efflux was used 
with either no modulator, or modulator at eight various concentrations depending on 
solubility and the expected potency for the modifier. The modulator concentrations for 
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GPV01 that were used for mutant characterization ranged from 164 nM to 100 µM 
(1:2.5 serial dilutions). For each concentration of the inhibitor, the time dependent ef-
flux of rhodamine 123 was followed over 6 minutes (time points 90, 180, 270 and 360 
seconds). From these data points the initial efflux rate was calculated by determining 
the slope of the tangent to the extrapolated 0 time point which was normalised to obtain 
the first order rate constant (FORC). The first order rate constants (Vmax/Km) were then 
plotted as a function of inhibitor concentration in a linear and a half-logarithmic plot 
(shown in Figure 4.28 - Figure 4.48). Hyperbolic curves were fitted to the data points 
using the solver add-in of the MS-office Excel computer program. G185V P-gp and wt 
P-gp expressing cells were loaded with the fluorescent dye rhodamine 123 and the time-
dependent decrease of cell-associated fluorescence in the presence of different concen-
trations of inhibitors was measured. Mock transfected cells served as negative control. 
Plotting the first order rate constants versus inhibitor concentration led to dose/response 
curves, which allowed calculation of the IC50 values. These IC50 values refer to those 
concentrations, which are required to inhibit efflux first order rate constants of rhoda-
mine 123 by 50%. IC50 values were determined by fitting a Hill equation onto data 
points by the method of nonlinear least-squares. A representative experiment for com-
pound GPV01 is shown in Figure 4.29 - Figure 4.31 and for GPV31 in Figure 4.32 - 
Figure 4.34. Cell surface labelling was carried out for all cell lines in parallel with the 
efflux experiment (Figure 4.28). 
 
Figure 4.28: MRK16 staining of wt P-gp, G185V P-gp and mock transfectd clells. Each experiment 
was performed in duplicate.  
 
The expression level for wt and G185V P-gp was similar. 
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Figure 4.29: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V P-gp expressing NIH3T3 cells. From measurements in the absence and pres-
ence of 8 different concentrations of the propafenone analogue GPV01, IC50 values were calculated 
using a hyperbolic curve fit. 
  
 
Figure 4.30: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in wt P-gp expressing NIH3T3 cells. From measurements in the absence and presence of 
8 different concentrations of the propafenone analogue GPV01, IC50 values were calculated using a 
hyperbolic curve fit.  
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Figure 4.31: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in mock transfected NIH3T3 cells in the absence and presence of 8 different concentra-
tions of the propafenone analogue GPV01. 
 
For all efflux experiments the IC50 values of GPV01 were 0.780 µM (95% CI: 0.49 µM 
– 1.07 µM, N=10) for G185V and 0.73 µM (95% CI: 0.62 µM – 0.84 µM, N=3) for wt 
cells. It was not possible to calculate an IC50 value for mock transfected cells.  
 
Figure 4.32: Dose-response curve for compound GPV31, showing the effect on the rhodamine 123 
efflux rate in G185V P-gp expressing NIH3T3 cells. From measurements in the absence and pres-
ence of 8 different concentrations of the propafenone analogue GPV31, IC50 values were calculated 
using a hyperbolic curve fit.  
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Figure 4.33: Dose-response curve for compound GPV31, showing the effect on the rhodamine 123 
efflux rate in wt P-gp expressing NIH3T3 cells. From measurements in the absence and presence of 
8 different concentrations of the propafenone analogue GPV31, IC50 values were calculated using a 
hyperbolic curve fit.  
 
 
 
 
 
 
Figure 4.34: Dose-response curve for the compound GPV31, showing the effect on rhodamine 123 
efflux rate in mock transfected NIH3T3 cells in the absence and presence of 8 different concentra-
tions of the propafenone analogue GPV31. 
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For all rhodamine 123 efflux inhibition experiments with GPV31 the IC50 values were 
0.18 µM (95% CI: 0.10 µM – 0.27 µM, N=3) for G185V P-gp and 0.27 µM (N=1) for 
wt P-gp. As before, no effect of GPV31 was observed in mock transfected cells, be-
cause of a lack of expression of P-gp. The rate constant observed in these cells corre-
sponds to rhodamine 123 diffusion rates. 
 
The IC50 values for all 6 propafenone analogues are reported in Table 4.3. It was not 
possible to calculate IC50 values for mock transfected cells for any of the propafenone 
analogues, because these cells do not express significant levels of P-gp. The most active 
compounds are GPV01, GPV02, and GPV31. For these three compounds comparably 
low inhibitor concentrations are needed to modulate activity. IC50 values of these com-
pounds are lower than those observed for GPV12, GPV46, and GPV57. The modulators 
GPV01, GPV02, GPV12, GPV31, GPV46 and GPV57 were tested once before the mu-
tants were characterized.  
 
Table 4.3: Different propafenone analogues and their respective IC50 values for inhibition of G185V 
P-gp and wt P-gp obtained in rhodamine 123 efflux experiments. It was not possible to calculate 
IC50 values for mock transfected cells. 
 
Because of generally low expression rates of stable transfectants, use of the G185V 
background was considered to increase the likelihood of being able to functionally char-
acterize mutant P-gp with reduced pump activity. Indeed, the G185V P-gp had higher 
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rhodamine 123 efflux rates as compared to wt P-gp. This observation is consistent with 
the cytotoxicity experiments where the G185V P-gp showed a higher resistance to rho-
damine 123 compared to wt P-gp. The FORCs for these 6 rhodamine 123 efflux ex-
periments of G185V P-gp, wt P-gp and mock transfected cells are shown in Figure 4.35.  
 
Figure 4.35: Transport rates (FORCs) of G185V P-gp, wt P-gp and mock transfected cells for rho-
damine 123. 
 
The mean of all rhodamine 123 zero trans efflux experiments resulted in a FORC of 
1.55 1/sec x 1000 (95% CI: 1.44 – 1.65, N=17) for G185V P-gp, 1.46 1/sec x 1000 
(95% CI: 1.33 – 1.59, N=8) for wt P-gp and 0.59 1/sec x 1000 (95% CI: 0.51 – 0.67, 
N=14) for mock transfected cells. These FORCs of G185V P-gp and wt P-gp have been 
normalized for expression rate to compare flux rates to each other (shown in Figure 
4.36). The slope of this relationship provided the pump activity. The slopes of the linear 
regressions are shown in Table 4.4. The pump activity for wt and G185V P-gp was 
similar. The mock transfected cells were close to the origin indicating that the rate con-
stant observed in these cells corresponds to rhodamine 123 diffusion rates. 
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Figure 4.36: Correlation (origin forced to 0) of surface expression (measured by MRK16 staining) 
and FORC for G185V P-gp and wt P-gp. 
 
 
Table 4.4: Pump activity of G185V P-gp and wt P-gp. The slopes were obtained through linear 
regression of FORC versus surface expression (MFU value). N: number of data points that were 
used, r: correlation coefficient, and p: significance 
 
The next step was to characterize the P-gp mutants. All three mutant combinations for 
example Q132A, Q773A and Q132A/Q773A in the G185V background were compared 
with G185V P-gp and mock transfected cells in rhodamine 123 efflux experiments on 
the same day. A representative experiment for each cell line for compound GPV01 is 
shown in Figure 4.38 - Figure 4.42; Figure 4.44 - Figure 4.48; Figure 4.50 - Figure 4.54; 
and Figure 4.56 - Figure 4.59. In general the rhodamine 123 zero trans efflux experi-
ments were performed in at least two independent experiments and cell surface labelling 
of P-gp was carried out for all cell lines in parallel in repeat determinations for each 
experiment (Figure 4.37, Figure 4.43, Figure 4.49, and Figure 4.55). 
We tested compound GPV01 as inhibitor for all P-gp mutants.  
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Figure 4.37: MRK16 staining of G185V P-gp, Q132A, Q773A and Q132A/Q773A P-gp mutants in 
G185V background, and mock transfected cells. Each experiment was performed in duplicate. 
 
 
 
 
 
Figure 4.38: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V-Q132A P-gp expressing NIH3T3 cells. From measurements in the absence and 
presence of 8 different concentrations of the propafenone analogue GPV01, IC50 values were calcu-
lated using a hyperbolic curve fit. 
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Figure 4.39. Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V-Q773A P-gp expressing NIH3T3 cells. From measurements in the absence and 
presence of 8 different concentrations of the propafenone analogue GPV01, IC50 values were calcu-
lated using a hyperbolic curve fit. 
 
 
Figure 4.40: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V-Q132A/Q773A P-gp expressing NIH3T3 cells. From measurements in the 
absence and presence of 8 different concentrations of the propafenone analogue GPV01, IC50 values 
were calculated using a hyperbolic curve fit. 
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Figure 4.41: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V P-gp expressing NIH3T3 cells. From measurements in the absence and pres-
ence of 8 different concentrations of the propafenone analogue GPV01, IC50 values were calculated 
using a hyperbolic curve fit. 
 
Figure 4.42: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in mock transfected NIH3T3 cells in the absence and presence of 8 different concentra-
tions of the propafenone analogue GPV01. 
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IC50 values for rhodamine 123 efflux inhibition with GPV01 were 0.66 µM (95% CI: 
0.52 µM – 0.81 µM, N=2) for G185V-Q132A, 0.57 µM (95% CI: 0.24 µM – 0.90 µM, 
N=2) for G185V-Q773A, and 1.64 µM (95% CI: -0.13 µM – 3.40 µM, N=2) for the 
double A mutant.  
Because of the fact that the G185V-Q132A/Q773A P-gp mutant had a very low expres-
sion level the experiments were performed again. To enhance expression of P-gp, the 
G185V, all alanine mutants in the G185V background as well as the mock transfected 
cells were shifted to a growth temperature of 28°C prior to assessing substrate flux. The 
expression level increased in all mutants (shown in Figure 4.43). 
 
 
Figure 4.43: MRK16 staining of G185V P-gp, Q132A, Q773A and Q132A/Q773A P-gp mutants in 
G185V background, and mock transfected cells. Comparison of incubation at 28°C (left) and 37°C 
(top-right, see Figure 4.37). The cells were shifted to a growth temperature of 28°C / 37°C prior to 
assessing substrate flux. Each experiment was performed in duplicate. 
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Figure 4.44: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V-Q132A P-gp expressing NIH3T3 cells. From measurements in the absence and 
presence of 8 different concentrations of the propafenone analogue GPV01, IC50 values were calcu-
lated using a hyperbolic curve fit. The cells were shifted to a growth temperature of 28°C prior to 
assessing substrate flux. 
 
 
Figure 4.45: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V-Q773A P-gp expressing NIH3T3 cells. From measurements in the absence and 
presence of 8 different concentrations of the propafenone analogue GPV01, IC50 values were calcu-
lated using a hyperbolic curve fit. The cells were shifted to a growth temperature of 28°C prior to 
assessing substrate flux. 
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Figure 4.46: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V-Q132A/Q773A P-gp expressing NIH3T3 cells. From measurements in the 
absence and presence of 8 different concentrations of the propafenone analogue GPV01, IC50 values 
were calculated using a hyperbolic curve fit. The cells were shifted to a growth temperature of 28°C 
prior to assessing substrate flux. 
 
 
Figure 4.47: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V P-gp expressing NIH3T3 cells. From measurements in the absence and pres-
ence of 8 different concentrations of the propafenone analogue GPV01, IC50 values were calculated 
using a hyperbolic curve fit. The cells were shifted to a growth temperature of 28°C prior to assess-
ing substrate flux. 
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Figure 4.48: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in mock transfected NIH3T3 cells in the absence and presence of 8 different concentra-
tions of the propafenone analogue GPV01. The cells were shifted to a growth temperature of 28°C 
prior to assessing substrate flux. 
 
After shifting the cells to a growth temperature of 28°C prior to assessing substrate flux, 
the IC50 values for rhodamine 123 efflux inhibition with GPV01 were 0.58 µM (95% 
CI: 0.20 µM – 0.95 µM, N=3 for G185V-Q132A, 0.24 µM (95% CI: 0.18 µM – 0.31 
µM, N=3) for G185V-Q773A, and 1.06 µM (95% CI: -0.19 µM – 2.31 µM, N=3) for 
the double A mutant. For G185V P-gp an IC50 value of 0.76 µM (95% CI: 0.62 µM – 
0.94 µM, N=6) was obtained. At both temperatures, 28°C and 37°C, the G185V-Q773A 
and G185V-Q132A mutants showed a better modulating activity for compound GPV01 
compared to G185V P-gp and wt P-gp, however confidence intervals indicate that this 
is not a significant difference. 
 
The next three mutant combinations Q132E, Q773E and Q132E/Q773E in the G185V 
background were tested and compared with G185V P-gp and mock transfected cells in 
rhodamine 123 efflux experiments on the same day. 
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Figure 4.49: MRK16 staining of G185V P-gp, Q132E, Q773E and Q132E/Q773E P-gp mutants in 
G185V background, and mock transfected cells. The cells grew at 37°C prior to assessing substrate 
flux. Each experiment was performed in duplicate. 
 
 
 
Figure 4.50: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V-Q132E P-gp expressing NIH3T3 cells. From measurements in the absence and 
presence of 8 different concentrations of the propafenone analogue GPV01, IC50 values were calcu-
lated using a hyperbolic curve fit.  
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Figure 4.51: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V-Q773E P-gp expressing NIH3T3 cells. From measurements in the absence and 
presence of 8 different concentrations of the propafenone analogue GPV01, IC50 values were calcu-
lated using a hyperbolic curve fit.  
 
 
Figure 4.52: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V-Q132E/Q773E P-gp expressing NIH3T3 cells. From measurements in the ab-
sence and presence of 8 different concentrations of the propafenone analogue GPV01, IC50 values 
were calculated using a hyperbolic curve fit.  
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Figure 4.53: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V P-gp expressing NIH3T3 cells. From measurements in the absence and pres-
ence of 8 different concentrations of the propafenone analogue GPV01, IC50 values were calculated 
using a hyperbolic curve fit.  
 
Figure 4.54: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in mock transfected NIH3T3 cells in the absence and presence of 8 different concentra-
tions of the propafenone analogue GPV01. 
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The IC50 values for Q132E and Q773E in the G185V background were 0.74 µM (95% 
CI: 0.40 µM – 1.08 µM, N=3) and 0.98 µM (95% CI: 0.78 µM – 1.19 µM, N=2). For 
the double E mutant the IC50 value was 0.98 µM (95% CI: 0.91 µM – 1.04 µM, N=2). 
All E mutants showed similar IC50 values compared to G185V and wt P-gp. 
 
The R mutants’ combination Q132R, Q773R and Q132R/Q773R in the G185V back-
ground were also tested and compared with G185V P-gp and mock transfected cells in 
the same rhodamine 123 efflux experiments. 
Because of the fact that the R mutants did not show trafficking to the plasma membrane 
the cells were shifted to a growth temperature of 28°C. Cells cultured at a growth tem-
perature of 37°C were analyzed in parallel. The expression level increased in all of the 
R mutants at 28°C (Figure 4.55). 
 
 
Figure 4.55: MRK16 staining of G185V P-gp, Q132R, Q773R and Q132R/Q773R P-gp mutants in 
G185V background, and mock transfected cells. The cells were shifted to a growth temperature of 
28°C prior to assessing substrate flux. In parallel, a growth temperature of 37°C was selected for 
comparison. Experiments in each cell line were performed in duplicate. 
 
  
Figure 4.56: Dose-response curve for compound GPV01, showing the effect on
efflux rate in G185V-Q132R P-gp expressing 
in the absence and presence of 8 different concent
values were calculated using a hyperbolic curve fit.
Figure 4.57: Dose-response curve for compound GPV01, showing the effect on 
efflux rate in G185V-Q773R P-gp expressing 
in the absence and presence of 8 different concentrations of t
values were calculated using a hyperbolic curve fit.
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Figure 4.58: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V-Q132R/Q773R P-gp expressing NIH3T3 cells at 28°C and 37°C. From meas-
urements in the absence and presence of 8 different concentrations of the propafenone analogue 
GPV01, IC50 values were calculated using a hyperbolic curve fit. 
 
Figure 4.59: Dose-response curve for compound GPV01, showing the effect on the rhodamine 123 
efflux rate in G185V P-gp expressing NIH3T3 cells at 28°C and 37°C. From measurements in the 
absence and presence of 8 different concentrations of the propafenone analogue GPV01, IC50 values 
were calculated using a hyperbolic curve fit. 
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At 37°C the IC50 values for Q132R and Q773R in the G185V background were 2.89 
µM (95% CI: 1.77 µM – 4.01 µM, N=2) and 1.10 µM. For the double mutant 
Q132R/Q773R the IC50 value was 1.59 µM. 
The IC50 values at 28°C for Q132R and Q773R in the G185V background were 1.30 
µM (95% CI: 1.30 µM – 1.30 µM, N=2) and 1.16 µM (95% CI: -0.42 µM – 2.74 µM, 
N=2). For the double R mutant the IC50 value was 2.20 µM. 
It was not possible to calculate IC50 values for all rhodamine 123 efflux experiments for 
the Q773R at 37°C and for the double R mutant at either temperature, 28°C or 37°C, in 
the G185V background, since some mutants showed a similar behaviour as the mock 
transfected cells – i.e. did not show a concentration dependent difference in flux rates. 
For compound GPV01 as an inhibitor, the IC50 values for G185V were 0.78 µM (95% 
CI: 0.49 µM – 1.07 µM, N=10) at 37°C and 0.78 µM (95% CI: 0.62 µM – 0.94 µM, 
N=6) at 28°C. Mock transfected cells did not show a concentration dependent difference 
in flux rates indicating that membrane diffusion is not changed by the inhibitor.  
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All rhodamine 123 zero trans experiments are summarized in Table 4.5. 
 
Table 4.5: IC50 and FORC values of the propafenone analogue GPV01 for G185V P-gp, wt P-gp, 
and P-gp mutants in the G185V and wt background. IC50 values for inhibition of P-gp and P-gp 
mutants were obtained in rhodamine 123 efflux experiments. It was not possible to calculate IC50 
values for mock transfected cells. In addition to the IC50 values, FORCs were calculated for P-gp, 
P-gp mutants and mock transfected cells. Values in parentheses brackets correspond to the 95% 
confidence interval (CI). 
 
Rhodamine 123 zero trans efflux analysis revealed that all mutants except G185V-
Q773R and G185V-Q132R/Q773R showed similar activity as compared to G185V 
cells. Each mutant in the G185V background was tested in at least two independent ex-
periments. IC50 values for G185V P-gp and P-gp mutants in the G185V background 
inhibition using GPV01 were compared. Wt P-gp and some P-gp mutants in the wt 
background were also tested. Table 4.5 summarizes the IC50 values for inhibition of P-
gp mediated rhodamine 123 efflux. Values in parentheses correspond to the 95% confi-
dence interval (CI). The transporters behaved differently with respect to inhibition by 
GPV01 resulting in different IC50 values for each mutant. GPV01 showed the strongest 
modulating activity for G185V-Q773A, followed by G185V-Q132A both at 37°C and 
28°C (see Table 4.5). The IC50 value for G185V-Q132A was 0.66 µM (95% CI: 0.52 
µM – 0.81 µM, N=2) at 37°C and 0.58 µM (95% CI: 0.20 µM – 0.95 µM, N=3) at 
28°C. The arginine mutants required expression at 28°C for maturation of P-gp. 
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Table 4.5 shows the non-normalized FORCs. The mock transfected cells showed a 
FORC of 0.59 1/sec x 1000 (95% CI: 0.51 – 0.67, N=14) at 37°C and 0.62 1/sec x 1000 
(95% CI: 0.42 – 0.83, N=4) at 28°C. These results showed that the temperature shift had 
no influence on flux (diffusion) rates in NIH 3T3 cells and that expression of endoge-
nous mouse P-gp was thus not detectable. To compare different flux rates in mutants to 
each other, transport rates have to be normalized for expression rates (shown in Figure 
4.60, Figure 4.61 and Figure 4.62). As noted before, the slope of this relationship is a 
reflection of the pump activity. The slopes of the linear regressions are summarized in 
Table 4.6. 
 
 
Figure 4.60: Correlation (origin forced to 0) of surface expression (measured by MRK16 staining) 
and FORC for G185V P-gp, Q132A, Q773A and Q132A/Q773A P-gp mutants in G185V back-
ground. The cells were shifted to a growth temperature of 28°C prior to performing the experi-
ments. 
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Figure 4.61: Correlation (origin forced to 0) of surface expression (measured by MRK16 staining) 
and FORC for G185V P-gp, Q132E, Q773E and Q132E/Q773E P-gp mutants in G185V back-
ground. 
 
 
Figure 4.62: Correlation (origin forced to 0) of surface expression (measured by MRK16 staining) 
and FORC for G185V P-gp, Q132R, Q773R and Q132R/Q773R P-gp mutants in G185V back-
ground. The cells were shifted to a growth temperature of 28°C prior to performing the experi-
ments. 
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Table 4.6: Pump activity of G185V P-gp and mutant P-gps. The slopes were obtained through li-
near regression of FORC versus surface expression (MFU value). N: number of data points that 
were used, r: correlation coefficient, and p: significance. 
 
The most active mutants in the G185V background were Q132A, Q132E and Q132R. 
The Q132A mutant showed 118% pump activity of G185V control, Q773A and the 
double A mutant showed 71% and 85%, respectively. The pump activity for the Q132E, 
Q773E and double E mutants were 106%, 71% and 75% of G185V control. The results 
for Q132R, Q773R and Q132R/Q773R mutants were 96%, 53% and 25%. The most A 
and R mutants at 37°C were not analyzed due to their poor efflux pump activity which 
was close to that of the mock transfected cells and as such not interpretable by linear 
regression. 
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5 Discussion 
 
The escape of cancer cells from chemotherapy through activation of MDR mechanisms 
is a major reason for treatment failure in systemic (metastasized) cancers. Since the dis-
covery of P-gp, many groups have focussed on understanding how a single protein is 
capable of transporting so many unrelated compounds. Due to the broad substrate rec-
ognition, it has been a challenge to predict effects of disrupting P-gp-mediated transport 
(Yang, Wu et al. 2008). 
During the course of this project, four structures for complete ABC transporters were 
published: the metal-chelate-type transporter HI1470/1 from Haemophilus influenzae 
(Pinkett, Lee et al. 2007), the molybdate transporter ModBC from Archaeoglobus ful-
gidus in complex with its binding protein (ModA) (Hollenstein, Frei et al. 2007), and 
two structures of Sav1866 (one bound to the nucleotide analogue AMP-PNP, and an-
other with ADP) (Dawson and Locher 2006; Dawson and Locher 2007). The recent 
publication of the high resolution crystal structure of Sav1866 was a significant advance 
in the understanding of the molecular mechanism of ABC transporter function (Zolner-
ciks, Wooding et al. 2007). Following publication of the Sav1866 structure several pre-
viously lower resolution MsbA structures were retracted. 
Upon issuing of this thesis, the x-ray structure of mouse P-gp (ABCB1), which has 87% 
sequence identity to human P-gp, was described by Aller et al. in Chang’s group (Aller, 
Yu et al. 2009). Chang’s group determined apo and drug-bound P-gp structures. The 
apo P-gp at 3.8 Å represents a nucleotide-free inward-facing conformation forming two 
bundles of six transmembrane helices (TMs 1, 2, 3, 6, 10, 11 and TMs 4, 5, 7, 8, 9, 12). 
This results in a large internal cavity of ~6000 Å open to both the cytoplasm and the 
inner leaflet, cubed with a 30 Å separation of the two nucleotide-binding domains. In 
addition, Chang’s group described two P-gp structures with cyclic peptide inhibitors, 
cyclic-tris-(R)-valineselenazole (QZ59-RRR) and cyclic-tris-(S)-valineselenazole 
(QZ59-SSS). These drug-bound P-gp structures reveal distinct drug-binding sites in the 
internal cavity. 
The Sav1866 structures represented good templates for the clinically relevant P-gp. This 
ABC-half transporter is a member of the MDR-class, and is homologous to both the N- 
and C-terminal halves of human P-gp. 
The ATP-switch model is the product of biochemical data interpreted in the light of 
advances in structure determination for several ABC transporters. Recently, Linton and 
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Higgins (Linton and Higgins 2007) postulated that the different conformations of P-gp 
might have different affinities for drug substrates. It is possible that conversion of dif-
ferent sites, from high- to low-affinity states, may take place during different stages of 
the reaction cycle (Loo, Bartlett et al. 2007). 
 
The aim of this project at initiation was to investigate the role of conserved amino acids 
in the molecular mechanism of the human multidrug transporter, P-glycoprotein. Identi-
fication of the drug-binding sites in P-gp would help to understand the mechanism of 
drug interaction and transport. Studies on the TMDs suggested that the drug-binding 
sites lie within the TMDs because the TMDs alone retain the ability to interact with a 
variety of drug substrates in the absence of both ATP-binding domains (Loo and Clarke 
1999). P-gp has been reported to contain multiple operationally defined drug-binding 
sites. It contains two distinct binding sites for rhodamine 123 (R-site) and Hoechst 
33342 (H-site) and a third site which binds prazosin and progesterone (Shapiro and Ling 
1997; Shapiro, Fox et al. 1999). The presence of at least four distinct drug interaction 
sites on P-gp was detected using radioligand binding studies (Martin, Berridge et al. 
2000). Mapping the residues that line the drug-binding sites has been a challenging task. 
P-gp can bind dozens of structurally unrelated compounds, multiple drug substrates can 
bind at the same time (Loo, Bartlett et al. 2003; Lugo and Sharom 2005), and binding of 
drug substrate may occur by an induced-fit mechanism (Loo, Bartlett et al. 2003). How-
ever, the mechanism of drug binding is complex. The group of David Clarke used cys-
teine mutagenesis and reaction with thiol-reactive drug substrates such as MTS-
verapamil (Loo and Clarke 2001; Loo, Bartlett et al. 2006; Loo, Bartlett et al. 2006) and 
MTS-rhodamine (Loo and Clarke 2002; Loo, Bartlett et al. 2007) to map the locations 
of the drug-binding sites. The generation of a cysteine-less P-gp mutant in which all 
cysteine residues were replaced with alanine was first described by Loo and Clarke 
(Loo and Clarke 1995). The removal of endogenous cysteine residues from P-gp has a 
minimal impact upon the function of the protein, thus the use of cysteine-less P-gp in 
cysteine mutagenesis and cross-linking studies is justified. For example, Blott et al. 
showed, that this cysteine-less P-gp transported the fluorescent dye rhodamine 123 with 
similar efficiency to wild-type protein (Blott, Higgins et al. 1999).  
The observation that TMD-NBD interactions are important for folding and activity has 
been reported for CFTR (Serohijos, Hegedus et al. 2008). 
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Our group showed the participation of multiple TM segments in mediating P-gp-drug 
interactions by photolabelling of P-gp with drug analogues, followed by analysis by 
MALDI-TOF mass spectrometry (Ecker, Csaszar et al. 2002; Pleban, Kopp et al. 2005). 
The initial homology model of P-gp generated by our group was generated based on the 
MsbA template structure, which was the only available structure at this time (Chang and 
Roth 2001; Chang 2003; Seigneuret and Garnier-Suillerot 2003; Stenham, Campbell et 
al. 2003; Pleban, Kopp et al. 2005; Reyes and Chang 2005). In the resulting homology 
model both amino acids Q132 (TM2) in the N-terminal half and Q773 (TM8) in the C-
terminal half were in close proximity to the binding sites that were detected using the 
photoaffinity labelling. These glutamine residues align with each other in alignments of 
the N- and C-terminal half of P-gp and were considered to be located between the most 
strongly photolabelled residues F951 and M197 at the TM3/TM11 interface, and A311 
and T769 at the TM5/TM8 interface. Q132 and Q773 were also predicted to form H-
bonds with propafenone type ligands in data driven docking experiments (Shown in 
Figure 2.8 and Figure 2.9). Studies in our lab were performed to clarify the P-gp-
mediated transport mechanisms by replacement of Q132 and Q773 by nonpolar alanine 
residues, positively charged arginine or negatively charged glutamic acid residue, indi-
vidually, or in combination. Results indicating that a charge is tolerated in this position 
of the protein were obtained. A replacement was expected to lead to altered substrate 
binding characteristics and transport. This was confirmed for rhodamine 123 efflux. P-
gp drug transport activity requires interactions between the two halves of the molecule, 
although they do not have to be covalently linked. A functional transporter could only 
be generated when the two half-molecules were co-expressed in the same cells (Loo and 
Clarke 1996; Loo and Clarke 1998). We expected that the substitution of Q132 and 
Q773 with alanine, individually or in combination, does not cause a change that is large 
enough to abolish binding of a drug completely, but if these residues would be close to 
the substrate recognition site, a substitution with arginine was expected to disrupt P-gp 
interactions with some drug substrates because of its relatively large and positively 
charged side chain. Initial studies on P-gp using arginine mutagenesis showed that in-
troduction of arginines at some positons in TM1 disrupts binding of some drugs (Ta-
guchi, Kino et al. 1997). For a negatively charged substitution glutamic acid was cho-
sen. 
To examine our hypothesis, nine P-gp mutants were generated in the pEF5 vector in 
order to examine their impact on P-gp cell surface expression and on P-gp function. 
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Using stable FlpIn HEK 293 or NIH 3T3 cell lines, expressing either MDR, wild-type or 
MDR1 mutants, we have characterised the functional differences between cells express-
ing wild-type and mutant P-gp. Expression and function were measured by FACS 
analysis using MRK16 staining, cytotoxicity assays and rhodamine 123 efflux in the 
presence of propafenone analogues. The mutants were generated in the wt and in the 
G185V background. The latter represents a gain of function mutation for the transport 
of rhodamine 123 and was thus expected to improve the signal to noise ratio for mutants 
with low expression levels of P-gp. The amino acid sequence of proteins is generally 
believed to determine protein expression, folding and function. Thus, mutations which 
alter the primary structure of a protein can affect these properties. Mutations that cause 
an amino acid change in a corresponding protein are often responsible for genetic 
changes known to cause disease. A common observation is, that mutant proteins synthe-
sized in the endoplasmatic reticulum are defective in folding and trafficking, leading to 
reduced levels or absence of functional protein at a required location, because most is 
degraded soon after synthesis in the endoplasmic reticulum. Maturation of processing 
mutants can be induced by chemical or pharmacological chaperones or by expression at 
low temperature. 
Because of the fact that our mutations are located at the TMD domain interface, not all 
mutants showed uncompromised trafficking to the plasma membrane. This was reme-
died by either adding cyclosporin A at a concentration of 10 µM for 24 hours or by 
shifting cells to a growth temperature of 28°C. Expression in the presence of drug sub-
strate CsA induced maturation of the P-gp mutants. Inducing maturation of P-gp mu-
tants by growth at lower temperatures also correctly targeted the protein to the mem-
brane. We found that CsA does not modify the expression of any of the MDR1 genes 
containing the mutation by SYBR green real-time reverse transcription PCR. Neverthe-
less, shifting the cells to a growth temperature of 28°C to induce maturation of process-
ing mutants was given preference, because it proved difficult to completely remove CsA 
from the cultures prior to assessing substrate efflux. 
The expression level of P-gp in different mutants was shown in comparison to wt P-gp, 
G185V P-gp and mock transfected cells. P-gp expression was similar for wt and G185V 
P-gp. The Q132E mutant in the G185V background showed a slightly higher expression 
level in comparison to G185V P-gp. The same effect was observed for the Q132R, the 
double R and Q773A mutants in the G185V background after a shift to a growth tem-
perature of 28°C. A temperature shift promoted expression of all mutant P-gps. The 
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expression level was similar for the Q132A and Q132A/Q773A mutants in the G185V 
background after a shift to a growth temperature of 28°C. At 37°C the double A mutant 
had a somewhat higher expression level than the mock transfected cells. Reducing the 
growth temperature of the cells expressing double A, Q773R or double R mutation be-
low 30°C resulted in a portion of the mutant protein trafficking to the plasma mem-
brane. The Q132A and double A mutants showed a somewhat decreased expression 
compared to the G185V P-gp. The same pattern was observed for the Q773R, Q773E 
and double E mutants in the G185V background. An exactly identical expression was 
not required, because first order rate constants of efflux were determined in a zero trans 
efflux protocol. These rate constants can directly be related to protein expression rates. 
In order to obtain evidence that the resulting protein products are indeed functionally 
expressed, rhodamine 123 zero trans efflux studies were used for mutant characterisa-
tion, because they yield first order rate constants which are directly related to transporter 
expression rates. Cells were preloaded with rhodamine 123 for 30 min; after this time a 
steady state of fluorophore accumulation was reached. Transport activities of mutated P-
gps were measured by determining the accumulation of rhodamine 123 in the absence 
and presence of different concentrations of the P-gp inhibitor GPV01. When cells were 
incubated at 37°C, there was a decrease in the fluorescence of cells due to P-gp-
mediated rhodamine 123 efflux, indicating that P-gp actively extruded rhodamine 123 
from the cells. 
 In contrast, in the presence of GPV01, rhodamine 123 fluorescence increased depend-
ing on the GPV01 concentration, indicative of inhibition of P-gp transport. IC50 values 
of GPV01 were calculated from dose-response curves of FORC (Vmax/Km) versus 
GPV01 concentration. Different IC50 values were observed for each kind of P-gp mutant 
indicating different modulating activity and interaction properties with those membrane 
pumps. 
All alanine single mutants were active. The Q773A and Q132A/Q773A showed only 
somewhat decreased pump activity as compared to wt and G185V P-gp. In contrast to 
the G185V background, the Q132A mutant showed an increased pump activity. This 
indicated that the glutamine residues are not directly involved in interaction with rho-
damine 123. The Q132E, showing a slightly increased pump activity, and Q132R mu-
tants also were fully functional. Compared to the G185V background, the Q773E mu-
tant showed a decreased pump activity, while the Q773R mutant showed a deficient 
pump activity compared to G185V P-gp. The Q132A/Q773A and Q132E/Q773E mu-
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tants also were functional, while the Q132R/Q773R mutant was dysfunctional, the latter 
apparently being impaired functionally by the Q773R mutation alone. 
The reduction in affinity of mutants Q773R and Q132R/Q773R in the G185V back-
ground for rhodamine at both 28°C and 37°C growth temperatures is consistent with the 
observation that they had reduced ability to confer resistance to rhodamine123 in cyto-
toxicity studies. The mock transfected cells showed a higher IC50 value than the 
Q132R/Q773R double mutant, suggesting that the negative effect of the Q773R muta-
tion could not be compensated by a Q132R mutation. The higher IC50 value of the 
Q132E/Q773E double mutant compared to the Q773E mutant in cytotoxicity assays 
may thus also be explained by a compensatory influence of the Q132E mutation. 
 
An explanation for the observation that the mutants Q773R had much lower and 
Q132R/Q773R had no transport activity may be explained by the fact that an arginine 
residue in position 773 appears to reduce P-gp interaction with rhodamine 123 because 
of its positively charged side chain. 
 
Like many P-gp substrates, rhodamine 123 is a protonatable compound, which, after 
entering the central water filled cavity, is likely to be present in a charged form. This 
indicates that charge repulsion might be responsible for the inability of the mutant to 
transport rhodamine 123. In addition, these results indicate that residue 773 but not resi-
due 132 may be close to the rhodamine binding site. 
Our data show that the nature of the amino acid side chain at position 132 and 773 
strongly influences the function of P-gp. Nevertheless, the majority of the mutants were 
capable of transporting rhodamine 123. Small side chains at these positions result in 
proteins with only modest changes in substrate specificity. One mutant, G185V-Q773R, 
did not transport rhodamine 123 well. Transmembrane segments can change their shape 
to accommodate structurally different compounds. Thus, slight rotational and/or lateral 
movement in any transmembrane segment could result in numerous permutations of 
residues contributing to the drug-binding site. A substrate with one structure would 
cause specific shifts in the different transmembrane segments responsible for its binding 
(induced-fit) (Rosenberg, Velarde et al. 2001). 
Several residues line the TMD/TMD contact interfaces in helices 2, 5, 8 and 11, indicat-
ing that mobility at these interfaces is required for function (Loo, Bartlett et al. 2004). 
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In summary our data indicate that residue 773 in P-gp plays an important role in the 
activity of the transporter, but may not be directly involved in the interaction between P-
gp and its substrates. During the transport cycle, P-gp displays different affinities for its 
substrates and alternates between high-affinity and low-affinity binding sites (Sauna and 
Ambudkar 2000; Higgins and Linton 2004). It is possible that the transport-deficient P-
gp Q773R mutant is unable to undergo conformational changes required for substrate 
transport. Substrate might be bound, but not released and therefore not be transported 
effectively. ABC transporters change conformations and affinities for substrates 
throughout the transport cycle. It is difficult to draw conclusions about the role this spe-
cific arginine residue may play in determining conformational changes, substrate inter-
actions and transport function of P-gp. These results are consistent with alanine-
scanning mutagenesis of P-gp which was not successful in mapping the drug-binding 
sites in P-gp (Loo and Clarke 1993) because most mutations either had no effect or 
caused only modest changes in substrate specificity. Initial studies on P-gp using argin-
ine mutagenesis showed that introduction of arginines at some positions appeared to 
disrupt P-gp interactions with some drug substrates (Taguchi, Kino et al. 1997). Based 
on these considerations, we propose that the amino acid replacements at these two sites 
affect the ability of a drug to enter the binding pocket or to make appropriate binding 
contacts that trigger hydrolysis of ATP and the subsequent efflux of the drug. 
The transfer of rhodamine 123 through the cell membrane from the inside to the outside 
involves both, passive diffusion and active transport by either P-gp or other transporters. 
To control for passive diffusion as well as the action of other transporters, FlpIn 3T3 
cells were transfected with the empty pEF5 vector. These mock transfected cells served 
as control. 
In particular, we hoped to determine whether the charged side chains participated in 
substrate recognition and binding. Mutations to A132, E132, R773 and R132/R773, 
substantially altered the ability of the protein to confer resistance to rhodamine 123. The 
R132 mutation had a surprisingly high level of activity. 
Further studies are necessary to clarify the role of these two glutamine residues. The 
present analyses have not yet reveiled changes in substrate specificity of P-gp because 
only a limited number of substrates and inhibitors was used. Therefore, investigating 
additional substrates and inhibitors will be necessary to demonstrate the relevance of 
these two amino acids. We also attempted to study mitoxantrone as a solute in steady 
state experiments. Here the endogenous P-gp was a handicap because no difference be-
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tween G185V P-gp and mock transfected cells was observed (data not shown). An ex-
planation for this observation may be that the expression level of the G185V P-gp is too 
low and/or mitoxantrone is not as good a P-gp substrate as rhodamine 123. 
 
Another objective of this work was to evaluate the influence of various specific P-gp 
substrates/ ligands as pharmacological chaperones in order to study the ability of the 
protein to bind these solutes by monitoring surface expression of trafficking deficient 
mutants. Several mutations lead to reduced levels or absence of functional protein at the 
plasma membrane. 
In these experiment, we tested whether mutations introduced in TM segments 2 and 8 
inhibit maturation of the protein. Surface expression of P-gp and P-gp mutants in HEK 
293 and NIH 3T3 cells was monitored by flow cytometry using the selective mono-
clonal antibody MRK16 and an FITC-labelled secondary antibody. The fluorescence 
intensity of some P-gp mutants was comparable to the background fluorescence inten-
sity, thus the level of P-gp expression was negligible. Pharmacological chaperones such 
as cyclosporin A and verapamil are predicted to promote maturation of P-gp processing 
mutants. In fact, most trafficking deficient P-gp mutants have been shown to be rescued 
by using CsA as a pharmacological chaperone (Loo, Bartlett et al. 2005). The binding 
sites for propafenones have previously been characterized by our group using photo-
labelling (Pleban, Kopp et al. 2005). These sites were suggested to be different from 
those for verapamil and cyclosporin A. This allowed a screening concept to be applied, 
which uses the property of specific P-glycoprotein ligands to act as pharmacological 
chaperones. When the mutants show impaired binding, surface expression of the protein 
is not altered. The minimal effect the pharmacological chaperones had on P-gp expres-
sion in mock transfected cells indicaed that the expression of endogenous mouse P-gp 
was low. 
We used 10 µM CsA, 50 µM verapamil and 50 µM GPV51 as pharmacological chaper-
ones. Interestingly, we noticed that higher GPV51 levels, especially the presence of 300 
µM GPV51, did not stimulate maturation of G185V P-gp to an extent that was observed 
with lower concentrations. The impact of GPV51 on the 773R mutant is higher than on 
the 132R mutant. This indicates preferential binding to the 2/11 interface. At a concen-
tration of 300 µM GPV51, an increased cell death rate in the mock transfected cell cul-
tures was observed (data not shown), this might be interpreted as a negative influence of 
GPV51 on protein assembly at this concentration. 
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 DMSO was required as a solvent to prepare solutions of the highly lipophilic com-
pounds CsA and GPV51 stocks. The solvent alone was shown not to have an influence 
on P-gp expression levels (data not shown). The G185V P-gp, and all mutants in the 
G185V background were stably expressed in NIH 3T3 fibroblasts. The expression lev-
els of the mutants were increased by a 24 hour pre-treatment with the pharmacological 
chaperones cyclosporine A, verapamil and GPV51, indicating that these chaperones are 
still able to bind to the protein. In the case of CsA, these results are consistent with 
those of Loo and Clarke. 
However, GPV51 did not have a considerable impact on P-gp expression in NIH 3T3 
cells. G185V P-gp, Q773R and the double mutant Q132R/Q773R in the G185V back-
ground were stably expressed in HEK 293 cells, too. The expression level of the 
132R/773R double mutant was increased by a 24 hour pre-treatment with CsA, indicat-
ing that CsA was still able to bind to the protein. Verapamil increased the expression 
level, too. As with the NIH 3T3 cell line, the propafenone analogue GPV51 did not 
have a major impact on the expression level, however relative expression gain was still 
higher than in the NIH 3T3 cell line. 
These observations support our hypothesis that propafenones might have a different 
binding site than the classical pharmacological chaperones CsA and verapamil, estab-
lishing the propafenones as a solitary class of P-gp chaperones. 
 
An understanding of multidrug resistance is of wide clinical importance. MDR1 is asso-
ciated with drug failure in various cancers. MDR1 is associated with drug resistance in 
malaria, too. The human malaria parasite Plasmodium falciparum possesses a P-gp 
homologue termed Pgh-1 (Foote, Thompson et al. 1989). Pgh-1 exhibits a domain struc-
ture typical of a P-gp-type ABC transporter. Both P-gp and Pgh-1 pump vinblastine 
(Sanchez, Rotmann et al. 2008). Analogies with P-gp may help explain the transport 
properties and substrate specificity of Pgh-1, possibly opening a window of opportunity 
for treatment of patients infected with highly drug resistant malaria parasites. 
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6 Conclusion 
 
In this study, mutational analyses of two conserved residues within the TMDs of P-gp 
have shown that the nature of the amino acid residues at position 132 and 773 affects 
the function of P-gp. These two residues were selected for substitution with alanine, 
glutamic acid and arginine, individually or in combination. Residue 773 is involved in 
the active rhodamine 123 efflux transport. The substitution of glutamine at position 773 
with arginine markedly decreased the active transport of rhodamine 123. These results 
indicate that residue 773 but not residue 132 is close to the rhodamine binding site. 
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7 Outlook 
 
In the present study, we have studied rhodamine 123 transport to evaluate functional 
changes associated with replacement at amino positions Q132 and Q773 by a nonpolar 
alanine residue, a positively charged arginine or a negatively charged glutamic acid 
residue, individually or in combination. Based on ATPase activity measurements of P-
gp, we will be able to gain insight into the impact of these replacements. The measure-
ment of drug-stimulated ATPase activity was widely used by different research groups 
to investigate the function of P-gp. The aim will be to establish whether the different 
effects described in the previous chapter correlate with ATPase activity. For the analysis 
of the ATPase activity of the wt and mutant proteins, insect cells are convenient expres-
sion systems to produce large quantities of proteins. Therefore, preparation of plasma 
membrane vesicles from insect cells should be performed. In our lab the preparation of 
plasma membrane vesicles was performed as described by Schlemmer and Sirotnak 
(Schlemmer and Sirotnak 1994; Schmid, Ecker et al. 1999). For high yield expression in 
Sf9 insect cells, the gene was inserted into a baculovirus destination vector, which is 
compatible with the entry vector. Baculovirus transfer vectors containing G185V, 
G185V-Q132R, G185V-Q773R, and G185V-Q132R/Q773R are presently ready for 
transfection of monolayers of Sf9 cells. 
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8 List of abbreviations 
 
ABC   ATP-binding cassette 
ADP   Adenosine diphosphate 
AMP-PNP  Adenosine 5’-(ß, γ-imido) triphosphate 
APS   Ammonium persulphate 
ATP   Adenosine triphosphate 
ATP-γ-S  Adenosine 5’-( γ-thio) triphosphate 
Å   Angstrom 
BCRP   Breast cancer resistance protein 
BSA   Bovine serum albumin 
bp   Base pair 
°C   Degree Celsius 
cDNA   Complementary DNA 
cryo-EM  Cryo-electron microscopy 
C-terminal  Carboxy-terminal 
DEPC   Diethylpyrocarbonate 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DBS    Donor bovine serum 
EDTA   Ethylene diamine tetraacetic acid  
ER   Endoplasmic reticulum 
FACS   Fluorescence-activated cell sorting  
GAM Ig FITC Goat anti-mouse Ig fluorescein isothiocyanate 
ICL   Intracellular loop 
HADDOCK  High Ambiguity Driven DOCKing  
HPRT    Hypoxanthine-guanine phosphoribosyltransferase  
hr   Hour 
ICL   Intracellular loop 
Km   Michaelis-Menten constant 
kb   Kilobase 
kDa   Kilodalton 
LB   Lysogeny broth 
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M   Molarity 
MALDI-TOF  Matrix-assisted laser desorption/ionization time-of-flight 
MDR   Multidrug resistance 
MFU   Mean fluorescence units 
ml   Milligram 
min   Minute 
MOPS   3-(N-Morpholino)propanesulphonic acid 
MRP   Multidrug resistance-associated protein 
mRNA  Messenger Ribonucleic acid 
MSAs   Multiple sequence alignments 
NBD   Nucleotide-binding domain 
NMR   Nuclear magnetic resonance 
Nt   Nucleotide 
N-terminal  Amino-terminal 
OE-PCR  Overlap extension polymerase chain reaction 
PAGE   Polyacrylamide Gel Electrophoresis 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
P-gp   P-glycoprotein 
Real-time RT-PCR Real-time reverse transcription PCR 
Rh123   Rhodamine 123 
RNA   Ribonucleic acid 
RT   Room temperature 
rvET   Real valued evolutionary trace 
SDS   Sodium dodecyl sulphate 
sec   Second 
TAE   Tris-acetate EDTA buffer 
TEMED  N, N, N´ ,N´ -tetramethylethane-1, 2-diamine   
TM   Transmembrane helix 
TMD   Transmembrane domain 
Tris   Trihydoxymethylaminomethane 
U   Unit 
UV   Ultra violet 
V   Voltage 
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Vmax   Maximum velocity 
Wt   Wild-type 
 
 
Symbols of amino acids 
 
A Ala  Alanine 
C Cys  Cysteine 
E Glu  Glutamic acid 
H His  Histidine 
Q Gln  Glutamine  
R Arg  Arginine 
V Val  Valine 
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9 Zusammenfassung 
 
Das humane „multidrug resistance“ P-Glycoprotein, welches durch das MDR1 Gen ko-
diert wird, gehört zu der Familie der ATP-binding cassette (ABC) Transporter, die unter 
ATP-Verbrauch zelltoxische, strukturell nicht näher verwandte Stoffe aus der Zelle 
pumpt. Dieses Protein hat klinisch eine große Bedeutung aufgrund des Phänomens der 
zellulären Resistenz gegen viele Wirkstoffe, auch „multidrug resistance“ genannt. Re-
sistenzen gegen verschiedene Medikamente sind eines der Hauptprobleme in der Be-
handlung von Krebs. Das P-Glycoprotein besteht aus zwei homologen Hälften, die 
durch einen Linker miteinander verbunden sind. Jede Hälfte besteht aus einer Trans-
membrandomäne, die sechs Transmembransegmente besitzt, und einer hydrophilen 
Nukleotidbindungsdomäne, der Nukleotidbindungsstelle. 
Ziel dieser Arbeit war die Identifizierung und Charakterisierung von TMD1/TMD2 
Kontakt-Interface-Aminosäurenresten, die eine wichtige Rolle beim Transport von lös-
lichen Substanzen spielen. Funktionelle Untersuchungen wurden mit P-gp Mutanten 
durchgeführt, deren TMD1/TMD2 Kontakt-Interface-Aminosäuren mittels zielgerichte-
ter Mutagenese zu anderen Resten außer Cystein mutiert wurden. Die zielgerichtete 
Mutagenese basierte auf „overlap extension“ Polymerase-Kettenreaktion (OE-PCR). 
Das Mutationskonzept wurde durch Photoaffinitätsmarkierung, vorhandene Proteinho-
mologiemodelle, in-silico Vorhersage von wichtigen Aminosäure-Resten mittels der 
„real valued evolutionary trace“ Methode und „data-driven docking“, basierend auf Da-
ten von vorhergegangenen zielgerichteten Mutationen, gesteuert. 
Diesen Erkenntnissen zufolge wurden P-gp Mutanten hergestellt, die Aminosäure-Reste 
besitzen, die vom Protein toleriert werden, um eine hohe Anzahl von richtig gefalteten 
und funktionellen Transportern zu erhalten. Die Glutaminreste Q132 (TM2) in der N-
terminalen Hälfte und Q773 (TM8) in der C-terminalen Hälfte wurden in Betracht ge-
zogen. P-gp Homologiemodelle zeigen, dass diese beiden Q-Reste in der Nähe von 
stark photomarkierten Resten im TM2/11 Interface und im contralateralen TM5/8 Inter-
face liegen. 
In einigen Tierarten ist einer der beiden Q-Reste zu R oder E mutiert, was darauf hin-
weist, dass eine Ladung in dieser Position im Protein toleriert wird. Deshalb wurde 
Q132 zu Q132A, Q132E und Q132R, und Q773 zu Q773A, Q773E und Q773R mutiert. 
Zusätzlich wurden die Doppelmutanten Q132A/Q773A, Q132E/Q773E und 
Q132R/Q773R generiert. Alle Mutanten wurden mittels Efflux-Studien, MRK16 Fär-
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bungen und Toxizitätstests charakterisiert. Die Q773R Mutante zeigte für das Substrat 
Rhodamin 123 einen mangelhaften Transport, während sowohl die Q773E Mutante als 
auch die Q773A Mutante einen aktiven Transport aufwiesen. Ein unbeeinträchtigten 
Rhodamin 123 Transport konnte für die A, E und R Mutanten in der Position 132 ge-
zeigt werden. Die Q132R/Q773R Doppelmutante war wenig aktiv. 
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